PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 6937526-0 1981 Binding of eugenol and o-ethoxybenzoic acid to bovine serum albumin. Eugenol 11-18 albumin Homo sapiens 54-67 3626186-5 1987 The leakage of GPT from hepatocytes was inhibited by eugenol at 0.1 mM and 0.4 to 4 mM and menthol at 0.1 to 0.6 mM. Eugenol 53-60 glutamic--pyruvic transaminase Rattus norvegicus 15-18 3537779-5 1986 In eugenol-treated microsomes, cytochrome P-450 content, AHH activity and total B[a]P hydroxylase activity were decreased to 81, 29 and 48% of the control values, respectively. Eugenol 3-10 cytochrome P450, family 1, subfamily a, polypeptide 1 Rattus norvegicus 57-60 2562421-0 1989 Metabolic activation of eugenol by myeloperoxidase and polymorphonuclear leukocytes. Eugenol 24-31 myeloperoxidase Homo sapiens 35-50 2562421-3 1989 Myeloperoxidase, isolated and purified from human PMNs, catalyzed the oxidation of eugenol to a reactive intermediate which is likely to be a quinone methide. Eugenol 83-90 myeloperoxidase Homo sapiens 0-15 3125837-0 1988 Enhancement of UDP-glucuronyltransferase, UDP-glucose dehydrogenase, and glutathione S-transferase activities in rat liver by dietary administration of eugenol. Eugenol 152-159 UDP-glucose 6-dehydrogenase Rattus norvegicus 42-67 3125837-0 1988 Enhancement of UDP-glucuronyltransferase, UDP-glucose dehydrogenase, and glutathione S-transferase activities in rat liver by dietary administration of eugenol. Eugenol 152-159 hematopoietic prostaglandin D synthase Rattus norvegicus 73-98 3125837-7 1988 Similar results on DH and GST activities in the liver cytosol were obtained by dietary administration of eugenol, while no effect on cytochrome P-450 content in the liver microsomes from the rats fed the eugenol diet was observed during 13 weeks. Eugenol 105-112 hematopoietic prostaglandin D synthase Rattus norvegicus 26-29 3856016-0 1985 Pin-retained reinforced zinc oxide-eugenol temporary restorations. Eugenol 35-42 dynein light chain LC8-type 1 Homo sapiens 0-3 6944322-0 1981 Pulpal reaction to IRM cement: an intermediate restorative material containing eugenol. Eugenol 79-86 maternally expressed 8, small nucleolar RNA host gene Homo sapiens 19-22 7447003-0 1980 The localization of trehalase in polyacrylamide gels with eugenol by a coupled enzyme assay. Eugenol 58-65 trehalase Homo sapiens 20-29 33829648-3 2021 Molecular docking studies of the hybrids with the essential bacterial enzyme DHPS showed complexes with low binding energies, suggesting that DHPS could be a possible target for the antibacterial sulfonamide-eugenol hybrids. Eugenol 208-215 deoxyhypusine synthase Homo sapiens 77-81 5248192-0 1968 [Zinc-oxide-eugenol paste as an aid in jaw registration]. Eugenol 12-19 activation induced cytidine deaminase Homo sapiens 32-35 33839411-0 2021 Mode-selective inhibitory effects of eugenol on the mouse TRPV1 channel. Eugenol 37-44 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 58-63 33839411-4 2021 Eugenol is a vanilloid that has been used as an analgesic in the dental treatment, and its TRPV1 activation ability has been reported. Eugenol 0-7 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 91-96 33839411-5 2021 However, our knowledge about the underlying mechanisms of the antagonistic effects of eugenol on TRPV1 activation induced by three different modes is limited. Eugenol 86-93 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 97-102 33839411-6 2021 Here, we show that eugenol dose-dependently inhibited the capsaicin-activated inward currents of mouse TRPV1 expressed in human embryonic kidney 293 (HEK293) cells. Eugenol 19-26 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 103-108 33839411-7 2021 Under low pH conditions, low concentrations of eugenol only enhanced the proton-induced TRPV1 currents, whereas high eugenol concentrations initially potentiated but then immediately abrogated TRPV1 currents. Eugenol 47-54 transient receptor potential cation channel subfamily V member 1 Homo sapiens 88-93 33839411-7 2021 Under low pH conditions, low concentrations of eugenol only enhanced the proton-induced TRPV1 currents, whereas high eugenol concentrations initially potentiated but then immediately abrogated TRPV1 currents. Eugenol 117-124 transient receptor potential cation channel subfamily V member 1 Homo sapiens 193-198 33839411-9 2021 Our results demonstrate that eugenol is a mode-selective antagonist of TRPV1 and can be evaluated as a lead compound of analgesics targeting TRPV1 without serious side effects. Eugenol 29-36 transient receptor potential cation channel subfamily V member 1 Homo sapiens 71-76 33839411-9 2021 Our results demonstrate that eugenol is a mode-selective antagonist of TRPV1 and can be evaluated as a lead compound of analgesics targeting TRPV1 without serious side effects. Eugenol 29-36 transient receptor potential cation channel subfamily V member 1 Homo sapiens 141-146 33829648-3 2021 Molecular docking studies of the hybrids with the essential bacterial enzyme DHPS showed complexes with low binding energies, suggesting that DHPS could be a possible target for the antibacterial sulfonamide-eugenol hybrids. Eugenol 208-215 deoxyhypusine synthase Homo sapiens 142-146 32458455-5 2021 Though, eugenol had greater inhibitory effect against AChE and BChE activities. Eugenol 8-15 acetylcholinesterase (Cartwright blood group) Homo sapiens 54-58 33861370-9 2021 Among the nine eugenol and thymol derivatives tested, four were active against the evaluated strains (MIC = 32 microg mL-1) within CLSI standard values. Eugenol 15-22 L1 cell adhesion molecule Mus musculus 118-122 32458455-1 2021 This research work examined and likened effect of eugenol a natural phenolic compound with butylated hydroxylanisole (BHA) and butylated hydroxyl toluene (BHT) synthetic phenolic compounds with key biomolecules [acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidase (MAO)] relevant to Alzheimer"s diseases (AD) in vitro. Eugenol 50-57 acetylcholinesterase (Cartwright blood group) Homo sapiens 234-238 32458455-5 2021 Though, eugenol had greater inhibitory effect against AChE and BChE activities. Eugenol 8-15 butyrylcholinesterase Homo sapiens 63-67 32458455-1 2021 This research work examined and likened effect of eugenol a natural phenolic compound with butylated hydroxylanisole (BHA) and butylated hydroxyl toluene (BHT) synthetic phenolic compounds with key biomolecules [acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidase (MAO)] relevant to Alzheimer"s diseases (AD) in vitro. Eugenol 50-57 butyrylcholinesterase Homo sapiens 241-262 32458455-1 2021 This research work examined and likened effect of eugenol a natural phenolic compound with butylated hydroxylanisole (BHA) and butylated hydroxyl toluene (BHT) synthetic phenolic compounds with key biomolecules [acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidase (MAO)] relevant to Alzheimer"s diseases (AD) in vitro. Eugenol 50-57 butyrylcholinesterase Homo sapiens 264-268 33597054-0 2021 Eugenol influences the expression of messenger RNAs for superoxide dismutase and glutathione peroxidase 1 in bovine secondary follicles cultured in vitro. Eugenol 0-7 glutathione peroxidase 1 Bos taurus 81-105 32458455-4 2021 The results revealed eugenol, BHT, and BHA inhibited AChE, BChE, and MAO activities dose-dependently. Eugenol 21-28 acetylcholinesterase (Cartwright blood group) Homo sapiens 53-57 32458455-4 2021 The results revealed eugenol, BHT, and BHA inhibited AChE, BChE, and MAO activities dose-dependently. Eugenol 21-28 butyrylcholinesterase Homo sapiens 59-63 33597054-10 2021 Eugenol (5.0 and 50.0 muM) increased mRNA levels for GPX1 in cultured follicles, but 0.5 muM eugenol reduced mRNA levels for SOD. Eugenol 0-7 glutathione peroxidase 1 Bos taurus 53-57 33597054-12 2021 In conclusion, eugenol supplementation reduces mRNA levels for SOD and increases mRNA levels of GPX1 in bovine secondary follicles cultured in vitro. Eugenol 15-22 glutathione peroxidase 1 Bos taurus 96-100 33443517-0 2021 Eugenol emerges as an elixir by targeting beta-catenin, the central cancer stem cell regulator in lung carcinogenesis: an in vivo and in vitro rationale. Eugenol 0-7 catenin (cadherin associated protein), beta 1 Mus musculus 42-54 33443517-12 2021 In another way, eugenol was proven to significantly enhance the degradation of beta-catenin when treated with the CK1alpha inhibitor D4476 in vitro by Western blot. Eugenol 16-23 catenin (cadherin associated protein), beta 1 Mus musculus 79-91 33509300-13 2021 Combination of DOX with EUG induced apoptosis through the higher BAX/ BCl2 ratio, while with AST was through the increase in caspase 8 expressions. Eugenol 24-27 BCL2 associated X, apoptosis regulator Homo sapiens 65-68 33335570-0 2021 Eugenol protects cells against oxidative stress via Nrf2. Eugenol 0-7 nuclear factor, erythroid derived 2, like 2 Mus musculus 52-56 33335570-4 2021 Among the three natural compounds tested, namely eugenol, methyleugenol and acetyleugenol, eugenol was found to increase the transcriptional activity and expression level of nuclear factor erythroid 2-related factor 2 (Nrf2), a central regulator of cellular responses to oxidative stress, in a dose-dependent manner. Eugenol 49-56 nuclear factor, erythroid derived 2, like 2 Mus musculus 174-217 33335570-4 2021 Among the three natural compounds tested, namely eugenol, methyleugenol and acetyleugenol, eugenol was found to increase the transcriptional activity and expression level of nuclear factor erythroid 2-related factor 2 (Nrf2), a central regulator of cellular responses to oxidative stress, in a dose-dependent manner. Eugenol 49-56 nuclear factor, erythroid derived 2, like 2 Mus musculus 219-223 33335570-4 2021 Among the three natural compounds tested, namely eugenol, methyleugenol and acetyleugenol, eugenol was found to increase the transcriptional activity and expression level of nuclear factor erythroid 2-related factor 2 (Nrf2), a central regulator of cellular responses to oxidative stress, in a dose-dependent manner. Eugenol 64-71 nuclear factor, erythroid derived 2, like 2 Mus musculus 174-217 33335570-4 2021 Among the three natural compounds tested, namely eugenol, methyleugenol and acetyleugenol, eugenol was found to increase the transcriptional activity and expression level of nuclear factor erythroid 2-related factor 2 (Nrf2), a central regulator of cellular responses to oxidative stress, in a dose-dependent manner. Eugenol 64-71 nuclear factor, erythroid derived 2, like 2 Mus musculus 219-223 33335570-5 2021 The mRNA levels of Nrf2 target genes glutamate-cysteine ligase modifier regulatory subunit and glutathione S-transferase A1, were also found to be upregulated following eugenol treatment. Eugenol 169-176 nuclear factor, erythroid derived 2, like 2 Mus musculus 19-23 33335570-5 2021 The mRNA levels of Nrf2 target genes glutamate-cysteine ligase modifier regulatory subunit and glutathione S-transferase A1, were also found to be upregulated following eugenol treatment. Eugenol 169-176 glutathione S-transferase, alpha 1 (Ya) Mus musculus 95-123 33335570-6 2021 Further study revealed that eugenol enhanced the stabilization and nuclear translocation of Nrf2. Eugenol 28-35 nuclear factor, erythroid derived 2, like 2 Mus musculus 92-96 33335570-7 2021 Additionally, treatment with eugenol was found to reduce intracellular ROS levels while increasing cellular resistance to H2O2, in a manner that was dependent on Nrf2. Eugenol 29-36 nuclear factor, erythroid derived 2, like 2 Mus musculus 162-166 33335570-8 2021 In conclusion, data from the present study suggest that eugenol is a protective agent against oxidative stress that exerts its effects through a Nrf2-dependent pathway, rendering eugenol and its derivatives to be promising candidates for the future development of antioxidants. Eugenol 56-63 nuclear factor, erythroid derived 2, like 2 Mus musculus 145-149 33335570-8 2021 In conclusion, data from the present study suggest that eugenol is a protective agent against oxidative stress that exerts its effects through a Nrf2-dependent pathway, rendering eugenol and its derivatives to be promising candidates for the future development of antioxidants. Eugenol 179-186 nuclear factor, erythroid derived 2, like 2 Mus musculus 145-149 33509300-13 2021 Combination of DOX with EUG induced apoptosis through the higher BAX/ BCl2 ratio, while with AST was through the increase in caspase 8 expressions. Eugenol 24-27 BCL2 apoptosis regulator Homo sapiens 70-74 33245926-6 2021 The healing actions of eugenol were accompanied by the rescue on the histological architecture and the normalization of the superoxide dismutase and catalase activity. Eugenol 23-30 catalase Rattus norvegicus 149-157 33245926-7 2021 Moreover, eugenol (1 mg/kg, p.o) reduced the gastric mucosal myeloperoxidase activity and increased the mucin secretion. Eugenol 10-17 solute carrier family 13 member 2 Rattus norvegicus 104-109 33456468-0 2020 Polymodal Activation and Desensitization of TRPV1 Receptor in Human Odontoblasts-Like Cells with Eugenol. Eugenol 97-104 transient receptor potential cation channel subfamily V member 1 Homo sapiens 44-49 33249607-4 2021 Eugenol showed inhibitory activity against MAO-B enzyme, free radical scavenging activity, and anti-aggregation activity against Abeta peptides than other phytoconstituents. Eugenol 0-7 monoamine oxidase B Homo sapiens 43-48 33249607-9 2021 Eugenol can bind to different Alzheimer"s targets such as beta-secretase (BACE1), Monoamine oxidase B (MAO-B), Cholinesterase"s, and amyloid beta1-42 fibrils and might have a disease-modifying potential. Eugenol 0-7 beta-secretase 1 Homo sapiens 74-79 33249607-9 2021 Eugenol can bind to different Alzheimer"s targets such as beta-secretase (BACE1), Monoamine oxidase B (MAO-B), Cholinesterase"s, and amyloid beta1-42 fibrils and might have a disease-modifying potential. Eugenol 0-7 monoamine oxidase B Homo sapiens 82-101 33249607-9 2021 Eugenol can bind to different Alzheimer"s targets such as beta-secretase (BACE1), Monoamine oxidase B (MAO-B), Cholinesterase"s, and amyloid beta1-42 fibrils and might have a disease-modifying potential. Eugenol 0-7 monoamine oxidase B Homo sapiens 103-108 33249607-9 2021 Eugenol can bind to different Alzheimer"s targets such as beta-secretase (BACE1), Monoamine oxidase B (MAO-B), Cholinesterase"s, and amyloid beta1-42 fibrils and might have a disease-modifying potential. Eugenol 0-7 butyrylcholinesterase Homo sapiens 111-125 33457017-12 2020 Also, CAT increased in the H2O2+eugenol 50 (P < 0.05) group in comparison with the H2O2 group. Eugenol 32-39 catalase Mus musculus 6-9 33457017-13 2020 Conclusions: In conclusion, H2O2 induced oxidative stress and lipid peroxidation in the islets, and administration of eugenol recovered these alterations by raising the level of TAC and CAT, while reducing MDA as a lipid peroxidation biomarker. Eugenol 118-125 catalase Mus musculus 186-189 33059262-0 2020 Anterior gradient 2 is a novel pro-tumor factor in pancreatic cancer under NF-kappaB subunit RelA trans-regulation that can be suppressed by eugenic acid. Eugenol 141-153 anterior gradient 2 Mus musculus 0-19 33059262-0 2020 Anterior gradient 2 is a novel pro-tumor factor in pancreatic cancer under NF-kappaB subunit RelA trans-regulation that can be suppressed by eugenic acid. Eugenol 141-153 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 75-84 33059262-0 2020 Anterior gradient 2 is a novel pro-tumor factor in pancreatic cancer under NF-kappaB subunit RelA trans-regulation that can be suppressed by eugenic acid. Eugenol 141-153 v-rel reticuloendotheliosis viral oncogene homolog A (avian) Mus musculus 93-97 32961187-1 2020 Steric and energetic characterizations were performed for the adsorption of eugenol (EG), vanillin and ethyl vanillin (EV) onto the mouse eugenol olfactory receptor mOR-EG by using a proposed model expression established by statistical physics methods. Eugenol 76-83 olfactory receptor family 5 subfamily D member 18 Mus musculus 165-171 32961187-1 2020 Steric and energetic characterizations were performed for the adsorption of eugenol (EG), vanillin and ethyl vanillin (EV) onto the mouse eugenol olfactory receptor mOR-EG by using a proposed model expression established by statistical physics methods. Eugenol 85-87 olfactory receptor family 5 subfamily D member 18 Mus musculus 165-171 33167484-4 2020 This study aimed to investigate the long-lasting analgesic effect of eugenol alone, as well as that of the combination of eugenol as a noxious-heat-sensitive transient receptor potential vanilloid 1 (TRPV1) channel agonist and a permanently charged sodium channel blocker (QX-314), on neuronal excitability in trigeminal ganglion (TG) neurons. Eugenol 122-129 transient receptor potential cation channel subfamily V member 1 Homo sapiens 158-198 33167484-4 2020 This study aimed to investigate the long-lasting analgesic effect of eugenol alone, as well as that of the combination of eugenol as a noxious-heat-sensitive transient receptor potential vanilloid 1 (TRPV1) channel agonist and a permanently charged sodium channel blocker (QX-314), on neuronal excitability in trigeminal ganglion (TG) neurons. Eugenol 122-129 transient receptor potential cation channel subfamily V member 1 Homo sapiens 200-205 33167484-11 2020 Taken together, our results suggest that, in contrast to the effect of eugenol alone, the combination of eugenol and QX-314 irreversibly and selectively blocked VGSCs in TG neurons expressing TRPV1. Eugenol 105-112 transient receptor potential cation channel subfamily V member 1 Homo sapiens 192-197 33204288-10 2020 The compounds-targets network analysis indicated that the 6 compounds, including quercetin, kaempferol, baicalein, wogonin, beta-sitosterol, and eugenol, were linked to >=10 target genes, and the 10 target genes (PTGS1, ESR1, AR, PGR, CHRM3, PPARG, CHRM2, BCL2, CASP3, and RELA) were core target genes in the network. Eugenol 145-152 cholinergic receptor muscarinic 2 Homo sapiens 249-254 33204288-10 2020 The compounds-targets network analysis indicated that the 6 compounds, including quercetin, kaempferol, baicalein, wogonin, beta-sitosterol, and eugenol, were linked to >=10 target genes, and the 10 target genes (PTGS1, ESR1, AR, PGR, CHRM3, PPARG, CHRM2, BCL2, CASP3, and RELA) were core target genes in the network. Eugenol 145-152 BCL2 apoptosis regulator Homo sapiens 256-260 33204288-10 2020 The compounds-targets network analysis indicated that the 6 compounds, including quercetin, kaempferol, baicalein, wogonin, beta-sitosterol, and eugenol, were linked to >=10 target genes, and the 10 target genes (PTGS1, ESR1, AR, PGR, CHRM3, PPARG, CHRM2, BCL2, CASP3, and RELA) were core target genes in the network. Eugenol 145-152 prostaglandin-endoperoxide synthase 1 Homo sapiens 213-218 33204288-10 2020 The compounds-targets network analysis indicated that the 6 compounds, including quercetin, kaempferol, baicalein, wogonin, beta-sitosterol, and eugenol, were linked to >=10 target genes, and the 10 target genes (PTGS1, ESR1, AR, PGR, CHRM3, PPARG, CHRM2, BCL2, CASP3, and RELA) were core target genes in the network. Eugenol 145-152 caspase 3 Homo sapiens 262-267 33204288-10 2020 The compounds-targets network analysis indicated that the 6 compounds, including quercetin, kaempferol, baicalein, wogonin, beta-sitosterol, and eugenol, were linked to >=10 target genes, and the 10 target genes (PTGS1, ESR1, AR, PGR, CHRM3, PPARG, CHRM2, BCL2, CASP3, and RELA) were core target genes in the network. Eugenol 145-152 estrogen receptor 1 Homo sapiens 220-224 33204288-10 2020 The compounds-targets network analysis indicated that the 6 compounds, including quercetin, kaempferol, baicalein, wogonin, beta-sitosterol, and eugenol, were linked to >=10 target genes, and the 10 target genes (PTGS1, ESR1, AR, PGR, CHRM3, PPARG, CHRM2, BCL2, CASP3, and RELA) were core target genes in the network. Eugenol 145-152 RELA proto-oncogene, NF-kB subunit Homo sapiens 273-277 33204288-10 2020 The compounds-targets network analysis indicated that the 6 compounds, including quercetin, kaempferol, baicalein, wogonin, beta-sitosterol, and eugenol, were linked to >=10 target genes, and the 10 target genes (PTGS1, ESR1, AR, PGR, CHRM3, PPARG, CHRM2, BCL2, CASP3, and RELA) were core target genes in the network. Eugenol 145-152 progesterone receptor Homo sapiens 230-233 33016967-5 2020 Furthermore, the use of recombinant TGF-beta and TGF-beta receptor inhibitor LY2109761 confirmed that the anti-metastatic activity of eugenol is partially and that of capsaicin is principally mediated through the TGF-beta signaling pathway. Eugenol 134-141 transforming growth factor alpha Homo sapiens 36-44 33204288-10 2020 The compounds-targets network analysis indicated that the 6 compounds, including quercetin, kaempferol, baicalein, wogonin, beta-sitosterol, and eugenol, were linked to >=10 target genes, and the 10 target genes (PTGS1, ESR1, AR, PGR, CHRM3, PPARG, CHRM2, BCL2, CASP3, and RELA) were core target genes in the network. Eugenol 145-152 cholinergic receptor muscarinic 3 Homo sapiens 235-240 33204288-10 2020 The compounds-targets network analysis indicated that the 6 compounds, including quercetin, kaempferol, baicalein, wogonin, beta-sitosterol, and eugenol, were linked to >=10 target genes, and the 10 target genes (PTGS1, ESR1, AR, PGR, CHRM3, PPARG, CHRM2, BCL2, CASP3, and RELA) were core target genes in the network. Eugenol 145-152 peroxisome proliferator activated receptor gamma Homo sapiens 242-247 33016967-5 2020 Furthermore, the use of recombinant TGF-beta and TGF-beta receptor inhibitor LY2109761 confirmed that the anti-metastatic activity of eugenol is partially and that of capsaicin is principally mediated through the TGF-beta signaling pathway. Eugenol 134-141 transforming growth factor alpha Homo sapiens 49-57 33016967-0 2020 Eugenol and capsaicin exhibit anti-metastatic activity via modulating TGF-beta signaling in gastric carcinoma. Eugenol 0-7 transforming growth factor alpha Homo sapiens 70-78 33032468-0 2022 Synthesis of eugenol-derived glucosides and evaluation of their ability in inhibiting the angiotensin converting enzyme. Eugenol 13-20 angiotensin I converting enzyme Homo sapiens 90-119 33032468-4 2022 A glucoside derived from eugenol, carrying a carboxylic group in the aglycone, was the most active of them (with an IC50 of 0.4 mM) and showed good binding energies in docking studies with ACE. Eugenol 25-32 angiotensin I converting enzyme Homo sapiens 189-192 33841528-10 2020 Finally, according on molecular docking analysis, lapatinib-ERBB2 and eugenol-ESR1 exhibited highest and lowest binding energy, respectively. Eugenol 70-77 estrogen receptor 1 Homo sapiens 78-82 32717226-13 2020 CONCLUSION: The obtained data demonstrate, for the first time, that dehydrodieugenol was more effective than eugenol in counteracting allergic airway inflammation in mice, especially its inhibition of the JNK, p38 and ERK1/2, components of MAPK pathway. Eugenol 77-84 mitogen-activated protein kinase 8 Mus musculus 205-208 32717226-13 2020 CONCLUSION: The obtained data demonstrate, for the first time, that dehydrodieugenol was more effective than eugenol in counteracting allergic airway inflammation in mice, especially its inhibition of the JNK, p38 and ERK1/2, components of MAPK pathway. Eugenol 77-84 mitogen-activated protein kinase 14 Mus musculus 210-213 32717226-13 2020 CONCLUSION: The obtained data demonstrate, for the first time, that dehydrodieugenol was more effective than eugenol in counteracting allergic airway inflammation in mice, especially its inhibition of the JNK, p38 and ERK1/2, components of MAPK pathway. Eugenol 77-84 mitogen-activated protein kinase 3 Mus musculus 218-224 33004893-8 2020 The results of bioinformatics reinforce studies that try to propose eugenol as an anti-inflammatory compound that can act in the COX-2/5-LOX pathways, replacing some NSAIDs in different diseases. Eugenol 68-75 mitochondrially encoded cytochrome c oxidase II Homo sapiens 129-134 33004893-8 2020 The results of bioinformatics reinforce studies that try to propose eugenol as an anti-inflammatory compound that can act in the COX-2/5-LOX pathways, replacing some NSAIDs in different diseases. Eugenol 68-75 arachidonate 5-lipoxygenase Homo sapiens 135-140 33832901-14 2020 It is concluded that the eugenol and its liposome-based nanocarriers exert anxiolytic activity by down-regulating NK1R protein expression in mice. Eugenol 25-32 tachykinin receptor 1 Mus musculus 114-118 32784818-0 2020 Rapid Non-Destructive Quantification of Eugenol in Curdlan Biofilms by Electronic Nose Combined with Gas Chromatography-Mass Spectrometry. Eugenol 40-47 gastrin Homo sapiens 101-104 32357811-3 2020 In thecase of MAO-B the rhamnetin, quercetin, piperine, eugenol,and umbelliferone exhibited highest dock score -10.57, -9.938, -9.445, - 8.757and 7.821respectively. Eugenol 56-63 monoamine oxidase B Homo sapiens 14-19 32735667-4 2020 The results showed that eugenol pretreatment significantly suppressed the LPS-stimulated interleukin-8 level and the mRNA abundance of tumor necrosis factor-alpha and restored the LPS-stimulated decrease of the mRNA abundance of tight junction proteins, such as ZO-1 and occludin, and the mRNA abundance of nutrient transporters, such as B0 1 system ASC sodium-dependent neutral amino acid exchanger 2, sodium-dependent glucose transporter 1, excitatory amino acid transporter 1, and peptide transporter 1. Eugenol 24-31 LOC100620730 Sus scrofa 89-102 32735667-4 2020 The results showed that eugenol pretreatment significantly suppressed the LPS-stimulated interleukin-8 level and the mRNA abundance of tumor necrosis factor-alpha and restored the LPS-stimulated decrease of the mRNA abundance of tight junction proteins, such as ZO-1 and occludin, and the mRNA abundance of nutrient transporters, such as B0 1 system ASC sodium-dependent neutral amino acid exchanger 2, sodium-dependent glucose transporter 1, excitatory amino acid transporter 1, and peptide transporter 1. Eugenol 24-31 tumor necrosis factor Sus scrofa 135-162 32735667-4 2020 The results showed that eugenol pretreatment significantly suppressed the LPS-stimulated interleukin-8 level and the mRNA abundance of tumor necrosis factor-alpha and restored the LPS-stimulated decrease of the mRNA abundance of tight junction proteins, such as ZO-1 and occludin, and the mRNA abundance of nutrient transporters, such as B0 1 system ASC sodium-dependent neutral amino acid exchanger 2, sodium-dependent glucose transporter 1, excitatory amino acid transporter 1, and peptide transporter 1. Eugenol 24-31 zonula occludens 1 Sus scrofa 262-266 32735667-4 2020 The results showed that eugenol pretreatment significantly suppressed the LPS-stimulated interleukin-8 level and the mRNA abundance of tumor necrosis factor-alpha and restored the LPS-stimulated decrease of the mRNA abundance of tight junction proteins, such as ZO-1 and occludin, and the mRNA abundance of nutrient transporters, such as B0 1 system ASC sodium-dependent neutral amino acid exchanger 2, sodium-dependent glucose transporter 1, excitatory amino acid transporter 1, and peptide transporter 1. Eugenol 24-31 occludin Sus scrofa 271-279 32735667-4 2020 The results showed that eugenol pretreatment significantly suppressed the LPS-stimulated interleukin-8 level and the mRNA abundance of tumor necrosis factor-alpha and restored the LPS-stimulated decrease of the mRNA abundance of tight junction proteins, such as ZO-1 and occludin, and the mRNA abundance of nutrient transporters, such as B0 1 system ASC sodium-dependent neutral amino acid exchanger 2, sodium-dependent glucose transporter 1, excitatory amino acid transporter 1, and peptide transporter 1. Eugenol 24-31 solute carrier family 1 member 3 Sus scrofa 403-478 32735667-5 2020 In addition, eugenol improved the expression and even redistribution of ZO-1 and tended to increase TEER value and maintained the barrier integrity. Eugenol 13-20 zonula occludens 1 Sus scrofa 72-76 32096903-0 2020 Aerobic exercise and eugenol supplementation ameliorated liver injury induced by chlorpyrifos via modulation acetylcholinesterase activation and antioxidant defense. Eugenol 21-28 acetylcholinesterase Rattus norvegicus 109-129 32447218-5 2020 Based on these results, Methotrexate and Eugenol encapsulated by Chitosan Nanoparticles, a significant decrease is observed in the serum level of MDA and FOXO3 protein expression in comparison to the control group. Eugenol 41-48 forkhead box O3 Rattus norvegicus 154-159 32357508-8 2020 Eugenol improved their self-renewal, proliferation and migration abilities and significantly increased their expression of c-Met, reduced expression 1 (Rex1), octamer-binding transcription factor 4 (Oct4) and nanog genes. Eugenol 0-7 MET proto-oncogene, receptor tyrosine kinase Rattus norvegicus 123-128 32357508-12 2020 In addition, we demonstrated that eugenol-preconditioning significantly enhanced the therapeutic abilities of the injected ASCs against CCl4-induced hepatic fibrosis. Eugenol 34-41 C-C motif chemokine ligand 4 Rattus norvegicus 136-140 31926151-6 2020 Significant downregulation of various CSC markers was also observed in vivo after eugenol treatment those are regulated by the intracellular status of beta-catenin. Eugenol 82-89 catenin beta 1 Homo sapiens 151-163 32153404-11 2020 Mechanically, eugenol promoted autophagy through regulating AMPK/mTOR/P70S6K signaling pathway in vivo and in vitro. Eugenol 14-21 mechanistic target of rapamycin kinase Mus musculus 65-69 32153404-11 2020 Mechanically, eugenol promoted autophagy through regulating AMPK/mTOR/P70S6K signaling pathway in vivo and in vitro. Eugenol 14-21 ribosomal protein S6 kinase, polypeptide 1 Mus musculus 70-76 32153404-12 2020 In conclusion, pretreatment with eugenol attenuated cerebral I/R injury by inducing autophagy via AMPK/mTOR/P70S6K signaling pathway. Eugenol 33-40 mechanistic target of rapamycin kinase Mus musculus 103-107 32153404-12 2020 In conclusion, pretreatment with eugenol attenuated cerebral I/R injury by inducing autophagy via AMPK/mTOR/P70S6K signaling pathway. Eugenol 33-40 ribosomal protein S6 kinase, polypeptide 1 Mus musculus 108-114 31926151-0 2020 Eugenol restricts Cancer Stem Cell population by degradation of beta-catenin via N-terminal Ser37 phosphorylation-an in vivo and in vitro experimental evaluation. Eugenol 0-7 catenin beta 1 Homo sapiens 64-76 31926151-3 2020 In this study, the effect of eugenol on CSC (Cancer Stem Cell) markers and its main regulator beta-catenin both in vivo Ehrlich Ascites Carcinoma (EAC) cell line and in vitro MCF-7 cell line was investigated with that of the untreated group. Eugenol 29-36 catenin (cadherin associated protein), beta 1 Mus musculus 94-106 31812013-0 2020 Could PCSK9 be a new therapeutic target of Eugenol? Eugenol 43-50 proprotein convertase subtilisin/kexin type 9 Homo sapiens 6-11 31812013-12 2020 Molecular docking revealed hydrophobic interactions between ligand eugenol and macromolecules PCSK9 and LOX1. Eugenol 67-74 proprotein convertase subtilisin/kexin type 9 Homo sapiens 94-99 31812013-12 2020 Molecular docking revealed hydrophobic interactions between ligand eugenol and macromolecules PCSK9 and LOX1. Eugenol 67-74 oxidized low density lipoprotein receptor 1 Homo sapiens 104-108 31812013-13 2020 Expression of both PCSK9 and LOX1 were significantly reduced by eugenol in Jurkat cells. Eugenol 64-71 proprotein convertase subtilisin/kexin type 9 Homo sapiens 19-24 31812013-13 2020 Expression of both PCSK9 and LOX1 were significantly reduced by eugenol in Jurkat cells. Eugenol 64-71 oxidized low density lipoprotein receptor 1 Homo sapiens 29-33 31812013-14 2020 To conclude, PCSK9 could therapeutically be targeted by eugenol in leukemia cells. Eugenol 56-63 proprotein convertase subtilisin/kexin type 9 Homo sapiens 13-18 32089784-10 2020 However, treatment with eugenol resulted in a significant reduction (p < 0.01) in the levels of nitric oxide (NO) and 8-hydroxy-2-deoxyguanosine (8-OHdG) levels, inhibited the activity of caspase-3, increased levels of Bcl-2 and significantly (p < 0.05) reduced levels of Bax protein, respectively, and also significantly (p < 0.05) increased the levels of SOD and GPx. Eugenol 24-31 caspase 3 Rattus norvegicus 191-200 32089784-10 2020 However, treatment with eugenol resulted in a significant reduction (p < 0.01) in the levels of nitric oxide (NO) and 8-hydroxy-2-deoxyguanosine (8-OHdG) levels, inhibited the activity of caspase-3, increased levels of Bcl-2 and significantly (p < 0.05) reduced levels of Bax protein, respectively, and also significantly (p < 0.05) increased the levels of SOD and GPx. Eugenol 24-31 BCL2, apoptosis regulator Rattus norvegicus 222-227 32089784-10 2020 However, treatment with eugenol resulted in a significant reduction (p < 0.01) in the levels of nitric oxide (NO) and 8-hydroxy-2-deoxyguanosine (8-OHdG) levels, inhibited the activity of caspase-3, increased levels of Bcl-2 and significantly (p < 0.05) reduced levels of Bax protein, respectively, and also significantly (p < 0.05) increased the levels of SOD and GPx. Eugenol 24-31 BCL2 associated X, apoptosis regulator Rattus norvegicus 278-281 31926151-8 2020 Notable downregulation of the enriched stemness of secondary mammosphere was detected by the significantly decreased percentage of CD44+/CD24-/low population after eugenol treatment along with their distorted morphology and smaller the number of spheres. Eugenol 164-171 CD44 molecule (Indian blood group) Homo sapiens 131-135 31926151-10 2020 Therefore, it can be concluded from the study that eugenol exerts its chemotherapeutic potential by impeding beta-catenin nuclear translocation thereby promoting its cytoplasmic degradation as a result stemness is being suppressed potentially even if in the enriched state. Eugenol 51-58 catenin beta 1 Homo sapiens 109-121 31952158-0 2020 AT-MSCs Antifibrotic Activity is Improved by Eugenol through Modulation of TGF-beta/Smad Signaling Pathway in Rats. Eugenol 45-52 transforming growth factor alpha Rattus norvegicus 75-83 30580605-6 2020 Among all derivatives, ST8 [Chloroeugenol (6-chloro, 2-methoxy-4-(prop-2-en-1-yl)-phenol)] exhibited most potent anti-inflammatory activity without any cytotoxic effect. Eugenol 53-88 Oncogene OVC (ovarian adenocarcinoma oncogene) Homo sapiens 23-26 32377265-4 2020 Here, we identified that the "olfactory three-needle" therapy and eugenol olfactory stimulation both reduced the deposition of beta-amyloid (Abeta) protein and increased the expression of synaptophysin (SYP), but only the "olfactory three-needle" enhanced the spatial learning and memory ability of SAMP8. Eugenol 66-73 amyloid beta (A4) precursor protein Mus musculus 127-147 32377265-4 2020 Here, we identified that the "olfactory three-needle" therapy and eugenol olfactory stimulation both reduced the deposition of beta-amyloid (Abeta) protein and increased the expression of synaptophysin (SYP), but only the "olfactory three-needle" enhanced the spatial learning and memory ability of SAMP8. Eugenol 66-73 synaptophysin Mus musculus 188-201 32377265-4 2020 Here, we identified that the "olfactory three-needle" therapy and eugenol olfactory stimulation both reduced the deposition of beta-amyloid (Abeta) protein and increased the expression of synaptophysin (SYP), but only the "olfactory three-needle" enhanced the spatial learning and memory ability of SAMP8. Eugenol 66-73 synaptophysin Mus musculus 203-206 31549464-3 2019 Now, the concept is investigated of the CSM for monitoring the structural evolution of nanoconfined supramolecular aggregates of eugenol guests with displacement of DMF inside the cavities of the flexible MOF, PUM168. Eugenol 129-136 lysine acetyltransferase 8 Homo sapiens 205-208 31811262-0 2019 Eugenol prevents fMLF-induced superoxide anion production in human neutrophils by inhibiting ERK1/2 signaling pathway and p47phox phosphorylation. Eugenol 0-7 mitogen-activated protein kinase 3 Homo sapiens 93-99 31811262-0 2019 Eugenol prevents fMLF-induced superoxide anion production in human neutrophils by inhibiting ERK1/2 signaling pathway and p47phox phosphorylation. Eugenol 0-7 neutrophil cytosolic factor 1 Homo sapiens 122-129 31811262-8 2019 Results showed that eugenol decreased the phosphorylation of p47phox onSer-345 and Ser-328, the translocation of p47phox to the membranesand the phosphorylation of Raf, MEK1/2 and ERK1/2 proteins. Eugenol 20-27 neutrophil cytosolic factor 1 Homo sapiens 61-68 31811262-8 2019 Results showed that eugenol decreased the phosphorylation of p47phox onSer-345 and Ser-328, the translocation of p47phox to the membranesand the phosphorylation of Raf, MEK1/2 and ERK1/2 proteins. Eugenol 20-27 neutrophil cytosolic factor 1 Homo sapiens 113-120 31811262-8 2019 Results showed that eugenol decreased the phosphorylation of p47phox onSer-345 and Ser-328, the translocation of p47phox to the membranesand the phosphorylation of Raf, MEK1/2 and ERK1/2 proteins. Eugenol 20-27 zinc fingers and homeoboxes 2 Homo sapiens 164-167 31811262-8 2019 Results showed that eugenol decreased the phosphorylation of p47phox onSer-345 and Ser-328, the translocation of p47phox to the membranesand the phosphorylation of Raf, MEK1/2 and ERK1/2 proteins. Eugenol 20-27 mitogen-activated protein kinase kinase 1 Homo sapiens 169-175 31811262-8 2019 Results showed that eugenol decreased the phosphorylation of p47phox onSer-345 and Ser-328, the translocation of p47phox to the membranesand the phosphorylation of Raf, MEK1/2 and ERK1/2 proteins. Eugenol 20-27 mitogen-activated protein kinase 3 Homo sapiens 180-186 31811262-9 2019 Taken together, our results suggest that eugenol inhibits the generation of superoxide anion by neutrophils via the inhibition of Raf/MEK/ERK1/2/p47phox-phosphorylation pathway. Eugenol 41-48 zinc fingers and homeoboxes 2 Homo sapiens 130-133 31811262-9 2019 Taken together, our results suggest that eugenol inhibits the generation of superoxide anion by neutrophils via the inhibition of Raf/MEK/ERK1/2/p47phox-phosphorylation pathway. Eugenol 41-48 mitogen-activated protein kinase kinase 7 Homo sapiens 134-137 31811262-9 2019 Taken together, our results suggest that eugenol inhibits the generation of superoxide anion by neutrophils via the inhibition of Raf/MEK/ERK1/2/p47phox-phosphorylation pathway. Eugenol 41-48 mitogen-activated protein kinase 3 Homo sapiens 138-144 31811262-9 2019 Taken together, our results suggest that eugenol inhibits the generation of superoxide anion by neutrophils via the inhibition of Raf/MEK/ERK1/2/p47phox-phosphorylation pathway. Eugenol 41-48 neutrophil cytosolic factor 1 Homo sapiens 145-152 31794909-4 2020 A cost estimate was calculated to produce 1 L of a solution containing a concentration of thymol and eugenol, combined or not, that could cause a tick mortality rate greater than 95 %. Eugenol 101-108 thrombopoietin Mus musculus 44-45 31794909-8 2020 The estimated costs for producing a solution of 1 L with efficacy greater than 95 % was $5.97 using only thymol (15 mg/mL), $ 5.93 using only eugenol (15 mg/mL), and $ 3.97 using thymol + eugenol (1:1 - 5,0 mg/mL). Eugenol 142-149 thrombopoietin Mus musculus 50-51 31794909-8 2020 The estimated costs for producing a solution of 1 L with efficacy greater than 95 % was $5.97 using only thymol (15 mg/mL), $ 5.93 using only eugenol (15 mg/mL), and $ 3.97 using thymol + eugenol (1:1 - 5,0 mg/mL). Eugenol 188-195 thrombopoietin Mus musculus 50-51 31794909-9 2020 In tests with MDP, the combination of thymol + eugenol resulted in a mortality rate higher than 95 % at concentration of 10 mg/mL for unfed and engorged larvae and nymphs. Eugenol 47-54 thrombopoietin Mus musculus 127-129 31684176-9 2019 Eugenol increased caspase-3 activity and the expression of Bax, cytochrome c (Cyt-c), caspase-3, and caspase-9 and decreased the expression of B-cell lymphoma (Bcl)-2, cyclooxygenase-2 (Cox-2), and interleukin-1 beta (IL-1beta) indicating that eugenol mainly induced cell death by apoptosis. Eugenol 0-7 caspase 3 Homo sapiens 18-27 31684176-9 2019 Eugenol increased caspase-3 activity and the expression of Bax, cytochrome c (Cyt-c), caspase-3, and caspase-9 and decreased the expression of B-cell lymphoma (Bcl)-2, cyclooxygenase-2 (Cox-2), and interleukin-1 beta (IL-1beta) indicating that eugenol mainly induced cell death by apoptosis. Eugenol 0-7 BCL2 associated X, apoptosis regulator Homo sapiens 59-62 31684176-9 2019 Eugenol increased caspase-3 activity and the expression of Bax, cytochrome c (Cyt-c), caspase-3, and caspase-9 and decreased the expression of B-cell lymphoma (Bcl)-2, cyclooxygenase-2 (Cox-2), and interleukin-1 beta (IL-1beta) indicating that eugenol mainly induced cell death by apoptosis. Eugenol 0-7 cytochrome c, somatic Homo sapiens 64-76 31684176-9 2019 Eugenol increased caspase-3 activity and the expression of Bax, cytochrome c (Cyt-c), caspase-3, and caspase-9 and decreased the expression of B-cell lymphoma (Bcl)-2, cyclooxygenase-2 (Cox-2), and interleukin-1 beta (IL-1beta) indicating that eugenol mainly induced cell death by apoptosis. Eugenol 0-7 cytochrome c, somatic Homo sapiens 78-83 31684176-9 2019 Eugenol increased caspase-3 activity and the expression of Bax, cytochrome c (Cyt-c), caspase-3, and caspase-9 and decreased the expression of B-cell lymphoma (Bcl)-2, cyclooxygenase-2 (Cox-2), and interleukin-1 beta (IL-1beta) indicating that eugenol mainly induced cell death by apoptosis. Eugenol 0-7 caspase 3 Homo sapiens 86-95 31684176-9 2019 Eugenol increased caspase-3 activity and the expression of Bax, cytochrome c (Cyt-c), caspase-3, and caspase-9 and decreased the expression of B-cell lymphoma (Bcl)-2, cyclooxygenase-2 (Cox-2), and interleukin-1 beta (IL-1beta) indicating that eugenol mainly induced cell death by apoptosis. Eugenol 0-7 caspase 9 Homo sapiens 101-110 31684176-9 2019 Eugenol increased caspase-3 activity and the expression of Bax, cytochrome c (Cyt-c), caspase-3, and caspase-9 and decreased the expression of B-cell lymphoma (Bcl)-2, cyclooxygenase-2 (Cox-2), and interleukin-1 beta (IL-1beta) indicating that eugenol mainly induced cell death by apoptosis. Eugenol 0-7 BCL2 apoptosis regulator Homo sapiens 143-166 31684176-9 2019 Eugenol increased caspase-3 activity and the expression of Bax, cytochrome c (Cyt-c), caspase-3, and caspase-9 and decreased the expression of B-cell lymphoma (Bcl)-2, cyclooxygenase-2 (Cox-2), and interleukin-1 beta (IL-1beta) indicating that eugenol mainly induced cell death by apoptosis. Eugenol 0-7 prostaglandin-endoperoxide synthase 2 Homo sapiens 168-184 31684176-9 2019 Eugenol increased caspase-3 activity and the expression of Bax, cytochrome c (Cyt-c), caspase-3, and caspase-9 and decreased the expression of B-cell lymphoma (Bcl)-2, cyclooxygenase-2 (Cox-2), and interleukin-1 beta (IL-1beta) indicating that eugenol mainly induced cell death by apoptosis. Eugenol 0-7 prostaglandin-endoperoxide synthase 2 Homo sapiens 186-191 31684176-9 2019 Eugenol increased caspase-3 activity and the expression of Bax, cytochrome c (Cyt-c), caspase-3, and caspase-9 and decreased the expression of B-cell lymphoma (Bcl)-2, cyclooxygenase-2 (Cox-2), and interleukin-1 beta (IL-1beta) indicating that eugenol mainly induced cell death by apoptosis. Eugenol 0-7 interleukin 1 beta Homo sapiens 198-216 31684176-9 2019 Eugenol increased caspase-3 activity and the expression of Bax, cytochrome c (Cyt-c), caspase-3, and caspase-9 and decreased the expression of B-cell lymphoma (Bcl)-2, cyclooxygenase-2 (Cox-2), and interleukin-1 beta (IL-1beta) indicating that eugenol mainly induced cell death by apoptosis. Eugenol 0-7 interleukin 1 beta Homo sapiens 218-226 31684176-9 2019 Eugenol increased caspase-3 activity and the expression of Bax, cytochrome c (Cyt-c), caspase-3, and caspase-9 and decreased the expression of B-cell lymphoma (Bcl)-2, cyclooxygenase-2 (Cox-2), and interleukin-1 beta (IL-1beta) indicating that eugenol mainly induced cell death by apoptosis. Eugenol 244-251 caspase 3 Homo sapiens 18-27 31570745-0 2019 Eugenol Reduces LDL Cholesterol and Hepatic Steatosis in Hypercholesterolemic Rats by Modulating TRPV1 Receptor. Eugenol 0-7 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 97-102 31431258-7 2019 Formation of heat-induced insulin aggregation can be effectively inhibited by 1 mM eugenol and epinephrine and both compounds were found to preserve insulin activity to a considerable extent. Eugenol 83-90 insulin Homo sapiens 26-33 31570745-4 2019 Eugenol also decreased steatosis and hepatic inflammation in liver sections, decreased hepatomegaly, and the hepatic marker enzymes alanine aminotransferase (ALT) and alkaline phosphatase (ALP) activity and increased the antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT) activity in hypercholesterolemic rats. Eugenol 0-7 catalase Rattus norvegicus 272-280 31570745-4 2019 Eugenol also decreased steatosis and hepatic inflammation in liver sections, decreased hepatomegaly, and the hepatic marker enzymes alanine aminotransferase (ALT) and alkaline phosphatase (ALP) activity and increased the antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT) activity in hypercholesterolemic rats. Eugenol 0-7 catalase Rattus norvegicus 282-285 31570745-5 2019 Eugenol did not inhibit hepatic 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase but caused down-regulation of transient receptor potential vanilloid (TRPV1) channels in the liver. Eugenol 0-7 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 154-159 31570745-6 2019 Docking simulation using fast, rigid exhaustive docking (FRED) software indicated a tail-up/head-down interaction of eugenol with TRPV1 channel. Eugenol 117-124 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 130-135 31570745-7 2019 Data indicate that eugenol does not inhibit HMG-CoA reductase but rather induces its action by interaction with TRPV1 channels. Eugenol 19-26 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 112-117 31470883-0 2019 Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway. Eugenol 41-48 hes family bHLH transcription factor 1 Homo sapiens 101-105 31470883-11 2019 Additionally, while increase in the level of Hes1 promoted stemness and enhanced resistance to cisplatin, cisplatin/eugenol cotreatment inhibited the Notch-Hes1 pathway and strongly downregulated the drug resistance ABC transporter genes. Eugenol 116-123 hes family bHLH transcription factor 1 Mus musculus 156-160 31470883-13 2019 CONCLUSIONS: These results indicate that cisplatin/eugenol sequential combination could be of great therapeutic value for ovarian cancer patients through targeting the Notch-Hes1 pathway and the consequent elimination of the resistant cancer stem cells. Eugenol 51-58 hes family bHLH transcription factor 1 Homo sapiens 174-178 31155295-4 2019 In this study, the effect of olfactory stimulation (eugenol, EUG) on ISF flow in hippocampus and its association with aquaporin 4 (Aqp4) had been investigated. Eugenol 52-59 aquaporin 4 Rattus norvegicus 118-129 31155295-4 2019 In this study, the effect of olfactory stimulation (eugenol, EUG) on ISF flow in hippocampus and its association with aquaporin 4 (Aqp4) had been investigated. Eugenol 52-59 aquaporin 4 Rattus norvegicus 131-135 30796902-12 2019 Molecular docking results indicates interaction of cinnamaldehyde and eugenol with key residues of TNF-alpha and IL-6. Eugenol 70-77 tumor necrosis factor Homo sapiens 99-108 30796902-12 2019 Molecular docking results indicates interaction of cinnamaldehyde and eugenol with key residues of TNF-alpha and IL-6. Eugenol 70-77 interleukin 6 Homo sapiens 113-117 30737653-10 2019 Additionally, eugenol attenuated scopolamine-induced hippocampal cholinergic dysfunction (decrease in acetylcholine level, increase in acetylcholinesterase activity, and decrease in density and affinity of M1 and total muscarinic receptor), glutamate neurotoxicity (increase in levels of glutamate, calcium, calcium-dependent calpain-2, and brain-derived neurotropic factor), and mitochondrial dysfunction (decrease in formazan produced, membrane potential, and oxidative stress) in rats. Eugenol 14-21 acetylcholinesterase Rattus norvegicus 135-155 30724183-1 2019 The oxidation of eugenol, isoeugenol and vanillin natural antioxidants catalyzed by the soybean peroxidase enzyme was studied using uv-vis spectroscopy. Eugenol 17-24 peroxidase Glycine max 96-106 30932261-0 2019 Eugenol inhibits non-small cell lung cancer by repressing expression of NF-kappaB-regulated TRIM59. Eugenol 0-7 nuclear factor kappa B subunit 1 Homo sapiens 72-81 30932261-0 2019 Eugenol inhibits non-small cell lung cancer by repressing expression of NF-kappaB-regulated TRIM59. Eugenol 0-7 tripartite motif containing 59 Homo sapiens 92-98 30932261-9 2019 Mechanistically, eugenol suppressed p65 expression, which subsequently decreased TRIM59 expression. Eugenol 17-24 RELA proto-oncogene, NF-kB subunit Homo sapiens 36-39 30932261-9 2019 Mechanistically, eugenol suppressed p65 expression, which subsequently decreased TRIM59 expression. Eugenol 17-24 tripartite motif containing 59 Homo sapiens 81-87 30932261-10 2019 TRIM59 deficiency fully recapitulated the anti-tumoral phenotype elicited by eugenol. Eugenol 77-84 tripartite motif containing 59 Homo sapiens 0-6 30932261-11 2019 Ectopic expression of TRIM59 completely abolished the tumor suppressive effect of eugenol, which underlined the predominant role of TRIM59 in mediating the signaling downstream of eugenol treatment. Eugenol 82-89 tripartite motif containing 59 Homo sapiens 22-28 30932261-11 2019 Ectopic expression of TRIM59 completely abolished the tumor suppressive effect of eugenol, which underlined the predominant role of TRIM59 in mediating the signaling downstream of eugenol treatment. Eugenol 82-89 tripartite motif containing 59 Homo sapiens 132-138 30932261-11 2019 Ectopic expression of TRIM59 completely abolished the tumor suppressive effect of eugenol, which underlined the predominant role of TRIM59 in mediating the signaling downstream of eugenol treatment. Eugenol 180-187 tripartite motif containing 59 Homo sapiens 22-28 30932261-11 2019 Ectopic expression of TRIM59 completely abolished the tumor suppressive effect of eugenol, which underlined the predominant role of TRIM59 in mediating the signaling downstream of eugenol treatment. Eugenol 180-187 tripartite motif containing 59 Homo sapiens 132-138 30932261-12 2019 Eugenol inhibited NSCLC via repression NF-kappaB-TRIM59 pathway. Eugenol 0-7 nuclear factor kappa B subunit 1 Homo sapiens 39-48 30932261-12 2019 Eugenol inhibited NSCLC via repression NF-kappaB-TRIM59 pathway. Eugenol 0-7 tripartite motif containing 59 Homo sapiens 49-55 30452970-2 2019 Therefore, the objective of the current study was to elucidate the in vivo molecular mechanism underlying the hepatic preventive relevance of eugenol (EUG) and telmisartan (TEL) through iNOS pathway modulation against carbon tetrachloride (CCl4)-induced hepatic injury. Eugenol 142-149 nitric oxide synthase 2 Rattus norvegicus 186-190 30668414-16 2019 The levels of TNF-alpha, IL-6 and IL-10 were also ameliorated by cinnamaldehyde and eugenol treatment. Eugenol 84-91 tumor necrosis factor Rattus norvegicus 14-23 30668414-16 2019 The levels of TNF-alpha, IL-6 and IL-10 were also ameliorated by cinnamaldehyde and eugenol treatment. Eugenol 84-91 interleukin 6 Rattus norvegicus 25-29 30668414-16 2019 The levels of TNF-alpha, IL-6 and IL-10 were also ameliorated by cinnamaldehyde and eugenol treatment. Eugenol 84-91 interleukin 10 Rattus norvegicus 34-39 30878086-8 2019 Furthermore, the moderate inhibitory activities of eugenol against mites P450 and AChE were demonstrated. Eugenol 51-58 acetylcholinesterase (Cartwright blood group) Homo sapiens 82-86 30471518-2 2019 Although plant-derived compounds exhibiting antinociception (such as eugenol, carvacrol and thymol) activate TRPA1 channels to enhance spontaneous excitatory transmission while hyperpolarizing membranes in SG neurons without TRPA1 activation, specific chemical moieties involved in synaptic modulation are unknown. Eugenol 69-76 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 109-114 30366089-4 2019 We determined the optimal concentrations of MS-222 (100 mg L-1) and eugenol (20 mg L-1) by dose selection. Eugenol 68-75 L1 cell adhesion molecule Mus musculus 83-86 30448265-7 2019 RESULTS: The anti-diabetic effects of eugenol were demonstrated by the significant reduction in the levels of serum glucose, triglyceride, cholesterol, Low-density lipoprotein, malondialdehyde and interleukin-6 in the treated group compared to the diabetic group. Eugenol 38-45 interleukin 6 Rattus norvegicus 197-210 30452970-2 2019 Therefore, the objective of the current study was to elucidate the in vivo molecular mechanism underlying the hepatic preventive relevance of eugenol (EUG) and telmisartan (TEL) through iNOS pathway modulation against carbon tetrachloride (CCl4)-induced hepatic injury. Eugenol 142-149 C-C motif chemokine ligand 4 Rattus norvegicus 240-244 30448265-10 2019 The skeletal muscle protein contents of GLUT4 and AMPK were higher in the eugenol treated group than in the diabetic control group. Eugenol 74-81 solute carrier family 2 member 4 Rattus norvegicus 40-45 30518369-0 2018 Anti-metastatic and anti-proliferative activity of eugenol against triple negative and HER2 positive breast cancer cells. Eugenol 51-58 erb-b2 receptor tyrosine kinase 2 Homo sapiens 87-91 30448265-12 2019 Moreover, eugenol facilitates insulin sensitivity and stimulate skeletal muscle glucose uptake via activation of the GLUT4-AMPK signaling pathway. Eugenol 10-17 solute carrier family 2 member 4 Rattus norvegicus 117-122 30452970-0 2019 Modulation of inducible nitric oxide synthase pathway by eugenol and telmisartan in carbon tetrachloride-induced liver injury in rats. Eugenol 57-64 nitric oxide synthase 2 Rattus norvegicus 14-45 29997055-2 2019 In lipopolysaccharide (LPS)-stimulated macrophages, eugenol reduces cyclooxygenase-2 expression, NF-kappaB activation, and inflammatory mediators. Eugenol 52-59 prostaglandin-endoperoxide synthase 2 Mus musculus 68-84 29997055-7 2019 Furthermore, eugenol (150 mg/kg) was able to inhibit the release of inflammatory cytokines (TNF-alpha, IL-1beta and IL-6), NADPH oxidase activity, as well as antioxidant enzymes activity (superoxide dismutase, catalase and glutathione peroxidase). Eugenol 13-20 tumor necrosis factor Mus musculus 92-101 29997055-7 2019 Furthermore, eugenol (150 mg/kg) was able to inhibit the release of inflammatory cytokines (TNF-alpha, IL-1beta and IL-6), NADPH oxidase activity, as well as antioxidant enzymes activity (superoxide dismutase, catalase and glutathione peroxidase). Eugenol 13-20 interleukin 1 beta Mus musculus 103-111 29997055-7 2019 Furthermore, eugenol (150 mg/kg) was able to inhibit the release of inflammatory cytokines (TNF-alpha, IL-1beta and IL-6), NADPH oxidase activity, as well as antioxidant enzymes activity (superoxide dismutase, catalase and glutathione peroxidase). Eugenol 13-20 interleukin 6 Mus musculus 116-120 29997055-7 2019 Furthermore, eugenol (150 mg/kg) was able to inhibit the release of inflammatory cytokines (TNF-alpha, IL-1beta and IL-6), NADPH oxidase activity, as well as antioxidant enzymes activity (superoxide dismutase, catalase and glutathione peroxidase). Eugenol 13-20 catalase Mus musculus 210-218 30518369-5 2018 Annexin V analysis with flow cytometry was used to detect the effect of eugenol on cell death. Eugenol 72-79 annexin A5 Homo sapiens 0-9 30518369-7 2018 Real-time PCR was used to study the effect of eugenol on the expression of anti-metastatic genes such as MMP2, MMP9, and TIMP-1, and genes involved in apoptosis including Caspase3, Caspase7, and Caspase9. Eugenol 46-53 matrix metallopeptidase 2 Homo sapiens 105-109 30518369-7 2018 Real-time PCR was used to study the effect of eugenol on the expression of anti-metastatic genes such as MMP2, MMP9, and TIMP-1, and genes involved in apoptosis including Caspase3, Caspase7, and Caspase9. Eugenol 46-53 matrix metallopeptidase 9 Homo sapiens 111-115 30518369-7 2018 Real-time PCR was used to study the effect of eugenol on the expression of anti-metastatic genes such as MMP2, MMP9, and TIMP-1, and genes involved in apoptosis including Caspase3, Caspase7, and Caspase9. Eugenol 46-53 TIMP metallopeptidase inhibitor 1 Homo sapiens 121-127 30518369-7 2018 Real-time PCR was used to study the effect of eugenol on the expression of anti-metastatic genes such as MMP2, MMP9, and TIMP-1, and genes involved in apoptosis including Caspase3, Caspase7, and Caspase9. Eugenol 46-53 caspase 9 Homo sapiens 195-203 30518369-8 2018 RESULTS: Treatment with 4 muM and 8 muM eugenol for 48 h significantly inhibited cell proliferation of MDA-MB-231, with an inhibition rate of 76.4%, whereas 5 muM and 10 muM of eugenol for 48 h significantly inhibited the proliferation of SK-BR-3 cells with an inhibition rate of 68.1%. Eugenol 40-47 latexin Homo sapiens 36-39 30518369-8 2018 RESULTS: Treatment with 4 muM and 8 muM eugenol for 48 h significantly inhibited cell proliferation of MDA-MB-231, with an inhibition rate of 76.4%, whereas 5 muM and 10 muM of eugenol for 48 h significantly inhibited the proliferation of SK-BR-3 cells with an inhibition rate of 68.1%. Eugenol 40-47 latexin Homo sapiens 36-39 30518369-8 2018 RESULTS: Treatment with 4 muM and 8 muM eugenol for 48 h significantly inhibited cell proliferation of MDA-MB-231, with an inhibition rate of 76.4%, whereas 5 muM and 10 muM of eugenol for 48 h significantly inhibited the proliferation of SK-BR-3 cells with an inhibition rate of 68.1%. Eugenol 40-47 latexin Homo sapiens 36-39 30518369-8 2018 RESULTS: Treatment with 4 muM and 8 muM eugenol for 48 h significantly inhibited cell proliferation of MDA-MB-231, with an inhibition rate of 76.4%, whereas 5 muM and 10 muM of eugenol for 48 h significantly inhibited the proliferation of SK-BR-3 cells with an inhibition rate of 68.1%. Eugenol 177-184 latexin Homo sapiens 26-29 30518369-9 2018 Eugenol-treated cells showed significantly decreased MMP2 and MMP9 expression and an insignificant increase in TIMP1 expression in HER2 positive and triple negative breast cancer cells. Eugenol 0-7 matrix metallopeptidase 2 Homo sapiens 53-57 30518369-9 2018 Eugenol-treated cells showed significantly decreased MMP2 and MMP9 expression and an insignificant increase in TIMP1 expression in HER2 positive and triple negative breast cancer cells. Eugenol 0-7 matrix metallopeptidase 9 Homo sapiens 62-66 30518369-9 2018 Eugenol-treated cells showed significantly decreased MMP2 and MMP9 expression and an insignificant increase in TIMP1 expression in HER2 positive and triple negative breast cancer cells. Eugenol 0-7 TIMP metallopeptidase inhibitor 1 Homo sapiens 111-116 30518369-9 2018 Eugenol-treated cells showed significantly decreased MMP2 and MMP9 expression and an insignificant increase in TIMP1 expression in HER2 positive and triple negative breast cancer cells. Eugenol 0-7 erb-b2 receptor tyrosine kinase 2 Homo sapiens 131-135 30518369-10 2018 Eugenol significantly increased the proportion of MDA-MB-231 and SK-BR-3 cells in late apoptosis and increased the expression of Caspase3, Caspase7, and Caspase9. Eugenol 0-7 caspase 3 Homo sapiens 129-137 30518369-10 2018 Eugenol significantly increased the proportion of MDA-MB-231 and SK-BR-3 cells in late apoptosis and increased the expression of Caspase3, Caspase7, and Caspase9. Eugenol 0-7 caspase 7 Homo sapiens 139-147 30518369-10 2018 Eugenol significantly increased the proportion of MDA-MB-231 and SK-BR-3 cells in late apoptosis and increased the expression of Caspase3, Caspase7, and Caspase9. Eugenol 0-7 caspase 9 Homo sapiens 153-161 30233696-8 2018 Western blot analysis demonstrated that the protein expression of cleaved Poly (ADP-ribose) polymerase 1, BAX and active caspase-3 in the eugenol group were significantly decreased, while B-cell lymphoma 2 expression was significantly increased compared with the control group (P<0.05). Eugenol 138-145 poly (ADP-ribose) polymerase 1 Rattus norvegicus 74-104 30413989-6 2018 CONCLUSIONS: The synthesized eugenol based ester of caffeic acid compound 7 exhibited MAO-A inhibition with IC50 values of 07.03 +- 0.022 microM with good selectivity (SI = 0.291) towards MAO-A. Eugenol 29-36 monoamine oxidase A Homo sapiens 86-91 30413989-6 2018 CONCLUSIONS: The synthesized eugenol based ester of caffeic acid compound 7 exhibited MAO-A inhibition with IC50 values of 07.03 +- 0.022 microM with good selectivity (SI = 0.291) towards MAO-A. Eugenol 29-36 monoamine oxidase A Homo sapiens 188-193 30119237-0 2018 Modulatory effect of eugenol on arginase, nucleotidase, and adenosine deaminase activities of platelets in a carrageenan-induced arthritis rat model: A possible anti-arthritic mechanism of eugenol. Eugenol 21-28 adenosine deaminase Rattus norvegicus 60-79 30233696-7 2018 Compared with the control group, the eugenol treatment significantly reduced the myocardial malondialdehyde content, serum cardiac troponin I, creatine kinase-MB, tumor necresis factor-alpha and interleukin-6 levels (P<0.05) and significantly alleviated myocardial injury. Eugenol 37-44 troponin I3, cardiac type Rattus norvegicus 123-141 30233696-8 2018 Western blot analysis demonstrated that the protein expression of cleaved Poly (ADP-ribose) polymerase 1, BAX and active caspase-3 in the eugenol group were significantly decreased, while B-cell lymphoma 2 expression was significantly increased compared with the control group (P<0.05). Eugenol 138-145 BCL2 associated X, apoptosis regulator Rattus norvegicus 106-109 30233696-7 2018 Compared with the control group, the eugenol treatment significantly reduced the myocardial malondialdehyde content, serum cardiac troponin I, creatine kinase-MB, tumor necresis factor-alpha and interleukin-6 levels (P<0.05) and significantly alleviated myocardial injury. Eugenol 37-44 interleukin 6 Rattus norvegicus 195-208 30233696-8 2018 Western blot analysis demonstrated that the protein expression of cleaved Poly (ADP-ribose) polymerase 1, BAX and active caspase-3 in the eugenol group were significantly decreased, while B-cell lymphoma 2 expression was significantly increased compared with the control group (P<0.05). Eugenol 138-145 caspase 3 Rattus norvegicus 121-130 29277003-11 2018 The wound healing assay and gene expression analysis demonstrated that Eugenol promoted the migratory potential of MSCs through up-regulation of c-Met. Eugenol 71-78 met proto-oncogene Mus musculus 145-150 29126931-5 2018 Allylguaiacol increased the scavenging activities of free radicals 2,2"-azino-bis-(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) and 2,2-diphenyl-1-picrylhydrazyl (DPPH), and enhanced the expression of antioxidant enzymes manganese superoxide dismutase (MnSOD) and catalase. Eugenol 0-13 superoxide dismutase 2, mitochondrial Mus musculus 224-254 29126931-5 2018 Allylguaiacol increased the scavenging activities of free radicals 2,2"-azino-bis-(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) and 2,2-diphenyl-1-picrylhydrazyl (DPPH), and enhanced the expression of antioxidant enzymes manganese superoxide dismutase (MnSOD) and catalase. Eugenol 0-13 superoxide dismutase 2, mitochondrial Mus musculus 256-261 29126931-6 2018 In addition, allylguaiacol inhibited H2O2-induced damage of HT22 with increasing production of brain-derived neurotrophic factor (BDNF), phosphorylation of phosphoinositide 3-kinase (PI3K), and cyclic AMP response element-binding protein (CREB). Eugenol 13-26 brain derived neurotrophic factor Mus musculus 95-128 29126931-6 2018 In addition, allylguaiacol inhibited H2O2-induced damage of HT22 with increasing production of brain-derived neurotrophic factor (BDNF), phosphorylation of phosphoinositide 3-kinase (PI3K), and cyclic AMP response element-binding protein (CREB). Eugenol 13-26 brain derived neurotrophic factor Mus musculus 130-134 29126931-6 2018 In addition, allylguaiacol inhibited H2O2-induced damage of HT22 with increasing production of brain-derived neurotrophic factor (BDNF), phosphorylation of phosphoinositide 3-kinase (PI3K), and cyclic AMP response element-binding protein (CREB). Eugenol 13-26 phosphoinositide-3-kinase regulatory subunit 1 Mus musculus 156-181 29126931-6 2018 In addition, allylguaiacol inhibited H2O2-induced damage of HT22 with increasing production of brain-derived neurotrophic factor (BDNF), phosphorylation of phosphoinositide 3-kinase (PI3K), and cyclic AMP response element-binding protein (CREB). Eugenol 13-26 cAMP responsive element binding protein 1 Mus musculus 194-237 29126931-6 2018 In addition, allylguaiacol inhibited H2O2-induced damage of HT22 with increasing production of brain-derived neurotrophic factor (BDNF), phosphorylation of phosphoinositide 3-kinase (PI3K), and cyclic AMP response element-binding protein (CREB). Eugenol 13-26 cAMP responsive element binding protein 1 Mus musculus 239-243 29126931-9 2018 In addition, allylguaiacol significantly increased the expression of TrkA and B in the hippocampus from scopolamine-treated mice. Eugenol 13-26 neurotrophic tyrosine kinase, receptor, type 1 Mus musculus 69-73 29126931-10 2018 Taken together, our findings suggest that allylguaiacol exerts a neuroprotective effect through the antioxidant activation and protein regulation of NF-kappaB p65 and DAXX-related signaling. Eugenol 42-55 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 149-158 30188702-8 2018 Eugenol stimulated endogenous H2S (hydrogen sulfide) generation by upregulating the expression of BrLCD ( l-cysteine desulfhydrase) and BrDCD ( d-cysteine desulfhydrase) as well as their enzymatic activities in CdCl2-treated root. Eugenol 0-7 L-cysteine desulfhydrase Brassica rapa 106-130 29126931-10 2018 Taken together, our findings suggest that allylguaiacol exerts a neuroprotective effect through the antioxidant activation and protein regulation of NF-kappaB p65 and DAXX-related signaling. Eugenol 42-55 v-rel reticuloendotheliosis viral oncogene homolog A (avian) Mus musculus 159-162 29126931-10 2018 Taken together, our findings suggest that allylguaiacol exerts a neuroprotective effect through the antioxidant activation and protein regulation of NF-kappaB p65 and DAXX-related signaling. Eugenol 42-55 Fas death domain-associated protein Mus musculus 167-171 29156519-12 2018 Alveolar bone of OVX animals showed augmented expression of RANKL, OPG and inflammatory cytokines, which were corrected by eugenol treatment. Eugenol 123-130 TNF superfamily member 11 Rattus norvegicus 60-65 29156519-12 2018 Alveolar bone of OVX animals showed augmented expression of RANKL, OPG and inflammatory cytokines, which were corrected by eugenol treatment. Eugenol 123-130 TNF receptor superfamily member 11B Rattus norvegicus 67-70 29277003-12 2018 Moreover, Eugenol has enhanced the proliferation of MSCs via over-expression of Sox2, Rex1 and Tex10. Eugenol 10-17 SRY (sex determining region Y)-box 2 Mus musculus 80-84 29277003-12 2018 Moreover, Eugenol has enhanced the proliferation of MSCs via over-expression of Sox2, Rex1 and Tex10. Eugenol 10-17 REX1, RNA exonuclease 1 Mus musculus 86-90 29277003-12 2018 Moreover, Eugenol has enhanced the proliferation of MSCs via over-expression of Sox2, Rex1 and Tex10. Eugenol 10-17 testis expressed gene 10 Mus musculus 95-100 27984137-0 2017 Novel eugenol derivatives: Potent acetylcholinesterase and carbonic anhydrase inhibitors. Eugenol 6-13 acetylcholinesterase (Cartwright blood group) Homo sapiens 34-54 29024500-10 2018 Finally, the expression levels of phosphate-Akt and MMP-2 in lung cancer cells were reduced after treatment with eugenol. Eugenol 113-120 AKT serine/threonine kinase 1 Homo sapiens 44-47 29024500-10 2018 Finally, the expression levels of phosphate-Akt and MMP-2 in lung cancer cells were reduced after treatment with eugenol. Eugenol 113-120 matrix metallopeptidase 2 Homo sapiens 52-57 29024500-11 2018 CONCLUSION: Our results demonstrated the tumor suppressive roles of eugenol on lung cancer cell proliferation, migration, and invasion partially through the PI3K/Akt pathway and MMP activity in vitro. Eugenol 68-75 AKT serine/threonine kinase 1 Homo sapiens 162-165 29024500-11 2018 CONCLUSION: Our results demonstrated the tumor suppressive roles of eugenol on lung cancer cell proliferation, migration, and invasion partially through the PI3K/Akt pathway and MMP activity in vitro. Eugenol 68-75 matrix metallopeptidase 2 Homo sapiens 178-181 28852438-10 2017 Neuronal numbers were preserved by eugenol treatment in epileptic animals, while eugenol alone reduced the number by itself in all hippocampal sub-regions including DG, CA3, and CA1. Eugenol 81-88 carbonic anhydrase 1 Rattus norvegicus 178-181 28358602-0 2017 In Vitro Incorporation of Radioiodinated Eugenol on Adenocarcinoma Cell Lines (Caco2, MCF7, and PC3). Eugenol 41-48 chromobox 8 Homo sapiens 96-99 28145454-3 2017 We find that both spontaneous and seed-induced aggregation processes of insulin and serum albumin (BSA) are significantly suppressed in the presence of eugenol. Eugenol 152-159 insulin Homo sapiens 72-79 28145454-4 2017 Isothermal titration calorimetric data predict a single binding site for eugenol-insulin complex confirming the affinity of eugenol for native soluble insulin species. Eugenol 73-80 insulin Homo sapiens 81-88 28145454-4 2017 Isothermal titration calorimetric data predict a single binding site for eugenol-insulin complex confirming the affinity of eugenol for native soluble insulin species. Eugenol 73-80 insulin Homo sapiens 151-158 28145454-4 2017 Isothermal titration calorimetric data predict a single binding site for eugenol-insulin complex confirming the affinity of eugenol for native soluble insulin species. Eugenol 124-131 insulin Homo sapiens 81-88 28145454-4 2017 Isothermal titration calorimetric data predict a single binding site for eugenol-insulin complex confirming the affinity of eugenol for native soluble insulin species. Eugenol 124-131 insulin Homo sapiens 151-158 29191726-6 2018 We identified AhR partial agonists (carvacrol, ligustilide, eugenol, eugenyl acetate, thymol, ar-turmerone) and antagonists (trans-anethole, butylidine phtalide, R/S-carvones, p-cymene), which account for AhR-mediated activities of EOs of fennel, anise, star anise, caraway, spearmint, tarragon, cloves, dill, turmeric, lovage, thyme and oregano. Eugenol 60-67 aryl hydrocarbon receptor Homo sapiens 14-17 29018241-0 2017 Eugenol inhibits oxidative phosphorylation and fatty acid oxidation via downregulation of c-Myc/PGC-1beta/ERRalpha signaling pathway in MCF10A-ras cells. Eugenol 0-7 MYC proto-oncogene, bHLH transcription factor Homo sapiens 90-95 29018241-0 2017 Eugenol inhibits oxidative phosphorylation and fatty acid oxidation via downregulation of c-Myc/PGC-1beta/ERRalpha signaling pathway in MCF10A-ras cells. Eugenol 0-7 PPARG coactivator 1 beta Homo sapiens 96-105 29018241-0 2017 Eugenol inhibits oxidative phosphorylation and fatty acid oxidation via downregulation of c-Myc/PGC-1beta/ERRalpha signaling pathway in MCF10A-ras cells. Eugenol 0-7 estrogen related receptor alpha Homo sapiens 106-114 28882947-8 2017 The ability of methoxyphenols to inhibit LPS-stimulated Cox-2 gene expression declined in the order curcumin >> isoeugenol > bis-eugenol >> eugenol, and the rank of ability was related to their omega value. Eugenol 121-128 prostaglandin-endoperoxide synthase 2 Mus musculus 56-61 28882947-11 2017 Eugenol-related compounds may exert antioxidant and anti-inflammatory activity in LPS-stimulated RAW264.7 cells possibly by inhibiting the activation of nuclear factor-kappa B (Nf-kB), whereas bis-eugenol requires induction of HO-1 expression. Eugenol 0-7 heme oxygenase 1 Mus musculus 227-231 27927285-11 2017 Here, the acrylic resin, zinc oxide (eugenol), and zinc phosphate cements significantly reduced cellular viability after exposure with respect to HGF cells only. Eugenol 37-44 hepatocyte growth factor Mus musculus 146-149 28915591-0 2017 Eugenol alleviated breast precancerous lesions through HER2/PI3K-AKT pathway-induced cell apoptosis and S-phase arrest. Eugenol 0-7 erb-b2 receptor tyrosine kinase 2 Homo sapiens 55-59 28915591-0 2017 Eugenol alleviated breast precancerous lesions through HER2/PI3K-AKT pathway-induced cell apoptosis and S-phase arrest. Eugenol 0-7 AKT serine/threonine kinase 1 Homo sapiens 65-68 28915591-3 2017 In this study, 80 muM eugenol could significantly inhibit the proliferation of HER-2 positive MCF-10AT cells and the inhibition rate was up to 32.8%, but had no obvious inhibitory effect on MCF-7 and MCF-10A cells with HER2 weak expression. Eugenol 22-29 erb-b2 receptor tyrosine kinase 2 Homo sapiens 79-84 28915591-3 2017 In this study, 80 muM eugenol could significantly inhibit the proliferation of HER-2 positive MCF-10AT cells and the inhibition rate was up to 32.8%, but had no obvious inhibitory effect on MCF-7 and MCF-10A cells with HER2 weak expression. Eugenol 22-29 erb-b2 receptor tyrosine kinase 2 Homo sapiens 219-223 28915591-4 2017 Eugenol also significantly induced human breast precancerous lesion MCF-10AT cell apoptosis and cell cycle S-phase arrest, but the biological effects nearly disappeared after HER2 over-expression through transfecting pcDNA3.1-HER2. Eugenol 0-7 erb-b2 receptor tyrosine kinase 2 Homo sapiens 175-179 28915591-4 2017 Eugenol also significantly induced human breast precancerous lesion MCF-10AT cell apoptosis and cell cycle S-phase arrest, but the biological effects nearly disappeared after HER2 over-expression through transfecting pcDNA3.1-HER2. Eugenol 0-7 erb-b2 receptor tyrosine kinase 2 Homo sapiens 226-230 28915591-7 2017 Furthermore eugenol for external (1 mg) markedly decreased the protein expressions of HER2 (62.9%), AKT (58.6%), PDK1 (56.4%), p85 (54.3%), Bcl2 (59.3%), NF-kappaB (65.7%), Bad (64.0%), Cyclin D1 (43.0%), while p21, p27 and Bax protein expressions were respectively increased 1.83-, 2.52- and 2.51-fold. Eugenol 12-19 erb-b2 receptor tyrosine kinase 2 Homo sapiens 86-90 28915591-7 2017 Furthermore eugenol for external (1 mg) markedly decreased the protein expressions of HER2 (62.9%), AKT (58.6%), PDK1 (56.4%), p85 (54.3%), Bcl2 (59.3%), NF-kappaB (65.7%), Bad (64.0%), Cyclin D1 (43.0%), while p21, p27 and Bax protein expressions were respectively increased 1.83-, 2.52- and 2.51-fold. Eugenol 12-19 AKT serine/threonine kinase 1 Homo sapiens 100-103 28915591-7 2017 Furthermore eugenol for external (1 mg) markedly decreased the protein expressions of HER2 (62.9%), AKT (58.6%), PDK1 (56.4%), p85 (54.3%), Bcl2 (59.3%), NF-kappaB (65.7%), Bad (64.0%), Cyclin D1 (43.0%), while p21, p27 and Bax protein expressions were respectively increased 1.83-, 2.52- and 2.51-fold. Eugenol 12-19 pyruvate dehydrogenase kinase 1 Homo sapiens 113-117 28915591-7 2017 Furthermore eugenol for external (1 mg) markedly decreased the protein expressions of HER2 (62.9%), AKT (58.6%), PDK1 (56.4%), p85 (54.3%), Bcl2 (59.3%), NF-kappaB (65.7%), Bad (64.0%), Cyclin D1 (43.0%), while p21, p27 and Bax protein expressions were respectively increased 1.83-, 2.52- and 2.51-fold. Eugenol 12-19 phosphoinositide-3-kinase regulatory subunit 2 Homo sapiens 127-130 28915591-7 2017 Furthermore eugenol for external (1 mg) markedly decreased the protein expressions of HER2 (62.9%), AKT (58.6%), PDK1 (56.4%), p85 (54.3%), Bcl2 (59.3%), NF-kappaB (65.7%), Bad (64.0%), Cyclin D1 (43.0%), while p21, p27 and Bax protein expressions were respectively increased 1.83-, 2.52- and 2.51-fold. Eugenol 12-19 BCL2 apoptosis regulator Homo sapiens 140-144 28915591-7 2017 Furthermore eugenol for external (1 mg) markedly decreased the protein expressions of HER2 (62.9%), AKT (58.6%), PDK1 (56.4%), p85 (54.3%), Bcl2 (59.3%), NF-kappaB (65.7%), Bad (64.0%), Cyclin D1 (43.0%), while p21, p27 and Bax protein expressions were respectively increased 1.83-, 2.52- and 2.51-fold. Eugenol 12-19 nuclear factor kappa B subunit 1 Homo sapiens 154-163 28915591-7 2017 Furthermore eugenol for external (1 mg) markedly decreased the protein expressions of HER2 (62.9%), AKT (58.6%), PDK1 (56.4%), p85 (54.3%), Bcl2 (59.3%), NF-kappaB (65.7%), Bad (64.0%), Cyclin D1 (43.0%), while p21, p27 and Bax protein expressions were respectively increased 1.83-, 2.52- and 2.51-fold. Eugenol 12-19 cyclin D1 Homo sapiens 186-195 28915591-7 2017 Furthermore eugenol for external (1 mg) markedly decreased the protein expressions of HER2 (62.9%), AKT (58.6%), PDK1 (56.4%), p85 (54.3%), Bcl2 (59.3%), NF-kappaB (65.7%), Bad (64.0%), Cyclin D1 (43.0%), while p21, p27 and Bax protein expressions were respectively increased 1.83-, 2.52- and 2.51-fold. Eugenol 12-19 H3 histone pseudogene 16 Homo sapiens 211-214 28915591-7 2017 Furthermore eugenol for external (1 mg) markedly decreased the protein expressions of HER2 (62.9%), AKT (58.6%), PDK1 (56.4%), p85 (54.3%), Bcl2 (59.3%), NF-kappaB (65.7%), Bad (64.0%), Cyclin D1 (43.0%), while p21, p27 and Bax protein expressions were respectively increased 1.83-, 2.52- and 2.51-fold. Eugenol 12-19 interferon alpha inducible protein 27 Homo sapiens 216-219 28915591-7 2017 Furthermore eugenol for external (1 mg) markedly decreased the protein expressions of HER2 (62.9%), AKT (58.6%), PDK1 (56.4%), p85 (54.3%), Bcl2 (59.3%), NF-kappaB (65.7%), Bad (64.0%), Cyclin D1 (43.0%), while p21, p27 and Bax protein expressions were respectively increased 1.83-, 2.52- and 2.51-fold. Eugenol 12-19 BCL2 associated X, apoptosis regulator Homo sapiens 224-227 28915591-8 2017 The results showed eugenol could significantly inhibit the development of breast precancerous lesions by blocking HER2/PI3K-AKT signaling network. Eugenol 19-26 erb-b2 receptor tyrosine kinase 2 Homo sapiens 114-118 28915591-8 2017 The results showed eugenol could significantly inhibit the development of breast precancerous lesions by blocking HER2/PI3K-AKT signaling network. Eugenol 19-26 AKT serine/threonine kinase 1 Homo sapiens 124-127 28272477-0 2017 Chemosensitivity of MCF-7 cells to eugenol: release of cytochrome-c and lactate dehydrogenase. Eugenol 35-42 cytochrome c, somatic Homo sapiens 55-67 28272477-4 2017 Eugenol demonstrated: a dose-dependent decrease in viability (MTT assay), and proliferation (real time cell analysis) of MCF-7 cells, (EC50: 0.9 mM); an increase in reactive oxygen species; a decrease in ATP level and mitochondrial membrane potential (MitoPT JC-1 assay); and a release of cytochrome-c and lactate dehydrogenase (Cytotoxicity Detection Kit PLUS) into culture media at eugenol concentration >EC50. Eugenol 0-7 cytochrome c, somatic Homo sapiens 289-301 28272477-6 2017 Expression levels of both anti- and pro-apoptotic markers (Bcl-2 and Bax, respectively) decreased with increasing eugenol concentration, with no variation in their relative ratios. Eugenol 114-121 BCL2 apoptosis regulator Homo sapiens 59-64 28272477-6 2017 Expression levels of both anti- and pro-apoptotic markers (Bcl-2 and Bax, respectively) decreased with increasing eugenol concentration, with no variation in their relative ratios. Eugenol 114-121 BCL2 associated X, apoptosis regulator Homo sapiens 69-72 28272477-7 2017 Eugenol-treated MCF-7 cells overexpressing Bcl-2 exhibited results similar to those of MCF-7. Eugenol 0-7 BCL2 apoptosis regulator Homo sapiens 43-48 28272477-8 2017 Our findings indicate that eugenol toxicity is non-apoptotic Bcl-2 independent, affecting mitochondrial function and plasma membrane integrity with no effect on migration or invasion. Eugenol 27-34 BCL2 apoptosis regulator Homo sapiens 61-66 28392905-0 2017 Cinnamaldehyde and eugenol change the expression folds of AKT1 and DKC1 genes and decrease the telomere length of human adipose-derived stem cells (hASCs): An experimental and in silico study. Eugenol 19-26 AKT serine/threonine kinase 1 Homo sapiens 58-62 28392905-0 2017 Cinnamaldehyde and eugenol change the expression folds of AKT1 and DKC1 genes and decrease the telomere length of human adipose-derived stem cells (hASCs): An experimental and in silico study. Eugenol 19-26 dyskerin pseudouridine synthase 1 Homo sapiens 67-71 27984137-8 2017 Novel eugenol derivatives (1-6) were tested for the inhibition of two cytosolic CA isoforms I, and II (hCA I, and II) and AChE. Eugenol 6-13 carbonic anhydrase 1 Homo sapiens 103-108 27355133-10 2016 From these results, ortho-eugenol antinociceptive effects mediated by the adrenergic system and anti-inflammatory activity through regulation of proinflammatory cytokines and phosphorylation of NF-kB and p38 become evident for the first time. Eugenol 26-33 mitogen-activated protein kinase 14 Homo sapiens 204-207 27770925-9 2017 Eugenol-BSA complex did not induce colorimetric transition. Eugenol 0-7 albumin Bos taurus 8-11 26391896-6 2016 However, the administration of eugenol induced a clear improvement in cardiac biomarkers injury, reduced inflammatory mediators proteins, increased heart activities of superoxide dismutase and glutathione peroxidase with reduce in thiobarbituric acid-reactive substances content and inhibition of ventricular remodeling process through inhibition of ACE activity. Eugenol 31-38 angiotensin I converting enzyme Rattus norvegicus 350-353 26845070-2 2016 In this study, the kinetics and products of the gas-phase reactions of eugenol and 4-ethylguaiacol with NO3 radicals were investigated online using a vacuum ultraviolet photoionization gas time-of-flight mass spectrometer. Eugenol 71-78 NBL1, DAN family BMP antagonist Homo sapiens 104-107 27404051-3 2016 We previously reported that eugenol (EUG), which is an essential component of medicinal herbs and has anticonvulsant activity, is beneficial for treating epilepsy through its ability to inhibit GCD via suppression of mammalian target of rapamycin complex 1 (mTORC1) activation in the hippocampal DG in a kainic acid (KA)-treated mouse model of epilepsy in vivo. Eugenol 28-35 Fanconi anemia, complementation group L Mus musculus 194-197 27404051-3 2016 We previously reported that eugenol (EUG), which is an essential component of medicinal herbs and has anticonvulsant activity, is beneficial for treating epilepsy through its ability to inhibit GCD via suppression of mammalian target of rapamycin complex 1 (mTORC1) activation in the hippocampal DG in a kainic acid (KA)-treated mouse model of epilepsy in vivo. Eugenol 28-35 CREB regulated transcription coactivator 1 Mus musculus 258-264 26843581-6 2016 We confirmed low-level TRPV3 expression in vagal afferent neurons and observed direct activation with putative TRPV3 agonists eugenol, ethyl vanillin (EVA), and farnesyl pyrophosphate (FPP). Eugenol 126-133 transient receptor potential cation channel, subfamily V, member 3 Rattus norvegicus 111-116 26931617-3 2016 We studied the tyrosinase-inhibition activity (activity test) and structural changes (circular dichroism) of tyrosinase with ED and plasma activated eugenol derivatives (PAED) in a cell-free environment. Eugenol 149-156 tyrosinase Mus musculus 109-119 27245453-9 2016 RESULTS: Eugenol exhibited noticeable antioxidant potential in DPPH radical scavenging (81 %) and reducing power (1.12) assays at 1.0 muM/ml and 0.1 muM/ml concentrations, respectively. Eugenol 9-16 latexin Homo sapiens 134-137 27245453-9 2016 RESULTS: Eugenol exhibited noticeable antioxidant potential in DPPH radical scavenging (81 %) and reducing power (1.12) assays at 1.0 muM/ml and 0.1 muM/ml concentrations, respectively. Eugenol 9-16 latexin Homo sapiens 149-152 27245453-10 2016 IC50 value of eugenol for radical scavenging activity was found to be 0.495 muM/ml. Eugenol 14-21 latexin Homo sapiens 76-79 26960744-7 2016 Along with the lower levels of inflammatory cytokine gene expressions in the extract, treatment of the 2D IHOKs with Zn(2+) alone and treatment of the 3D IHOKs with Zn(2+) plus eugenol resulted in significantly lower expression levels of IL-1beta, IL-6, and IL-8 (P<0.05). Eugenol 177-184 interleukin 1 beta Homo sapiens 238-246 26960744-7 2016 Along with the lower levels of inflammatory cytokine gene expressions in the extract, treatment of the 2D IHOKs with Zn(2+) alone and treatment of the 3D IHOKs with Zn(2+) plus eugenol resulted in significantly lower expression levels of IL-1beta, IL-6, and IL-8 (P<0.05). Eugenol 177-184 interleukin 6 Homo sapiens 248-252 26960744-7 2016 Along with the lower levels of inflammatory cytokine gene expressions in the extract, treatment of the 2D IHOKs with Zn(2+) alone and treatment of the 3D IHOKs with Zn(2+) plus eugenol resulted in significantly lower expression levels of IL-1beta, IL-6, and IL-8 (P<0.05). Eugenol 177-184 C-X-C motif chemokine ligand 8 Homo sapiens 258-262 26845070-3 2016 The rate coefficients of the gaseous reactions of eugenol and 4-ethylguaiacol with NO3 radicals were (1.6 +- 0.4) x 10(-13) and (1.1 +- 0.2) x 10(-12) cm(3) molecule(-1) s(-1) (at 298 K), indicating that the atmospheric lifetimes of the NO3 radicals were 3.5 and 0.5 h, respectively. Eugenol 50-57 NBL1, DAN family BMP antagonist Homo sapiens 83-86 26845070-3 2016 The rate coefficients of the gaseous reactions of eugenol and 4-ethylguaiacol with NO3 radicals were (1.6 +- 0.4) x 10(-13) and (1.1 +- 0.2) x 10(-12) cm(3) molecule(-1) s(-1) (at 298 K), indicating that the atmospheric lifetimes of the NO3 radicals were 3.5 and 0.5 h, respectively. Eugenol 50-57 NBL1, DAN family BMP antagonist Homo sapiens 237-240 26706519-5 2016 Relative standard deviations of 2.4 and 4.8% were obtained for five successive determinations of 30.0 and 5.0 muM eugenol, respectively, which indicate acceptable repeatability. Eugenol 114-121 latexin Homo sapiens 110-113 25588851-0 2015 Antiasthmatic Effects of Eugenol in a Mouse Model of Allergic Asthma by Regulation of Vitamin D3 Upregulated Protein 1/NF-kappaB Pathway. Eugenol 25-32 thioredoxin interacting protein Mus musculus 86-118 26884642-8 2016 The group that was administered eugenol showed milder histopathological changes than the Control group, TNF-alpha activity was milder in the Eugenol group, and there was no difference in activity for MPO and IL-6. Eugenol 141-148 tumor necrosis factor Rattus norvegicus 104-113 26706519-4 2016 Under experimental conditions, the PGE had a linear response range from 0.3 muM to 50.0 muM eugenol with a detection limit of 0.085 muM (based on 3S(b)). Eugenol 92-99 latexin Homo sapiens 88-91 26706519-4 2016 Under experimental conditions, the PGE had a linear response range from 0.3 muM to 50.0 muM eugenol with a detection limit of 0.085 muM (based on 3S(b)). Eugenol 92-99 latexin Homo sapiens 88-91 26739611-7 2016 In vivo diabetic mice model studies with eugenol showed reduction in blood glucose levels by 38% likely due to inhibition of alpha-glucosidase while insulin and glycated hemoglobin levels remain unchanged. Eugenol 41-48 sucrase isomaltase (alpha-glucosidase) Mus musculus 125-142 26739611-10 2016 Thus, we propose eugenol has dual mode of action in combating diabetes; it lowers blood glucose by inhibiting alpha-glucosidase and prevents AGE formation by binding to epsilon-amine group on lysine, protecting it from glycation, offering potential use in diabetic management. Eugenol 17-24 sucrase isomaltase (alpha-glucosidase) Mus musculus 110-127 25036665-0 2015 Enhancement of mechanical properties, microstructure, and antimicrobial activities of zein films cross-linked using succinic anhydride, eugenol, and citric Acid. Eugenol 136-143 zein Zea mays 86-90 25036665-3 2015 In this study, zein proteins were modified using citric acid, succinic anhydride, and eugenol as natural cross-linking agents in the wet state. Eugenol 86-93 zein Zea mays 15-19 26388966-2 2015 We present new data assessing the effects of eugenol and carvacrol, agonists of the warmth-sensitive TRPV3, on thermal, mechanical and pain sensitivity in rats. Eugenol 45-52 transient receptor potential cation channel, subfamily V, member 3 Rattus norvegicus 101-106 25588851-0 2015 Antiasthmatic Effects of Eugenol in a Mouse Model of Allergic Asthma by Regulation of Vitamin D3 Upregulated Protein 1/NF-kappaB Pathway. Eugenol 25-32 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 119-128 25832173-0 2015 Eugenol dilates mesenteric arteries and reduces systemic BP by activating endothelial cell TRPV4 channels. Eugenol 0-7 transient receptor potential cation channel, subfamily V, member 4 Rattus norvegicus 91-96 26014302-0 2015 On the Importance of C-H/pi and C-H H-C Interactions in the Solid State Structure of 15-Lipoxygenase Inhibitors Based on Eugenol Derivatives. Eugenol 123-130 arachidonate 15-lipoxygenase Homo sapiens 87-102 25832173-8 2015 Short interfering RNA (siRNA)-mediated TRPV4 knockdown abolished eugenol-induced ICat activation. Eugenol 65-72 transient receptor potential cation channel, subfamily V, member 4 Rattus norvegicus 39-44 25832173-12 2015 CONCLUSIONS AND IMPLICATIONS: Eugenol activates TRPV4 channels in mesenteric artery endothelial cells, leading to vasorelaxation, and reduces systemic BP in vivo. Eugenol 30-37 transient receptor potential cation channel, subfamily V, member 4 Rattus norvegicus 48-53 25832173-13 2015 Eugenol may be therapeutically useful as an antihypertensive agent and is a viable molecular candidate from which to develop second-generation TRPV4 channel activators that reduce BP. Eugenol 0-7 transient receptor potential cation channel, subfamily V, member 4 Rattus norvegicus 143-148 25455450-5 2015 Eugenol-induced [Ca(2+)]i rises were not altered by store-operated Ca(2+) channel blockers but were inhibited by the PKC inhibitor GF109203X and the transient receptor potential channel melastatin 8 (TRPM8) antagonist capsazepine. Eugenol 0-7 transient receptor potential cation channel subfamily M member 8 Homo sapiens 149-198 25635877-6 2015 In HEK 293 cells expressing the alpha1beta2gamma2 subtype, eugenol inhibited GABA-induced currents in a dose-dependent manner. Eugenol 59-66 adrenoceptor alpha 1D Homo sapiens 32-49 25455450-9 2015 Eugenol induced apoptosis through increasing reactive oxygen species (ROS) production, decreasing mitochondrial membrane potential, releasing cytochrome c and activating caspase-9/caspase-3. Eugenol 0-7 cytochrome c, somatic Homo sapiens 142-154 25455450-9 2015 Eugenol induced apoptosis through increasing reactive oxygen species (ROS) production, decreasing mitochondrial membrane potential, releasing cytochrome c and activating caspase-9/caspase-3. Eugenol 0-7 caspase 9 Homo sapiens 170-179 25455450-5 2015 Eugenol-induced [Ca(2+)]i rises were not altered by store-operated Ca(2+) channel blockers but were inhibited by the PKC inhibitor GF109203X and the transient receptor potential channel melastatin 8 (TRPM8) antagonist capsazepine. Eugenol 0-7 transient receptor potential cation channel subfamily M member 8 Homo sapiens 200-205 25455450-9 2015 Eugenol induced apoptosis through increasing reactive oxygen species (ROS) production, decreasing mitochondrial membrane potential, releasing cytochrome c and activating caspase-9/caspase-3. Eugenol 0-7 caspase 3 Homo sapiens 180-189 25403255-1 2015 The mutual prodrugs of aceclofenac with various naturally available antioxidants; menthol, thymol, eugenol, guiacol and vanillin have been synthesized by the DCC coupling method, purified and characterized by spectral data, as well as, partition coefficient, solubility and hydrolytic studies. Eugenol 99-106 DCC netrin 1 receptor Homo sapiens 158-161 25455450-10 2015 Together, in DBTRG-05MG cells, eugenol evoked [Ca(2+)]i rises by inducing PLC-dependent release of Ca(2+) from the endoplasmic reticulum and caused Ca(2+) influx possibly through TRPM8 or PKC-sensitive channels. Eugenol 31-38 transient receptor potential cation channel subfamily M member 8 Homo sapiens 179-184 25685661-6 2015 Piperine also decreased the phosphorylation of CREB, which is up-regulated by eugenol. Eugenol 78-85 cAMP responsive element binding protein 1 Mus musculus 47-51 26434906-0 2015 Induction of Apoptosis by Eugenol and Capsaicin in Human Gastric Cancer AGS Cells--Elucidating the Role of p53. Eugenol 26-33 tumor protein p53 Homo sapiens 107-110 26434906-3 2015 The aim of the study was to elucidate the role of p53 in the induction of apoptosis by eugenol and capsaicin in a human gastric cancer cell line, AGS. Eugenol 87-94 tumor protein p53 Homo sapiens 50-53 26434906-8 2015 Western blot analysis of pro-apoptotic markers revealed that as opposed to capsaicin, eugenol could induce caspase-8 and caspase-3 even in the absence of p53. Eugenol 86-93 caspase 8 Homo sapiens 107-116 26434906-8 2015 Western blot analysis of pro-apoptotic markers revealed that as opposed to capsaicin, eugenol could induce caspase-8 and caspase-3 even in the absence of p53. Eugenol 86-93 caspase 3 Homo sapiens 121-130 26434906-9 2015 CONCLUSIONS: Unlike capsaicin, eugenol could induce apoptosis both in presence and absence of functional p53. Eugenol 31-38 tumor protein p53 Homo sapiens 105-108 24647791-13 2015 Aspirin and eugenol enhanced the IL-1beta-induced sICAM-1 production and ICAM-1 expression. Eugenol 12-19 interleukin 1 beta Homo sapiens 33-41 24647791-13 2015 Aspirin and eugenol enhanced the IL-1beta-induced sICAM-1 production and ICAM-1 expression. Eugenol 12-19 intercellular adhesion molecule 1 Homo sapiens 51-57 25685661-7 2015 These results suggest that piperine inhibits the eugenol-induced signal transduction pathway through modulation of cAMP and calcium levels and phosphorylation of CREB in non-chemosensory cells. Eugenol 49-56 cAMP responsive element binding protein 1 Mus musculus 162-166 24921632-2 2014 Eugenol has been demonstrated to relax conduit and ear arteries and reduce systemic blood pressure, but mechanisms involved are unclear. Eugenol 0-7 neurogenin 3 Rattus norvegicus 33-38 25411495-7 2014 Heterologous expression assays confirmed nine eugenol-responsive ORs (Olfr73, Olfr178, Olfr432, Olfr610, Olfr958, Olfr960, Olfr961, Olfr913, and Olfr1234) and four muscone-responsive ORs (Olfr74, Olfr235, Olfr816, and Olfr1440). Eugenol 46-53 olfactory receptor family 5 subfamily D member 18 Mus musculus 70-76 25411495-7 2014 Heterologous expression assays confirmed nine eugenol-responsive ORs (Olfr73, Olfr178, Olfr432, Olfr610, Olfr958, Olfr960, Olfr961, Olfr913, and Olfr1234) and four muscone-responsive ORs (Olfr74, Olfr235, Olfr816, and Olfr1440). Eugenol 46-53 olfactory receptor family 5 subfamily J member 15 Mus musculus 78-85 25411495-7 2014 Heterologous expression assays confirmed nine eugenol-responsive ORs (Olfr73, Olfr178, Olfr432, Olfr610, Olfr958, Olfr960, Olfr961, Olfr913, and Olfr1234) and four muscone-responsive ORs (Olfr74, Olfr235, Olfr816, and Olfr1440). Eugenol 46-53 olfactory receptor family 10 subfamily AA member 3 Mus musculus 87-94 25411495-7 2014 Heterologous expression assays confirmed nine eugenol-responsive ORs (Olfr73, Olfr178, Olfr432, Olfr610, Olfr958, Olfr960, Olfr961, Olfr913, and Olfr1234) and four muscone-responsive ORs (Olfr74, Olfr235, Olfr816, and Olfr1440). Eugenol 46-53 olfactory receptor family 51 subfamily AG member 1 Mus musculus 96-103 25411495-7 2014 Heterologous expression assays confirmed nine eugenol-responsive ORs (Olfr73, Olfr178, Olfr432, Olfr610, Olfr958, Olfr960, Olfr961, Olfr913, and Olfr1234) and four muscone-responsive ORs (Olfr74, Olfr235, Olfr816, and Olfr1440). Eugenol 46-53 olfactory receptor family 10 subfamily D member 3 Mus musculus 105-112 25411495-7 2014 Heterologous expression assays confirmed nine eugenol-responsive ORs (Olfr73, Olfr178, Olfr432, Olfr610, Olfr958, Olfr960, Olfr961, Olfr913, and Olfr1234) and four muscone-responsive ORs (Olfr74, Olfr235, Olfr816, and Olfr1440). Eugenol 46-53 olfactory receptor family 10 subfamily D member 4C Mus musculus 123-130 25411495-7 2014 Heterologous expression assays confirmed nine eugenol-responsive ORs (Olfr73, Olfr178, Olfr432, Olfr610, Olfr958, Olfr960, Olfr961, Olfr913, and Olfr1234) and four muscone-responsive ORs (Olfr74, Olfr235, Olfr816, and Olfr1440). Eugenol 46-53 olfactory receptor family 8 subfamily B member 49 Mus musculus 132-139 25411495-7 2014 Heterologous expression assays confirmed nine eugenol-responsive ORs (Olfr73, Olfr178, Olfr432, Olfr610, Olfr958, Olfr960, Olfr961, Olfr913, and Olfr1234) and four muscone-responsive ORs (Olfr74, Olfr235, Olfr816, and Olfr1440). Eugenol 46-53 olfactory receptor family 4 subfamily A member 15 Mus musculus 145-153 25411495-7 2014 Heterologous expression assays confirmed nine eugenol-responsive ORs (Olfr73, Olfr178, Olfr432, Olfr610, Olfr958, Olfr960, Olfr961, Olfr913, and Olfr1234) and four muscone-responsive ORs (Olfr74, Olfr235, Olfr816, and Olfr1440). Eugenol 46-53 olfactory receptor family 5 subfamily D member 47 Mus musculus 188-194 25411495-7 2014 Heterologous expression assays confirmed nine eugenol-responsive ORs (Olfr73, Olfr178, Olfr432, Olfr610, Olfr958, Olfr960, Olfr961, Olfr913, and Olfr1234) and four muscone-responsive ORs (Olfr74, Olfr235, Olfr816, and Olfr1440). Eugenol 46-53 olfactory receptor family 5 subfamily AN member 11 Mus musculus 196-203 25411495-7 2014 Heterologous expression assays confirmed nine eugenol-responsive ORs (Olfr73, Olfr178, Olfr432, Olfr610, Olfr958, Olfr960, Olfr961, Olfr913, and Olfr1234) and four muscone-responsive ORs (Olfr74, Olfr235, Olfr816, and Olfr1440). Eugenol 46-53 olfactory receptor family 6 subfamily C member 69 Mus musculus 205-212 25411495-7 2014 Heterologous expression assays confirmed nine eugenol-responsive ORs (Olfr73, Olfr178, Olfr432, Olfr610, Olfr958, Olfr960, Olfr961, Olfr913, and Olfr1234) and four muscone-responsive ORs (Olfr74, Olfr235, Olfr816, and Olfr1440). Eugenol 46-53 olfactory receptor family 5 subfamily AN member 6 Mus musculus 218-226 25313015-4 2014 Here we show that GRK3 attenuated the agonist responsiveness of a specific mouse odorant receptor for eugenol (mOR-EG) upon agonist pretreatment in HEK293 cells, but GRK3 did not affect the response amplitude or the recovery kinetics upon repeated agonist stimulation. Eugenol 102-109 G protein-coupled receptor kinase 3 Mus musculus 18-22 25313015-4 2014 Here we show that GRK3 attenuated the agonist responsiveness of a specific mouse odorant receptor for eugenol (mOR-EG) upon agonist pretreatment in HEK293 cells, but GRK3 did not affect the response amplitude or the recovery kinetics upon repeated agonist stimulation. Eugenol 102-109 olfactory receptor family 5 subfamily D member 18 Mus musculus 111-117 24384226-6 2014 In addition, eugenol response was observed in trigeminal ganglion neurons from TRPV1 knockout mice and human embryonic kidney 293 cell lines that express human TRPA1, which was inhibited by TRPA1-specific antagonist HC-030031. Eugenol 13-20 transient receptor potential cation channel subfamily A member 1 Homo sapiens 190-195 25065667-0 2014 Modulation of Pb(II) caused aortal constriction by eugenol and carvacrol. Eugenol 51-58 submaxillary gland androgen regulated protein 3B Homo sapiens 14-20 25065667-8 2014 At saturating concentrations of 100 mumol L(-1), eugenol and carvacrol caused a decrease in contraction by 38 and 42% in unexposed rings and 46 and 50% in Pb(II)-exposed rings. Eugenol 49-56 submaxillary gland androgen regulated protein 3B Homo sapiens 155-161 25036027-4 2014 Eugenol initiates increases in cytosolic Ca2+ in Saccharomyces cerevisiae which is partly dependent on the plasma membrane calcium channel, Cch1p. Eugenol 0-7 Cch1p Saccharomyces cerevisiae S288C 140-145 25036027-9 2014 In contrast, careful control of extracellular Ca2+ (using EGTA or BAPTA) revealed that tolerance of yeast to eugenol depended on Ca2+ influx via Cch1p. Eugenol 109-116 Cch1p Saccharomyces cerevisiae S288C 145-150 25103019-6 2014 Hypoexpression of TNF-alpha was also detected after cellular exposure to eugenol at the highest concentration (2.48 microg/mL). Eugenol 73-80 tumor necrosis factor Mus musculus 18-27 25149566-2 2014 To better understand the mechanisms and molecular range of such ligand selectivity, we expressed the mouse eugenol OR (mOR-EG) in HEK293T cells together with Galpha15 to monitor activation of the phospholipase-C (PLC) signaling pathway and/or Galphaolf to monitor activation of the adenylate cyclase (AC) signaling pathway, resulting in intracellular Ca(2+) release and/or Ca(2+) influx through a cyclic nucleotide-gated channel, respectively. Eugenol 107-114 olfactory receptor family 5 subfamily D member 18 Mus musculus 119-125 25149566-5 2014 Of 17 reported mOR-EG ligands tested, including eugenol, its analogs, and structurally dissimilar compounds (mousse cristal, nootkatone, orivone), some equally activated both signaling pathways, some differentially activated both signaling pathways, and some had no noticeable effect even at 1-5mM. Eugenol 48-55 olfactory receptor family 5 subfamily D member 18 Mus musculus 15-21 24732112-2 2014 The present study is designed to evaluate the antiinflammatory effect of O. sanctum and its phenolic compound and eugenol (EUG) in human monocytic (THP-1) cells and validate its traditional use for treating cardiovascular diseases. Eugenol 114-121 GLI family zinc finger 2 Homo sapiens 148-153 24384226-0 2014 Activation of transient receptor potential ankyrin 1 by eugenol. Eugenol 56-63 transient receptor potential cation channel subfamily A member 1 Homo sapiens 14-52 24384226-2 2014 The structural similarity of eugenol to cinnamaldehyde, an active ligand for transient receptor potential ankyrin 1 (TRPA1), suggests that eugenol might produce its effect via TRPA1, in addition to TRPV1 as we reported previously. Eugenol 29-36 transient receptor potential cation channel subfamily A member 1 Homo sapiens 77-115 24384226-2 2014 The structural similarity of eugenol to cinnamaldehyde, an active ligand for transient receptor potential ankyrin 1 (TRPA1), suggests that eugenol might produce its effect via TRPA1, in addition to TRPV1 as we reported previously. Eugenol 29-36 transient receptor potential cation channel subfamily A member 1 Homo sapiens 117-122 24384226-2 2014 The structural similarity of eugenol to cinnamaldehyde, an active ligand for transient receptor potential ankyrin 1 (TRPA1), suggests that eugenol might produce its effect via TRPA1, in addition to TRPV1 as we reported previously. Eugenol 29-36 transient receptor potential cation channel subfamily A member 1 Homo sapiens 176-181 24384226-2 2014 The structural similarity of eugenol to cinnamaldehyde, an active ligand for transient receptor potential ankyrin 1 (TRPA1), suggests that eugenol might produce its effect via TRPA1, in addition to TRPV1 as we reported previously. Eugenol 29-36 transient receptor potential cation channel subfamily V member 1 Homo sapiens 198-203 24384226-2 2014 The structural similarity of eugenol to cinnamaldehyde, an active ligand for transient receptor potential ankyrin 1 (TRPA1), suggests that eugenol might produce its effect via TRPA1, in addition to TRPV1 as we reported previously. Eugenol 139-146 transient receptor potential cation channel subfamily A member 1 Homo sapiens 77-115 24384226-2 2014 The structural similarity of eugenol to cinnamaldehyde, an active ligand for transient receptor potential ankyrin 1 (TRPA1), suggests that eugenol might produce its effect via TRPA1, in addition to TRPV1 as we reported previously. Eugenol 139-146 transient receptor potential cation channel subfamily A member 1 Homo sapiens 117-122 24384226-2 2014 The structural similarity of eugenol to cinnamaldehyde, an active ligand for transient receptor potential ankyrin 1 (TRPA1), suggests that eugenol might produce its effect via TRPA1, in addition to TRPV1 as we reported previously. Eugenol 139-146 transient receptor potential cation channel subfamily A member 1 Homo sapiens 176-181 24384226-2 2014 The structural similarity of eugenol to cinnamaldehyde, an active ligand for transient receptor potential ankyrin 1 (TRPA1), suggests that eugenol might produce its effect via TRPA1, in addition to TRPV1 as we reported previously. Eugenol 139-146 transient receptor potential cation channel subfamily V member 1 Homo sapiens 198-203 24384226-3 2014 In this study, we investigated the effect of eugenol on TRPA1, by fura-2-based calcium imaging and patch clamp recording in trigeminal ganglion neurons and in a heterologous expression system. Eugenol 45-52 transient receptor potential cation channel subfamily A member 1 Homo sapiens 56-61 24384226-4 2014 As the result, eugenol induced robust calcium responses in rat trigeminal ganglion neurons that responded to a specific TRPA1 agonist, allyl isothiocyanate (AITC), and not to capsaicin. Eugenol 15-22 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 120-125 24384226-7 2014 Eugenol-evoked TRPA1 single channel activity and eugenol-induced TRPA1 currents were dose-dependent with EC50 of 261.5muM. Eugenol 0-7 transient receptor potential cation channel subfamily A member 1 Homo sapiens 15-20 24384226-6 2014 In addition, eugenol response was observed in trigeminal ganglion neurons from TRPV1 knockout mice and human embryonic kidney 293 cell lines that express human TRPA1, which was inhibited by TRPA1-specific antagonist HC-030031. Eugenol 13-20 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 79-84 24384226-7 2014 Eugenol-evoked TRPA1 single channel activity and eugenol-induced TRPA1 currents were dose-dependent with EC50 of 261.5muM. Eugenol 0-7 latexin Homo sapiens 118-121 24384226-6 2014 In addition, eugenol response was observed in trigeminal ganglion neurons from TRPV1 knockout mice and human embryonic kidney 293 cell lines that express human TRPA1, which was inhibited by TRPA1-specific antagonist HC-030031. Eugenol 13-20 transient receptor potential cation channel subfamily A member 1 Homo sapiens 160-165 24384226-7 2014 Eugenol-evoked TRPA1 single channel activity and eugenol-induced TRPA1 currents were dose-dependent with EC50 of 261.5muM. Eugenol 49-56 transient receptor potential cation channel subfamily A member 1 Homo sapiens 65-70 24384226-7 2014 Eugenol-evoked TRPA1 single channel activity and eugenol-induced TRPA1 currents were dose-dependent with EC50 of 261.5muM. Eugenol 49-56 latexin Homo sapiens 118-121 24384226-8 2014 In summary, these results demonstrate that the activation of TRPA1 might account for another molecular mechanism underlying the pharmacological action of eugenol. Eugenol 154-161 transient receptor potential cation channel subfamily A member 1 Homo sapiens 61-66 24144396-0 2014 Effect of dietary eugenol on xenobiotic metabolism and mediation of UDP-glucuronosyltransferase and cytochrome P450 1A1 expression in rat liver. Eugenol 18-25 UDP glycosyltransferase 2 family, polypeptide B Rattus norvegicus 68-95 24418657-4 2014 Eugenol significantly inhibited glucagon-induced glucose production and phosphorylated AMPK in the HepG2 and primary rat hepatocytes, and these effects were reversed in the presence of compound C (an AMPK inhibitor) or STO-609 (a CAMKK inhibitor). Eugenol 0-7 protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus 87-91 24418657-4 2014 Eugenol significantly inhibited glucagon-induced glucose production and phosphorylated AMPK in the HepG2 and primary rat hepatocytes, and these effects were reversed in the presence of compound C (an AMPK inhibitor) or STO-609 (a CAMKK inhibitor). Eugenol 0-7 protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus 200-204 24418657-4 2014 Eugenol significantly inhibited glucagon-induced glucose production and phosphorylated AMPK in the HepG2 and primary rat hepatocytes, and these effects were reversed in the presence of compound C (an AMPK inhibitor) or STO-609 (a CAMKK inhibitor). Eugenol 0-7 calcium/calmodulin-dependent protein kinase kinase 1, alpha Mus musculus 230-235 24418657-6 2014 Moreover, inhibition of AMPK by over-expression of dominant negative AMPK prevented eugenol from suppressions of gluconeogenic gene expression and hepatic glucose production. Eugenol 84-91 protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus 24-28 24418657-6 2014 Moreover, inhibition of AMPK by over-expression of dominant negative AMPK prevented eugenol from suppressions of gluconeogenic gene expression and hepatic glucose production. Eugenol 84-91 protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus 69-73 24418657-9 2014 In summary, eugenol effectively ameliorates hyperglycemia through inhibition of hepatic gluconeogenesis via modulating CAMKK-AMPK-CREB signaling pathway. Eugenol 12-19 calcium/calmodulin-dependent protein kinase kinase 1, alpha Mus musculus 119-124 24418657-9 2014 In summary, eugenol effectively ameliorates hyperglycemia through inhibition of hepatic gluconeogenesis via modulating CAMKK-AMPK-CREB signaling pathway. Eugenol 12-19 protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus 125-129 24418657-9 2014 In summary, eugenol effectively ameliorates hyperglycemia through inhibition of hepatic gluconeogenesis via modulating CAMKK-AMPK-CREB signaling pathway. Eugenol 12-19 cAMP responsive element binding protein 1 Mus musculus 130-134 24144396-0 2014 Effect of dietary eugenol on xenobiotic metabolism and mediation of UDP-glucuronosyltransferase and cytochrome P450 1A1 expression in rat liver. Eugenol 18-25 cytochrome P450, family 1, subfamily a, polypeptide 1 Rattus norvegicus 100-119 24144396-5 2014 In rats administered dietary eugenol, expression levels of hepatic CYP1A 1 were reduced to 40% than of the controls, while expression of hepatic UGT1A6, UGT1A7 and UGT2B1 increased to 2-3 times than observed in the controls. Eugenol 29-36 cytochrome P450, family 1, subfamily a, polypeptide 1 Rattus norvegicus 67-74 24144396-5 2014 In rats administered dietary eugenol, expression levels of hepatic CYP1A 1 were reduced to 40% than of the controls, while expression of hepatic UGT1A6, UGT1A7 and UGT2B1 increased to 2-3 times than observed in the controls. Eugenol 29-36 UDP glucuronosyltransferase family 1 member A6 Rattus norvegicus 145-151 24144396-5 2014 In rats administered dietary eugenol, expression levels of hepatic CYP1A 1 were reduced to 40% than of the controls, while expression of hepatic UGT1A6, UGT1A7 and UGT2B1 increased to 2-3 times than observed in the controls. Eugenol 29-36 UDP glucuronosyltransferase family 1 member A6 Rattus norvegicus 153-159 24144396-5 2014 In rats administered dietary eugenol, expression levels of hepatic CYP1A 1 were reduced to 40% than of the controls, while expression of hepatic UGT1A6, UGT1A7 and UGT2B1 increased to 2-3 times than observed in the controls. Eugenol 29-36 UDP glucuronosyltransferase family 2 member B17 Rattus norvegicus 164-170 24144396-6 2014 Hepatic protein levels of UGT1A6 and 2B1 were also elevated in the eugenol-treated rats. Eugenol 67-74 UDP glucuronosyltransferase family 1 member A6 Rattus norvegicus 26-40 24144396-7 2014 These results suggest that the natural compound eugenol improves the xenobiotic-metabolizing systems that suppress and induce the expression of CYP1A1 and UGT, respectively. Eugenol 48-55 cytochrome P450, family 1, subfamily a, polypeptide 1 Rattus norvegicus 144-150 24144396-7 2014 These results suggest that the natural compound eugenol improves the xenobiotic-metabolizing systems that suppress and induce the expression of CYP1A1 and UGT, respectively. Eugenol 48-55 UDP glycosyltransferase 2 family, polypeptide B Rattus norvegicus 155-158 25087956-0 2014 Eugenol ameliorates hepatic steatosis and fibrosis by down-regulating SREBP1 gene expression via AMPK-mTOR-p70S6K signaling pathway. Eugenol 0-7 sterol regulatory element binding transcription factor 1 Mus musculus 70-76 24368084-2 2014 In vitro, eugenol showed weak activity against A. hydrophila, but in vivo, at a subinhibitory concentration (10 mg L(-1)), it promoted survival in infected silver catfish. Eugenol 10-17 L1 cell adhesion molecule Mus musculus 115-120 24368084-3 2014 Eugenol (50 mug mL(-1)) reduced the hemolytic activity of A. hydrophila supernatant in vitro in fish erythrocytes. Eugenol 0-7 L1 cell adhesion molecule Mus musculus 16-22 25087956-0 2014 Eugenol ameliorates hepatic steatosis and fibrosis by down-regulating SREBP1 gene expression via AMPK-mTOR-p70S6K signaling pathway. Eugenol 0-7 protein kinase AMP-activated catalytic subunit alpha 1 Homo sapiens 97-101 25087956-8 2014 Gene expressions of fibrosis marker protein such as alpha-smooth muscle actin (alpha-SMA), collagen type I (Col-I) and plasminogen activator inhibitor-1 (PAI-1) were also significantly reduced by 36%, 63% and 40% in eugenol-treated mice. Eugenol 216-223 actin alpha 2, smooth muscle, aorta Mus musculus 52-77 25087956-0 2014 Eugenol ameliorates hepatic steatosis and fibrosis by down-regulating SREBP1 gene expression via AMPK-mTOR-p70S6K signaling pathway. Eugenol 0-7 mechanistic target of rapamycin kinase Mus musculus 102-106 25087956-8 2014 Gene expressions of fibrosis marker protein such as alpha-smooth muscle actin (alpha-SMA), collagen type I (Col-I) and plasminogen activator inhibitor-1 (PAI-1) were also significantly reduced by 36%, 63% and 40% in eugenol-treated mice. Eugenol 216-223 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 119-152 25087956-8 2014 Gene expressions of fibrosis marker protein such as alpha-smooth muscle actin (alpha-SMA), collagen type I (Col-I) and plasminogen activator inhibitor-1 (PAI-1) were also significantly reduced by 36%, 63% and 40% in eugenol-treated mice. Eugenol 216-223 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 154-159 25087956-0 2014 Eugenol ameliorates hepatic steatosis and fibrosis by down-regulating SREBP1 gene expression via AMPK-mTOR-p70S6K signaling pathway. Eugenol 0-7 ribosomal protein S6 kinase B1 Homo sapiens 107-113 25087956-3 2014 Lipid contents were markedly decreased when hepatocytes were treated with eugenol for up to 24 h. Gene expressions of sterol regulatory element binding protein 1 (SREBP1) and its target enzymes were suppressed but those of lipolysis-related proteins were increased. Eugenol 74-81 sterol regulatory element binding transcription factor 1 Mus musculus 118-161 25087956-3 2014 Lipid contents were markedly decreased when hepatocytes were treated with eugenol for up to 24 h. Gene expressions of sterol regulatory element binding protein 1 (SREBP1) and its target enzymes were suppressed but those of lipolysis-related proteins were increased. Eugenol 74-81 sterol regulatory element binding transcription factor 1 Mus musculus 163-169 25087956-5 2014 Protein expressions of phosphorylated Ca(2+)-calmodulin dependent protein kinase kinase (CAMKK), AMPK and acetyl-CoA carboxylase (ACC) were significantly increased and those of phosphorylated mammalian target of rapamycin (mTOR) and p70S6K were suppressed when the hepatocytes were treated with eugenol at up to 100 microM. Eugenol 295-302 calcium/calmodulin dependent protein kinase kinase 2 Homo sapiens 89-94 23791894-11 2013 The brief heat hyperalgesia following eugenol may involve a TRPV3-mediated enhancement of thermal gating of TRPV1 expressed in lingual polymodal nociceptors. Eugenol 38-45 transient receptor potential cation channel subfamily V member 3 Homo sapiens 60-65 24330704-0 2013 Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation. Eugenol 0-7 E2F transcription factor 1 Homo sapiens 58-62 24330704-6 2013 While RT-PCR was used to determine eugenol effect on the E2F1 and survivin mRNA levels. Eugenol 35-42 E2F transcription factor 1 Homo sapiens 57-61 24330704-10 2013 Eugenol inhibited also several other breast cancer related oncogenes, such as NF-kappaB and cyclin D1. Eugenol 0-7 cyclin D1 Homo sapiens 92-101 24330704-11 2013 Moreover, eugenol up-regulated the versatile cyclin-dependent kinase inhibitor p21WAF1 protein, and inhibited the proliferation of breast cancer cells in a p53-independent manner. Eugenol 10-17 tumor protein p53 Homo sapiens 156-159 24330704-13 2013 CONCLUSION: Eugenol exhibits anti-breast cancer properties both in vitro and in vivo, indicating that it could be used to consolidate the adjuvant treatment of breast cancer through targeting the E2F1/survivin pathway, especially for the less responsive triple-negative subtype of the disease. Eugenol 12-19 E2F transcription factor 1 Homo sapiens 196-200 23886079-2 2013 In vitro enzyme activity was measured in the presence of eugenol, and it was found to inhibit pancreatic alpha-amylase (IC(50) = 62.53 microg/mL) and lipase (IC(50) = 72.34 microg/mL) as well as angiotensin converting enzyme (ACE) activity (IC50 = 130.67 microg/mL). Eugenol 57-64 amylase 2a3 Rattus norvegicus 94-118 23886079-2 2013 In vitro enzyme activity was measured in the presence of eugenol, and it was found to inhibit pancreatic alpha-amylase (IC(50) = 62.53 microg/mL) and lipase (IC(50) = 72.34 microg/mL) as well as angiotensin converting enzyme (ACE) activity (IC50 = 130.67 microg/mL). Eugenol 57-64 lipase, endothelial Mus musculus 142-156 23886079-2 2013 In vitro enzyme activity was measured in the presence of eugenol, and it was found to inhibit pancreatic alpha-amylase (IC(50) = 62.53 microg/mL) and lipase (IC(50) = 72.34 microg/mL) as well as angiotensin converting enzyme (ACE) activity (IC50 = 130.67 microg/mL). Eugenol 57-64 angiotensin I converting enzyme Rattus norvegicus 195-224 23886079-2 2013 In vitro enzyme activity was measured in the presence of eugenol, and it was found to inhibit pancreatic alpha-amylase (IC(50) = 62.53 microg/mL) and lipase (IC(50) = 72.34 microg/mL) as well as angiotensin converting enzyme (ACE) activity (IC50 = 130.67 microg/mL). Eugenol 57-64 angiotensin I converting enzyme Rattus norvegicus 226-229 23886079-4 2013 Furthermore, eugenol similar to acarbose reduced serum glycosylated hemoglobin (HbA1c), lipase and ACE levels. Eugenol 13-20 lipase G, endothelial type Rattus norvegicus 88-94 23886079-4 2013 Furthermore, eugenol similar to acarbose reduced serum glycosylated hemoglobin (HbA1c), lipase and ACE levels. Eugenol 13-20 angiotensin I converting enzyme Rattus norvegicus 99-102 22775297-0 2013 Eugenol reduces acute pain in mice by modulating the glutamatergic and tumor necrosis factor alpha (TNF-alpha) pathways. Eugenol 0-7 tumor necrosis factor Mus musculus 71-98 22775297-0 2013 Eugenol reduces acute pain in mice by modulating the glutamatergic and tumor necrosis factor alpha (TNF-alpha) pathways. Eugenol 0-7 tumor necrosis factor Mus musculus 100-109 23791894-1 2013 Eugenol and carvacrol, from the spices clove and oregano, respectively, are agonists of TRPV3, which is implicated in transduction of warmth and possibly heat pain. Eugenol 0-7 transient receptor potential cation channel subfamily V member 3 Homo sapiens 88-93 23791894-10 2013 Eugenol and carvacrol enhancement of innocuous warmth may involve sensitization of thermal gating of TRPV3 expressed in peripheral warm fibers. Eugenol 0-7 transient receptor potential cation channel subfamily V member 3 Homo sapiens 101-106 24014106-5 2013 Application of eugenol inhibited Cav3.1, Cav3.2, and Cav3.3 currents in a concentration-dependent manner with IC50 values of 463, 486, and 708 muM, respectively. Eugenol 15-22 calcium voltage-gated channel subunit alpha1 G Homo sapiens 33-39 24014106-5 2013 Application of eugenol inhibited Cav3.1, Cav3.2, and Cav3.3 currents in a concentration-dependent manner with IC50 values of 463, 486, and 708 muM, respectively. Eugenol 15-22 calcium voltage-gated channel subunit alpha1 H Homo sapiens 41-47 24014106-5 2013 Application of eugenol inhibited Cav3.1, Cav3.2, and Cav3.3 currents in a concentration-dependent manner with IC50 values of 463, 486, and 708 muM, respectively. Eugenol 15-22 calcium voltage-gated channel subunit alpha1 I Homo sapiens 53-59 24014106-5 2013 Application of eugenol inhibited Cav3.1, Cav3.2, and Cav3.3 currents in a concentration-dependent manner with IC50 values of 463, 486, and 708 muM, respectively. Eugenol 15-22 latexin Homo sapiens 143-146 24014106-7 2013 In addition, eugenol had little effect on the current kinetics of Cav3.1 and Cav3.2, but it accelerated the inactivation kinetics of Cav3.3 currents. Eugenol 13-20 calcium voltage-gated channel subunit alpha1 I Homo sapiens 133-139 24014106-8 2013 Reduction of channel availability enhanced eugenol inhibition sensitivity for Cav3.1 and Cav3.2, but not for Cav3.3. Eugenol 43-50 calcium voltage-gated channel subunit alpha1 G Homo sapiens 78-84 24014106-8 2013 Reduction of channel availability enhanced eugenol inhibition sensitivity for Cav3.1 and Cav3.2, but not for Cav3.3. Eugenol 43-50 calcium voltage-gated channel subunit alpha1 H Homo sapiens 89-95 24204588-5 2013 Furthermore, phenotypic suppression analysis revealed that eugenol interferes with two permeases, Tat1p and Gap1p, which are both involved in dual transport of aromatic and branched-chain amino acids through the yeast cytoplasmic membrane. Eugenol 59-66 amino acid transporter TAT1 Saccharomyces cerevisiae S288C 98-103 24204588-5 2013 Furthermore, phenotypic suppression analysis revealed that eugenol interferes with two permeases, Tat1p and Gap1p, which are both involved in dual transport of aromatic and branched-chain amino acids through the yeast cytoplasmic membrane. Eugenol 59-66 amino acid permease GAP1 Saccharomyces cerevisiae S288C 108-113 23791894-11 2013 The brief heat hyperalgesia following eugenol may involve a TRPV3-mediated enhancement of thermal gating of TRPV1 expressed in lingual polymodal nociceptors. Eugenol 38-45 transient receptor potential cation channel subfamily V member 1 Homo sapiens 108-113 24358880-9 2013 TRPV1 knockouts showed deficiencies in the detection of benzaldehyde, cyclohexanone and eugenol in at least one assay. Eugenol 88-95 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 0-5 23613775-7 2013 We speculated that the mechanism underlying might be that eugenol inhibited the oxidative stress and the activation of ERK1/2, p38MAPK and IKK/NF-kappaB pathways, subsequently inhibited the dissociation of Beclin1-Bcl2 heterodimer and autophagy, and finally impaired IAV replication. Eugenol 58-65 beclin 1 Homo sapiens 206-213 23613775-7 2013 We speculated that the mechanism underlying might be that eugenol inhibited the oxidative stress and the activation of ERK1/2, p38MAPK and IKK/NF-kappaB pathways, subsequently inhibited the dissociation of Beclin1-Bcl2 heterodimer and autophagy, and finally impaired IAV replication. Eugenol 58-65 BCL2 apoptosis regulator Homo sapiens 214-218 23313798-0 2013 Eugenol with antioxidant activity inhibits MMP-9 related to metastasis in human fibrosarcoma cells. Eugenol 0-7 matrix metallopeptidase 9 Homo sapiens 43-48 23313798-7 2013 In addition, the inhibitory effects of eugenol on the activity and expression of MMP-9 activity related to metastasis were determined using gelatin zymography and western-blot. Eugenol 39-46 matrix metallopeptidase 9 Homo sapiens 81-86 23313798-9 2013 Furthermore, it was found that eugenol exerts inhibitory effects on MMP-9 via inactivation of ERK. Eugenol 31-38 matrix metallopeptidase 9 Homo sapiens 68-73 23313798-9 2013 Furthermore, it was found that eugenol exerts inhibitory effects on MMP-9 via inactivation of ERK. Eugenol 31-38 mitogen-activated protein kinase 1 Homo sapiens 94-97 21382956-7 2012 Furthermore, SFN and eugenol combinations at synergistic dose significantly downregulated the expression of Bcl-2, COX-2 and IL-beta but not the antagonistic combinations. Eugenol 21-28 BCL2 apoptosis regulator Homo sapiens 108-113 23239856-6 2013 RESULTS: When both oral OSCC and normal oral cells were incubated for 4 h with any of hydroquinone, benzoquinone, eugenol and phtharal, irreversible cell growth inhibition, accompanied by cell death occurred without induction of apoptotic markers, although caspase-3/-7 activation was observed at 6 h or later. Eugenol 114-121 caspase 3 Homo sapiens 257-266 23160676-0 2012 Comparative inhibitory effects of magnolol, honokiol, eugenol and bis-eugenol on cyclooxygenase-2 expression and nuclear factor-kappa B activation in RAW264.7 macrophage-like cells stimulated with fimbriae of Porphyromonas gingivalis. Eugenol 54-61 prostaglandin-endoperoxide synthase 2 Mus musculus 81-97 23160676-0 2012 Comparative inhibitory effects of magnolol, honokiol, eugenol and bis-eugenol on cyclooxygenase-2 expression and nuclear factor-kappa B activation in RAW264.7 macrophage-like cells stimulated with fimbriae of Porphyromonas gingivalis. Eugenol 54-61 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 113-135 23160676-10 2012 Both the fimbria-stimulated binding of NF-kappaB to its consensus sequence and phosphorylation-dependent proteolysis of inhibitor kappaB-alpha were markedly inhibited by magnilol and honokiol, whereas eugenol and bis-eugenol did not inhibit COX-2 expression and NF-kappaB activation. Eugenol 201-208 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 39-48 22946548-5 2012 In contrast, the pro-haptens eugenol, isoeugenol, and 2-aminophenol stimulated high levels of IL-8 release from neutrophils alone. Eugenol 29-36 C-X-C motif chemokine ligand 8 Homo sapiens 94-98 23015356-8 2012 Spinal pain-related peptide analysis revealed a decreased content of substance P and CGRP accompanied by an increase of dynorphin in animals treated with 40 mg/kg eugenol. Eugenol 163-170 calcitonin-related polypeptide alpha Rattus norvegicus 85-89 23422489-0 2013 Re-evaluation of anti-inflammatory potential of eugenol in IL-1beta-stimulated gingival fibroblast and pulp cells. Eugenol 48-55 interleukin 1 beta Homo sapiens 59-67 23422489-2 2013 In the present study, we investigated the effect of eugenol on interleukin-8 (IL-8) production by IL-1beta-stimulated oral cells. Eugenol 52-59 C-X-C motif chemokine ligand 8 Homo sapiens 63-76 23422489-2 2013 In the present study, we investigated the effect of eugenol on interleukin-8 (IL-8) production by IL-1beta-stimulated oral cells. Eugenol 52-59 C-X-C motif chemokine ligand 8 Homo sapiens 78-82 23422489-2 2013 In the present study, we investigated the effect of eugenol on interleukin-8 (IL-8) production by IL-1beta-stimulated oral cells. Eugenol 52-59 interleukin 1 beta Homo sapiens 98-106 23422489-8 2013 Eugenol (5-500 muM) significantly stimulated IL-8 production in HGF cells, but had bi-modal effects on HPCs, causing slight stimulation at lower concentration (5 muM) and a significant inhibition at higher concentration (500 muM), regardless of the presence or absence of serum. Eugenol 0-7 latexin Homo sapiens 15-18 23422489-8 2013 Eugenol (5-500 muM) significantly stimulated IL-8 production in HGF cells, but had bi-modal effects on HPCs, causing slight stimulation at lower concentration (5 muM) and a significant inhibition at higher concentration (500 muM), regardless of the presence or absence of serum. Eugenol 0-7 C-X-C motif chemokine ligand 8 Homo sapiens 45-49 23422489-8 2013 Eugenol (5-500 muM) significantly stimulated IL-8 production in HGF cells, but had bi-modal effects on HPCs, causing slight stimulation at lower concentration (5 muM) and a significant inhibition at higher concentration (500 muM), regardless of the presence or absence of serum. Eugenol 0-7 hepatocyte growth factor Homo sapiens 64-67 23422489-8 2013 Eugenol (5-500 muM) significantly stimulated IL-8 production in HGF cells, but had bi-modal effects on HPCs, causing slight stimulation at lower concentration (5 muM) and a significant inhibition at higher concentration (500 muM), regardless of the presence or absence of serum. Eugenol 0-7 latexin Homo sapiens 162-165 23422489-8 2013 Eugenol (5-500 muM) significantly stimulated IL-8 production in HGF cells, but had bi-modal effects on HPCs, causing slight stimulation at lower concentration (5 muM) and a significant inhibition at higher concentration (500 muM), regardless of the presence or absence of serum. Eugenol 0-7 latexin Homo sapiens 162-165 21382956-7 2012 Furthermore, SFN and eugenol combinations at synergistic dose significantly downregulated the expression of Bcl-2, COX-2 and IL-beta but not the antagonistic combinations. Eugenol 21-28 mitochondrially encoded cytochrome c oxidase II Homo sapiens 115-120 22426238-12 2012 It is concluded that eugenol activates TRPA1 channels in the SG, leading to an increase in the spontaneous release of L-glutamate to SG neurons, and that eugenol also produces a membrane hyperpolarization that is not mediated by TRP channels. Eugenol 21-28 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 39-44 22259019-9 2012 Inhibition of lorcaserin N-carbamoyl glucuronidation activities of UGT2B7, UGT2B15, and UGT2B17 in human liver microsomes by mefenamic acid, bisphenol A, and eugenol further substantiated the involvement of these UGT2B isoforms. Eugenol 158-165 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 67-73 22426238-10 2012 The effect of eugenol on sEPSC frequency was concentration-dependent with an EC(50) value of 3.8 mM and unaffected by a TRPV1 antagonist capsazepine, whereas inhibited by a nonspecific TRP antagonist ruthenium red and a TRPA1 antagonist HC-030031. Eugenol 14-21 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 220-225 22259019-9 2012 Inhibition of lorcaserin N-carbamoyl glucuronidation activities of UGT2B7, UGT2B15, and UGT2B17 in human liver microsomes by mefenamic acid, bisphenol A, and eugenol further substantiated the involvement of these UGT2B isoforms. Eugenol 158-165 UDP glucuronosyltransferase family 2 member B17 Homo sapiens 88-95 23028482-0 2012 Cch1p mediates Ca2+ influx to protect Saccharomyces cerevisiae against eugenol toxicity. Eugenol 71-78 Cch1p Saccharomyces cerevisiae S288C 0-5 23037170-4 2012 Furthermore, eugenol inhibited mononuclear cell infiltration into the knee joints of arthritic mice and also lowered the levels of cytokines (tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma and tumor growth factor (TGF)-beta) within the ankle joints. Eugenol 13-20 tumor necrosis factor Mus musculus 142-175 23037170-4 2012 Furthermore, eugenol inhibited mononuclear cell infiltration into the knee joints of arthritic mice and also lowered the levels of cytokines (tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma and tumor growth factor (TGF)-beta) within the ankle joints. Eugenol 13-20 interferon gamma Mus musculus 177-199 22686307-0 2012 Impact of eugenol and isoeugenol on AhR translocation, target gene expression, and proliferation in human HaCaT keratinocytes. Eugenol 10-17 aryl hydrocarbon receptor Homo sapiens 36-39 22686307-3 2012 In this study the effects of eugenol and isoeugenol were determined on intracellular localization of AhR, AhR target gene expression, AhR-dependent cell cycle regulation, and proliferation in HaCaT cells. Eugenol 29-36 aryl hydrocarbon receptor Homo sapiens 101-104 22686307-3 2012 In this study the effects of eugenol and isoeugenol were determined on intracellular localization of AhR, AhR target gene expression, AhR-dependent cell cycle regulation, and proliferation in HaCaT cells. Eugenol 29-36 aryl hydrocarbon receptor Homo sapiens 106-109 22686307-3 2012 In this study the effects of eugenol and isoeugenol were determined on intracellular localization of AhR, AhR target gene expression, AhR-dependent cell cycle regulation, and proliferation in HaCaT cells. Eugenol 29-36 aryl hydrocarbon receptor Homo sapiens 106-109 22686307-5 2012 Among the G(1) phase cell cycle-related proteins, levels of the retinoblastoma protein (RB), which is known to interact with AhR, and levels of the cyclin dependent kinase (CDK) 6 were reduced by eugenol and isoeugenol, whereas steady-state levels of CDK2 and CDK4 remained unaffected. Eugenol 196-203 aryl hydrocarbon receptor Homo sapiens 125-128 22686307-5 2012 Among the G(1) phase cell cycle-related proteins, levels of the retinoblastoma protein (RB), which is known to interact with AhR, and levels of the cyclin dependent kinase (CDK) 6 were reduced by eugenol and isoeugenol, whereas steady-state levels of CDK2 and CDK4 remained unaffected. Eugenol 196-203 cyclin dependent kinase 6 Homo sapiens 148-179 22686307-5 2012 Among the G(1) phase cell cycle-related proteins, levels of the retinoblastoma protein (RB), which is known to interact with AhR, and levels of the cyclin dependent kinase (CDK) 6 were reduced by eugenol and isoeugenol, whereas steady-state levels of CDK2 and CDK4 remained unaffected. Eugenol 196-203 cyclin dependent kinase 2 Homo sapiens 251-255 22686307-5 2012 Among the G(1) phase cell cycle-related proteins, levels of the retinoblastoma protein (RB), which is known to interact with AhR, and levels of the cyclin dependent kinase (CDK) 6 were reduced by eugenol and isoeugenol, whereas steady-state levels of CDK2 and CDK4 remained unaffected. Eugenol 196-203 cyclin dependent kinase 4 Homo sapiens 260-264 22686307-7 2012 In conclusion, data show that the antiproliferative properties of eugenol and isoeugenol in HaCaT cells are mediated through AhR, and thereby the molecular mechanisms of action in these cells were identified for the first time in this study. Eugenol 66-73 aryl hydrocarbon receptor Homo sapiens 125-128 23028482-6 2012 We show that the growth of yeast devoid the plasma membrane Ca(2+) channel, Cch1p, was hypersensitive to eugenol and that this correlated with reduced Ca(2+) elevations. Eugenol 105-112 Cch1p Saccharomyces cerevisiae S288C 76-81 23028482-7 2012 Taken together, these results indicate that a cch1p-mediated Ca(2+) influx is part of an intracellular signal which protects against eugenol toxicity. Eugenol 133-140 Cch1p Saccharomyces cerevisiae S288C 46-51 21593771-4 2011 In organ culture, TRPV3 activation by plant-derived (e.g., eugenol, 10-1,000 muM) or synthetic (e.g., 2-aminoethoxydiphenyl borate, 1-300 muM) agonists resulted in a dose-dependent inhibition of hair shaft elongation, suppression of proliferation, and induction of apoptosis and premature HF regression (catagen). Eugenol 59-66 transient receptor potential cation channel subfamily V member 3 Homo sapiens 18-23 21939359-9 2011 In addition, the expression analysis of genes involved in apoptosis and inflammation revealed significant downregulation of Bcl-2, COX-2, and IL-1beta on treatment with eugenol. Eugenol 169-176 BCL2 apoptosis regulator Homo sapiens 124-129 21939359-9 2011 In addition, the expression analysis of genes involved in apoptosis and inflammation revealed significant downregulation of Bcl-2, COX-2, and IL-1beta on treatment with eugenol. Eugenol 169-176 mitochondrially encoded cytochrome c oxidase II Homo sapiens 131-136 21939359-9 2011 In addition, the expression analysis of genes involved in apoptosis and inflammation revealed significant downregulation of Bcl-2, COX-2, and IL-1beta on treatment with eugenol. Eugenol 169-176 interleukin 1 beta Homo sapiens 142-150 21742781-7 2011 Under coculture conditions, the prohaptens eugenol, 2-methoxy-4-methylphenol, and benzo[a]pyrene induced a significantly higher upregulation of CD86 expression on THP-1. Eugenol 43-50 CD86 molecule Homo sapiens 144-148 21742781-7 2011 Under coculture conditions, the prohaptens eugenol, 2-methoxy-4-methylphenol, and benzo[a]pyrene induced a significantly higher upregulation of CD86 expression on THP-1. Eugenol 43-50 GLI family zinc finger 2 Homo sapiens 163-168 22666439-0 2012 Fractionation of a herbal antidiarrheal medicine reveals eugenol as an inhibitor of Ca2+-Activated Cl- channel TMEM16A. Eugenol 57-64 anoctamin 1, calcium activated chloride channel Mus musculus 111-118 22666439-5 2012 Eugenol fully inhibited TMEM16A Cl(-) conductance with single-site IC(50)~150 microM. Eugenol 0-7 anoctamin 1, calcium activated chloride channel Mus musculus 24-31 22666439-6 2012 Eugenol inhibition of TMEM16A in interstitial cells of Cajal produced strong inhibition of intestinal contraction in mouse ileal segments. Eugenol 0-7 anoctamin 1, calcium activated chloride channel Mus musculus 22-29 22666439-7 2012 TMEM16A Cl(-) channel inhibition adds to the list of eugenol molecular targets and may account for some of its biological activities. Eugenol 53-60 anoctamin 1, calcium activated chloride channel Mus musculus 0-7 21656368-7 2011 Immunohistochemical analysis revealed that eugenol prevented the doxorubicin-induced activation of caspase-3 in cardiomyocytes. Eugenol 43-50 caspase 3 Rattus norvegicus 99-108 21706355-4 2011 The mRNA expression of ALP was scarcely affected in cells exposed to eugenol, whereas the mRNA and protein expression of BSP was down-regulated depending on the concentrations of eugenol. Eugenol 69-76 alkaline phosphatase, placental Homo sapiens 23-26 21706355-4 2011 The mRNA expression of ALP was scarcely affected in cells exposed to eugenol, whereas the mRNA and protein expression of BSP was down-regulated depending on the concentrations of eugenol. Eugenol 179-186 integrin binding sialoprotein Homo sapiens 121-124 20434464-5 2010 Administration of eugenol induced apoptosis via the mitochondrial pathway by modulating the Bcl-2 family proteins, Apaf-1, cytochrome C, and caspases and inhibiting invasion, and angiogenesis as evidenced by changes in the activities of MMPs and the expression of MMP-2 and -9, VEGF, VEGFR1, TIMP-2 and RECK. Eugenol 18-25 caspase 9 Rattus norvegicus 141-149 21284934-6 2011 In addition by using MRP1 expressing inside-out membrane vesicles we revealed that the transport of eugenol is mediated by MRP1. Eugenol 100-107 ATP binding cassette subfamily C member 1 Homo sapiens 21-25 21284934-6 2011 In addition by using MRP1 expressing inside-out membrane vesicles we revealed that the transport of eugenol is mediated by MRP1. Eugenol 100-107 ATP binding cassette subfamily C member 1 Homo sapiens 123-127 21237301-5 2011 The effect of eugenol and N-acetylcysteine on the release of Th1 cytokines (TNF-alpha, IL-12) and Th2 cytokines (IL-10, TGF-beta) was measured by ELISA, and the expression of these cytokines at mRNA level were analyzed by real-time PCR. Eugenol 14-21 negative elongation factor complex member C/D, Th1l Mus musculus 61-64 21237301-5 2011 The effect of eugenol and N-acetylcysteine on the release of Th1 cytokines (TNF-alpha, IL-12) and Th2 cytokines (IL-10, TGF-beta) was measured by ELISA, and the expression of these cytokines at mRNA level were analyzed by real-time PCR. Eugenol 14-21 tumor necrosis factor Mus musculus 76-85 21237301-9 2011 Eugenol and N-acetylcysteine were found to down regulate the Th1 cytokines in nicotine treated macrophages with concurrent activation of Th2 responses. Eugenol 0-7 negative elongation factor complex member C/D, Th1l Mus musculus 61-64 21237301-9 2011 Eugenol and N-acetylcysteine were found to down regulate the Th1 cytokines in nicotine treated macrophages with concurrent activation of Th2 responses. Eugenol 0-7 heart and neural crest derivatives expressed 2 Mus musculus 137-140 20630305-3 2010 The aim of this study was to investigate the effects of an epoxy resin-based sealer AH26, a zinc oxide-eugenol-based sealer Canals, and a paste sealer N2 on the expression of ALP in human osteoblastic cell line U2OS cells. Eugenol 103-110 alkaline phosphatase, placental Homo sapiens 175-178 20434464-5 2010 Administration of eugenol induced apoptosis via the mitochondrial pathway by modulating the Bcl-2 family proteins, Apaf-1, cytochrome C, and caspases and inhibiting invasion, and angiogenesis as evidenced by changes in the activities of MMPs and the expression of MMP-2 and -9, VEGF, VEGFR1, TIMP-2 and RECK. Eugenol 18-25 BCL2, apoptosis regulator Rattus norvegicus 92-97 20434464-5 2010 Administration of eugenol induced apoptosis via the mitochondrial pathway by modulating the Bcl-2 family proteins, Apaf-1, cytochrome C, and caspases and inhibiting invasion, and angiogenesis as evidenced by changes in the activities of MMPs and the expression of MMP-2 and -9, VEGF, VEGFR1, TIMP-2 and RECK. Eugenol 18-25 apoptotic peptidase activating factor 1 Rattus norvegicus 115-121 21658309-2 2011 This study aims to examine the anti-inflammatory effects of eugenol, isoeugenol and four of their derivatives on expression of inducible nitric oxide synthase (iNOS) activated by lipopolysaccharide (LPS) in mouse macrophages (RAW 264.7), and to investigate molecular mechanisms underlying these effects. Eugenol 60-67 nitric oxide synthase 2, inducible Mus musculus 127-158 21658309-2 2011 This study aims to examine the anti-inflammatory effects of eugenol, isoeugenol and four of their derivatives on expression of inducible nitric oxide synthase (iNOS) activated by lipopolysaccharide (LPS) in mouse macrophages (RAW 264.7), and to investigate molecular mechanisms underlying these effects. Eugenol 60-67 nitric oxide synthase 2, inducible Mus musculus 160-164 20724125-8 2011 Eugenol and arecoline significantly increase the expressions of the glucose transporter type 4 (GLUT4) and phosphoinositide 3-kinase (PI3K) genes, but not the peroxisome proliferator-activated receptor (PPAR) gamma. Eugenol 0-7 solute carrier family 2 member 4 Homo sapiens 68-94 20724125-8 2011 Eugenol and arecoline significantly increase the expressions of the glucose transporter type 4 (GLUT4) and phosphoinositide 3-kinase (PI3K) genes, but not the peroxisome proliferator-activated receptor (PPAR) gamma. Eugenol 0-7 solute carrier family 2 member 4 Homo sapiens 96-101 20537511-0 2010 Eugenol restricts DMBA croton oil induced skin carcinogenesis in mice: downregulation of c-Myc and H-ras, and activation of p53 dependent apoptotic pathway. Eugenol 0-7 Harvey rat sarcoma virus oncogene Mus musculus 99-104 20537511-0 2010 Eugenol restricts DMBA croton oil induced skin carcinogenesis in mice: downregulation of c-Myc and H-ras, and activation of p53 dependent apoptotic pathway. Eugenol 0-7 transformation related protein 53, pseudogene Mus musculus 124-127 20537511-13 2010 Eugenol treatment led to the downregulation of c-Myc, H-ras and Bcl2 expression along with upregulation of P53, Bax and active Caspase-3 expression in the skin lesions. Eugenol 0-7 Harvey rat sarcoma virus oncogene Mus musculus 54-59 20537511-13 2010 Eugenol treatment led to the downregulation of c-Myc, H-ras and Bcl2 expression along with upregulation of P53, Bax and active Caspase-3 expression in the skin lesions. Eugenol 0-7 B cell leukemia/lymphoma 2 Mus musculus 64-68 20537511-13 2010 Eugenol treatment led to the downregulation of c-Myc, H-ras and Bcl2 expression along with upregulation of P53, Bax and active Caspase-3 expression in the skin lesions. Eugenol 0-7 transformation related protein 53, pseudogene Mus musculus 107-110 20537511-13 2010 Eugenol treatment led to the downregulation of c-Myc, H-ras and Bcl2 expression along with upregulation of P53, Bax and active Caspase-3 expression in the skin lesions. Eugenol 0-7 BCL2-associated X protein Mus musculus 112-115 20537511-13 2010 Eugenol treatment led to the downregulation of c-Myc, H-ras and Bcl2 expression along with upregulation of P53, Bax and active Caspase-3 expression in the skin lesions. Eugenol 0-7 caspase 3 Mus musculus 127-136 20537511-14 2010 CONCLUSION: Restriction of skin carcinogenesis at dysplastic stage by eugenol was due to attenuation of c-Myc, H-ras and modification of some p53 associated gene expression. Eugenol 70-77 Harvey rat sarcoma virus oncogene Mus musculus 111-116 20537511-14 2010 CONCLUSION: Restriction of skin carcinogenesis at dysplastic stage by eugenol was due to attenuation of c-Myc, H-ras and modification of some p53 associated gene expression. Eugenol 70-77 transformation related protein 53, pseudogene Mus musculus 142-145 20434464-5 2010 Administration of eugenol induced apoptosis via the mitochondrial pathway by modulating the Bcl-2 family proteins, Apaf-1, cytochrome C, and caspases and inhibiting invasion, and angiogenesis as evidenced by changes in the activities of MMPs and the expression of MMP-2 and -9, VEGF, VEGFR1, TIMP-2 and RECK. Eugenol 18-25 matrix metallopeptidase 2 Rattus norvegicus 237-241 20434464-5 2010 Administration of eugenol induced apoptosis via the mitochondrial pathway by modulating the Bcl-2 family proteins, Apaf-1, cytochrome C, and caspases and inhibiting invasion, and angiogenesis as evidenced by changes in the activities of MMPs and the expression of MMP-2 and -9, VEGF, VEGFR1, TIMP-2 and RECK. Eugenol 18-25 matrix metallopeptidase 2 Rattus norvegicus 264-276 20434464-5 2010 Administration of eugenol induced apoptosis via the mitochondrial pathway by modulating the Bcl-2 family proteins, Apaf-1, cytochrome C, and caspases and inhibiting invasion, and angiogenesis as evidenced by changes in the activities of MMPs and the expression of MMP-2 and -9, VEGF, VEGFR1, TIMP-2 and RECK. Eugenol 18-25 vascular endothelial growth factor A Rattus norvegicus 278-282 20434464-5 2010 Administration of eugenol induced apoptosis via the mitochondrial pathway by modulating the Bcl-2 family proteins, Apaf-1, cytochrome C, and caspases and inhibiting invasion, and angiogenesis as evidenced by changes in the activities of MMPs and the expression of MMP-2 and -9, VEGF, VEGFR1, TIMP-2 and RECK. Eugenol 18-25 Fms related receptor tyrosine kinase 1 Rattus norvegicus 284-290 19769960-7 2009 There was a significant increase in the level of radical generation, NADPH oxidase and myeloperoxidase activity, lipid, protein, DNA damage and oxidized glutathione level in nicotine-treated group, which were significantly reduced by eugenol and N-acetylcysteine supplementation. Eugenol 234-241 myeloperoxidase Mus musculus 87-102 20434464-5 2010 Administration of eugenol induced apoptosis via the mitochondrial pathway by modulating the Bcl-2 family proteins, Apaf-1, cytochrome C, and caspases and inhibiting invasion, and angiogenesis as evidenced by changes in the activities of MMPs and the expression of MMP-2 and -9, VEGF, VEGFR1, TIMP-2 and RECK. Eugenol 18-25 TIMP metallopeptidase inhibitor 2 Rattus norvegicus 292-298 20434464-5 2010 Administration of eugenol induced apoptosis via the mitochondrial pathway by modulating the Bcl-2 family proteins, Apaf-1, cytochrome C, and caspases and inhibiting invasion, and angiogenesis as evidenced by changes in the activities of MMPs and the expression of MMP-2 and -9, VEGF, VEGFR1, TIMP-2 and RECK. Eugenol 18-25 reversion-inducing-cysteine-rich protein with kazal motifs Rattus norvegicus 303-307 19969449-1 2010 The ability of a non-commercial immobilized Staphylococcus aureus lipase to catalyze the esterification of eugenol with benzoic acid was checked and the antioxidant power of the ester formed was evaluated. Eugenol 107-114 lipase Staphylococcus aureus 66-72 20075264-1 2010 Eugenol, a methoxyphenol component of clove oil, suppresses cyclooxygenase-2 expression, while eugenol dimers prevent nuclear factor-kappaB (NF-kappaB) activation and inflammatory cytokine expression in lipopolysaccharide-stimulated macrophages. Eugenol 95-102 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 141-150 20152883-2 2010 Eugenol possesses analgesic effects that may be related to the inhibition of voltage-dependent Na+ channels and/or to the activation of TRPV1 receptors or both. Eugenol 0-7 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 136-141 20043298-9 2010 To ascertain the molecular mechanisms implicated in the antitumor promoting activity of eugenol, its effect was investigated on markers of tumor promotion and inflammation: ODC activity and iNOS and COX-2 expression, and on levels of proinflammatory cytokines (IL-6, TNF-alpha, and PGE(2)). Eugenol 88-95 ornithine decarboxylase, structural 1 Mus musculus 173-176 20043298-9 2010 To ascertain the molecular mechanisms implicated in the antitumor promoting activity of eugenol, its effect was investigated on markers of tumor promotion and inflammation: ODC activity and iNOS and COX-2 expression, and on levels of proinflammatory cytokines (IL-6, TNF-alpha, and PGE(2)). Eugenol 88-95 nitric oxide synthase 2, inducible Mus musculus 190-194 20043298-9 2010 To ascertain the molecular mechanisms implicated in the antitumor promoting activity of eugenol, its effect was investigated on markers of tumor promotion and inflammation: ODC activity and iNOS and COX-2 expression, and on levels of proinflammatory cytokines (IL-6, TNF-alpha, and PGE(2)). Eugenol 88-95 interleukin 6 Mus musculus 261-265 20043298-9 2010 To ascertain the molecular mechanisms implicated in the antitumor promoting activity of eugenol, its effect was investigated on markers of tumor promotion and inflammation: ODC activity and iNOS and COX-2 expression, and on levels of proinflammatory cytokines (IL-6, TNF-alpha, and PGE(2)). Eugenol 88-95 tumor necrosis factor Mus musculus 267-276 20013178-12 2010 The protective action of eugenol has been found to be due to interception of secondary radicals derived from ER lipids rather than interfering with primary radicals of CCl(4) (CCl(3)/CCl(3)OO). Eugenol 25-32 C-C motif chemokine ligand 4 Homo sapiens 168-174 20013178-12 2010 The protective action of eugenol has been found to be due to interception of secondary radicals derived from ER lipids rather than interfering with primary radicals of CCl(4) (CCl(3)/CCl(3)OO). Eugenol 25-32 C-C motif chemokine ligand 3 Homo sapiens 176-182 20036707-11 2010 Eugenol pretreatment prevented liver injury by decreasing CYP2E1 activity, lipid peroxidation indices, protein oxidation and inflammatory markers and by improving the antioxidant status. Eugenol 0-7 cytochrome P450, family 2, subfamily e, polypeptide 1 Rattus norvegicus 58-64 19501497-9 2009 Eugenol and capsaicin inhibited thromboxane B2 (TXB2) formation in platelets in a dose-dependent manner challenged with AA apparently by the inhibition of the cyclooxygenase (COX-1). Eugenol 0-7 mitochondrially encoded cytochrome c oxidase I Homo sapiens 175-180 19376653-2 2009 Interestingly, eugenol shares several pharmacological actions with local anesthetics which include inhibition of voltage-gated sodium channel (VGSC) and activation of transient receptor potential vanilloid subtype 1 (TRPV1). Eugenol 15-22 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 167-215 19376653-2 2009 Interestingly, eugenol shares several pharmacological actions with local anesthetics which include inhibition of voltage-gated sodium channel (VGSC) and activation of transient receptor potential vanilloid subtype 1 (TRPV1). Eugenol 15-22 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 217-222 19376653-7 2009 At cellular level, eugenol reversibly inhibited APs and VGSCs in IB(4)+/TRPV1+/Na(v)1.8+ nociceptive TG neurons (Type I-Type III) and IB(4)-/TRPV1-/Na(v)1.8- nociceptive TG neurons (Type IV). Eugenol 19-26 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 72-77 19376653-7 2009 At cellular level, eugenol reversibly inhibited APs and VGSCs in IB(4)+/TRPV1+/Na(v)1.8+ nociceptive TG neurons (Type I-Type III) and IB(4)-/TRPV1-/Na(v)1.8- nociceptive TG neurons (Type IV). Eugenol 19-26 sodium voltage-gated channel alpha subunit 10 Rattus norvegicus 79-87 19376653-7 2009 At cellular level, eugenol reversibly inhibited APs and VGSCs in IB(4)+/TRPV1+/Na(v)1.8+ nociceptive TG neurons (Type I-Type III) and IB(4)-/TRPV1-/Na(v)1.8- nociceptive TG neurons (Type IV). Eugenol 19-26 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 141-146 19376653-7 2009 At cellular level, eugenol reversibly inhibited APs and VGSCs in IB(4)+/TRPV1+/Na(v)1.8+ nociceptive TG neurons (Type I-Type III) and IB(4)-/TRPV1-/Na(v)1.8- nociceptive TG neurons (Type IV). Eugenol 19-26 sodium voltage-gated channel alpha subunit 10 Rattus norvegicus 148-156 19101496-7 2009 RESULTS: Significant reductions were recorded in the expression ratio and/or the staining intensity of E-selectin, ICAM-1, and VCAM-1 in samples removed 48 h after treatment with eugenol-containing cement compared with intact teeth. Eugenol 179-186 selectin E Homo sapiens 103-113 19084597-6 2009 Combining 2-ME(2) with eugenol (i) inhibited growth of prostate cancer cells and induced apoptosis at lower concentrations than either single agent alone; (ii) analysis of the data using combination index (CI) showed CI values of 0.4 indicating strong synergistic interaction; (iii) increased population of cells G(2)/M phase by 4.5-fold (p=0.01); (iv) significantly reduced expression of antiapoptotic protein Bcl-2 and enhanced expression of proapoptotic protein Bax. Eugenol 23-30 BCL2 apoptosis regulator Homo sapiens 411-416 19084597-6 2009 Combining 2-ME(2) with eugenol (i) inhibited growth of prostate cancer cells and induced apoptosis at lower concentrations than either single agent alone; (ii) analysis of the data using combination index (CI) showed CI values of 0.4 indicating strong synergistic interaction; (iii) increased population of cells G(2)/M phase by 4.5-fold (p=0.01); (iv) significantly reduced expression of antiapoptotic protein Bcl-2 and enhanced expression of proapoptotic protein Bax. Eugenol 23-30 BCL2 associated X, apoptosis regulator Homo sapiens 465-468 19101496-7 2009 RESULTS: Significant reductions were recorded in the expression ratio and/or the staining intensity of E-selectin, ICAM-1, and VCAM-1 in samples removed 48 h after treatment with eugenol-containing cement compared with intact teeth. Eugenol 179-186 intercellular adhesion molecule 1 Homo sapiens 115-121 19101496-7 2009 RESULTS: Significant reductions were recorded in the expression ratio and/or the staining intensity of E-selectin, ICAM-1, and VCAM-1 in samples removed 48 h after treatment with eugenol-containing cement compared with intact teeth. Eugenol 179-186 vascular cell adhesion molecule 1 Homo sapiens 127-133 19101496-8 2009 This reduction was significant only for ICAM-1 for 48-h eugenol-free samples. Eugenol 56-63 intercellular adhesion molecule 1 Homo sapiens 40-46 19101496-9 2009 Moreover, the eugenol-free cement group indicated considerably higher E-selectin, ICAM-1, and VCAM-1 expression compared with the eugenol-containing group (P < .005) 48 h after the application. Eugenol 14-21 selectin E Homo sapiens 70-80 19101496-9 2009 Moreover, the eugenol-free cement group indicated considerably higher E-selectin, ICAM-1, and VCAM-1 expression compared with the eugenol-containing group (P < .005) 48 h after the application. Eugenol 14-21 intercellular adhesion molecule 1 Homo sapiens 82-88 19101496-9 2009 Moreover, the eugenol-free cement group indicated considerably higher E-selectin, ICAM-1, and VCAM-1 expression compared with the eugenol-containing group (P < .005) 48 h after the application. Eugenol 14-21 vascular cell adhesion molecule 1 Homo sapiens 94-100 19967073-6 2008 Eugenol inhibited not only Ca(2+) transients evoked by alpha ,beta-meATP, the selective P2X(3) agonist, in capsaicin-insensitive TG neurons, but also ATP-induced currents in P2X(3)-expressing HEK293 cells without co-expression of transient receptor potential vanilloid 1 (TRPV1). Eugenol 0-7 purinergic receptor P2X 3 Homo sapiens 88-94 19967073-6 2008 Eugenol inhibited not only Ca(2+) transients evoked by alpha ,beta-meATP, the selective P2X(3) agonist, in capsaicin-insensitive TG neurons, but also ATP-induced currents in P2X(3)-expressing HEK293 cells without co-expression of transient receptor potential vanilloid 1 (TRPV1). Eugenol 0-7 purinergic receptor P2X 3 Homo sapiens 174-180 19967073-2 2008 We have recently demonstrated voltage-gated Na(+) and Ca(2+) channels as molecular targets for its analgesic effects, and hypothesized that eugenol acts on P2X(3), another pain receptor expressed in trigeminal ganglion (TG), and tested the effects of eugenol by whole-cell patch clamp and Ca(2+) imaging techniques. Eugenol 140-147 purinergic receptor P2X 3 Homo sapiens 156-162 19967073-2 2008 We have recently demonstrated voltage-gated Na(+) and Ca(2+) channels as molecular targets for its analgesic effects, and hypothesized that eugenol acts on P2X(3), another pain receptor expressed in trigeminal ganglion (TG), and tested the effects of eugenol by whole-cell patch clamp and Ca(2+) imaging techniques. Eugenol 251-258 purinergic receptor P2X 3 Homo sapiens 156-162 19967073-6 2008 Eugenol inhibited not only Ca(2+) transients evoked by alpha ,beta-meATP, the selective P2X(3) agonist, in capsaicin-insensitive TG neurons, but also ATP-induced currents in P2X(3)-expressing HEK293 cells without co-expression of transient receptor potential vanilloid 1 (TRPV1). Eugenol 0-7 transient receptor potential cation channel subfamily V member 1 Homo sapiens 230-270 19967073-6 2008 Eugenol inhibited not only Ca(2+) transients evoked by alpha ,beta-meATP, the selective P2X(3) agonist, in capsaicin-insensitive TG neurons, but also ATP-induced currents in P2X(3)-expressing HEK293 cells without co-expression of transient receptor potential vanilloid 1 (TRPV1). Eugenol 0-7 transient receptor potential cation channel subfamily V member 1 Homo sapiens 272-277 19967073-7 2008 We suggest, therefore, that eugenol inhibits P2X(3) currents in a TRPV1-independent manner, which contributes to its analgesic effect. Eugenol 28-35 purinergic receptor P2X 3 Homo sapiens 45-51 19967073-7 2008 We suggest, therefore, that eugenol inhibits P2X(3) currents in a TRPV1-independent manner, which contributes to its analgesic effect. Eugenol 28-35 transient receptor potential cation channel subfamily V member 1 Homo sapiens 66-71 18291278-4 2008 The aim of this study was to investigate the effects of epoxy resin-based root canal sealer AH26 and zinc oxide-eugenol-based root canal sealer Canals and one paste sealer N2 on the expression of MMPs and PAs in human osteoblastic cell line U2OS cells. Eugenol 112-119 matrix metallopeptidase 2 Homo sapiens 196-200 18522382-3 2008 The lowest-energy conformers of eugenol (SAA+, SAA- and SAS) stabilized by the intramolecular hydrogen bond differ only in the arrangement of the allyl group with respect to the aromatic ring. Eugenol 32-39 serum amyloid A1 cluster Homo sapiens 41-44 18522382-3 2008 The lowest-energy conformers of eugenol (SAA+, SAA- and SAS) stabilized by the intramolecular hydrogen bond differ only in the arrangement of the allyl group with respect to the aromatic ring. Eugenol 32-39 serum amyloid A1 cluster Homo sapiens 47-50 18849043-5 2008 Free eugenol was not detectable in any of our samples, which necessitated enzymatic cleavage with beta-glucuronidase prior to HS-SPME sampling. Eugenol 5-12 glucuronidase beta Homo sapiens 98-116 18543354-4 2008 Pretreatment with a single dose of eugenol (100 mg/kg, orally), 1 h before indomethacin administration caused significant reductions in gastric mucosal lesions, gastric acid outputs and pepsin activity associated with a significant increase in mucin concentration. Eugenol 35-42 solute carrier family 13 member 2 Rattus norvegicus 244-249 18543354-6 2008 The protective effect afforded by eugenol was significantly inhibited by prior administration of glibenclamide, the ATP-sensitive potassium (K(ATP)) channel blocker, but not by prior use of ruthenium red, the transient receptor potential vanilloid 1 (TRPV1) antagonist. Eugenol 34-41 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 251-256 18543354-7 2008 The results indicate that the anti-ulcer effect of eugenol is mediated by opening of K(ATP) channels, scavenging free radicals, decreasing acid-pepsin secretion, increasing mucin production, and preventing the deleterious rise in nitric oxide level. Eugenol 51-58 solute carrier family 13 member 2 Rattus norvegicus 173-178 17698059-8 2007 The isoeugenol analogues eugenol and allylbenzene also inhibited LPS-induced NF-kappaB signaling and iNOS expression, albeit with less potency than isoeugenol. Eugenol 7-14 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 77-86 18218839-0 2008 Modulation of CaV2.3 calcium channel currents by eugenol. Eugenol 49-56 calcium voltage-gated channel subunit alpha1 E Homo sapiens 14-20 18218839-2 2008 We have recently demonstrated the inhibition of Ca(V)2.2 calcium channel and sodium channel currents to be molecular mechanisms underlying the analgesic effect of eugenol. Eugenol 163-170 calcium voltage-gated channel subunit alpha1 B Homo sapiens 48-56 18218839-3 2008 We hypothesized that Ca(V)2.3 channels are also modulated by eugenol and investigated its mode of action using the whole-cell patch-clamp technique in a heterologous expression system. Eugenol 61-68 calcium voltage-gated channel subunit alpha1 E Homo sapiens 21-29 18218839-4 2008 Eugenol inhibited calcium currents in the E52 cell line, stably expressing the human Ca(V)2.3 calcium channels, where TRPV1 is not endogenously expressed. Eugenol 0-7 calcium voltage-gated channel subunit alpha1 E Homo sapiens 85-93 18218839-4 2008 Eugenol inhibited calcium currents in the E52 cell line, stably expressing the human Ca(V)2.3 calcium channels, where TRPV1 is not endogenously expressed. Eugenol 0-7 transient receptor potential cation channel subfamily V member 1 Homo sapiens 118-123 18218839-7 2008 The results indicate that eugenol has mechanisms distinct from those of capsaicin for modulating Ca(V)2.3 channels. Eugenol 26-33 calcium voltage-gated channel subunit alpha1 E Homo sapiens 97-105 18218839-8 2008 We suggest that inhibition of Ca(V)2.3 channels by eugenol might contribute to its analgesic effect. Eugenol 51-58 calcium voltage-gated channel subunit alpha1 E Homo sapiens 30-38 17698059-8 2007 The isoeugenol analogues eugenol and allylbenzene also inhibited LPS-induced NF-kappaB signaling and iNOS expression, albeit with less potency than isoeugenol. Eugenol 7-14 nitric oxide synthase 2, inducible Mus musculus 101-105 17889685-0 2007 Eugenol modulates cyclooxygenase-2 expression through the activation of nuclear factor kappa B in human osteoblasts. Eugenol 0-7 prostaglandin-endoperoxide synthase 2 Homo sapiens 18-34 17936526-6 2007 Thus, DNBS, isoeugenol, eugenol and hydroxycitronellal consistently modulated CCR5, CCL27, CCL2 and CCR7, respectively, whereas the CXCL10 gene was regulated by SDS. Eugenol 15-22 C-C motif chemokine receptor 5 Homo sapiens 78-82 17936526-6 2007 Thus, DNBS, isoeugenol, eugenol and hydroxycitronellal consistently modulated CCR5, CCL27, CCL2 and CCR7, respectively, whereas the CXCL10 gene was regulated by SDS. Eugenol 15-22 C-C motif chemokine ligand 27 Homo sapiens 84-89 17936526-6 2007 Thus, DNBS, isoeugenol, eugenol and hydroxycitronellal consistently modulated CCR5, CCL27, CCL2 and CCR7, respectively, whereas the CXCL10 gene was regulated by SDS. Eugenol 15-22 C-C motif chemokine ligand 2 Homo sapiens 84-88 17936526-6 2007 Thus, DNBS, isoeugenol, eugenol and hydroxycitronellal consistently modulated CCR5, CCL27, CCL2 and CCR7, respectively, whereas the CXCL10 gene was regulated by SDS. Eugenol 15-22 C-C motif chemokine receptor 7 Homo sapiens 100-104 17889685-4 2007 In addition, COX-2 protein expression in osteoblasts was induced by eugenol in a dose-dependent manner. Eugenol 68-75 prostaglandin-endoperoxide synthase 2 Homo sapiens 13-18 17889685-0 2007 Eugenol modulates cyclooxygenase-2 expression through the activation of nuclear factor kappa B in human osteoblasts. Eugenol 0-7 nuclear factor kappa B subunit 1 Homo sapiens 72-94 17889685-5 2007 Furthermore, the eugenol-modulated COX-2 expression was inhibited by an NF-kappaB inhibitor, N-acetylcysteine. Eugenol 17-24 prostaglandin-endoperoxide synthase 2 Homo sapiens 35-40 17889685-5 2007 Furthermore, the eugenol-modulated COX-2 expression was inhibited by an NF-kappaB inhibitor, N-acetylcysteine. Eugenol 17-24 nuclear factor kappa B subunit 1 Homo sapiens 72-81 17889685-2 2007 In this study, the effects of eugenol on the activation of nuclear factor kappa B (NF-kappaB) and the expression of cyclooxygenase-2 (COX-2) in human osteoblasts were investigated. Eugenol 30-37 nuclear factor kappa B subunit 1 Homo sapiens 59-81 17889685-6 2007 Taken together, eugenol might induce COX-2 expression through the activation of NF-kappaB in human osteoblasts. Eugenol 16-23 prostaglandin-endoperoxide synthase 2 Homo sapiens 37-42 17889685-6 2007 Taken together, eugenol might induce COX-2 expression through the activation of NF-kappaB in human osteoblasts. Eugenol 16-23 nuclear factor kappa B subunit 1 Homo sapiens 80-89 17889685-2 2007 In this study, the effects of eugenol on the activation of nuclear factor kappa B (NF-kappaB) and the expression of cyclooxygenase-2 (COX-2) in human osteoblasts were investigated. Eugenol 30-37 nuclear factor kappa B subunit 1 Homo sapiens 83-92 17889685-3 2007 The results showed that eugenol activated the nuclear translocation of NF-kappaB. Eugenol 24-31 nuclear factor kappa B subunit 1 Homo sapiens 71-80 17720863-2 2007 Eugenol inhibits voltage-activated Na(+) and Ca(2+) channels in a transient receptor potential vanilloid 1 (TRPV1)-independent manner. Eugenol 0-7 transient receptor potential cation channel subfamily V member 1 Homo sapiens 66-106 17720863-2 2007 Eugenol inhibits voltage-activated Na(+) and Ca(2+) channels in a transient receptor potential vanilloid 1 (TRPV1)-independent manner. Eugenol 0-7 transient receptor potential cation channel subfamily V member 1 Homo sapiens 108-113 17720863-6 2007 Eugenol inhibited human Kv1.5 currents stably expressed in Ltk(-) cells, where TRPV1 is not endogenously expressed. Eugenol 0-7 potassium voltage-gated channel subfamily A member 5 Homo sapiens 24-29 17720863-6 2007 Eugenol inhibited human Kv1.5 currents stably expressed in Ltk(-) cells, where TRPV1 is not endogenously expressed. Eugenol 0-7 leukocyte receptor tyrosine kinase Homo sapiens 59-62 17720863-6 2007 Eugenol inhibited human Kv1.5 currents stably expressed in Ltk(-) cells, where TRPV1 is not endogenously expressed. Eugenol 0-7 transient receptor potential cation channel subfamily V member 1 Homo sapiens 79-84 17720863-7 2007 We conclude that eugenol inhibits voltage-gated K(+) currents in a TRPV1-independent manner. Eugenol 17-24 transient receptor potential cation channel subfamily V member 1 Homo sapiens 67-72 17275817-0 2007 Eugenol inhibit 7,12-dimethylbenz[a]anthracene-induced genotoxicity in MCF-7 cells: Bifunctional effects on CYP1 and NAD(P)H:quinone oxidoreductase. Eugenol 0-7 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 108-112 17275817-4 2007 CYP1A1 and CYP1B1 activity, which catalyze the biotransformation of DMBA, were strongly inhibited by eugenol. Eugenol 101-108 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 0-6 17533171-2 2007 We found Tsc-22 downregulation in livers from B6C3F1 mice following treatment for 2 weeks with carcinogenic doses of the antianxiety drug oxazepam (2500 ppm) or the peroxisome proliferator Wyeth-14,643 (500 ppm) but not with two other carcinogens such as o-nitrotoluene or methyleugenol or three noncarcinogens including p-nitrotoluene, eugenol, or acetaminophen. Eugenol 279-286 TSC22 domain family, member 1 Mus musculus 9-15 17760996-6 2007 The histone acetyltransferase GCN5 can acetylate the Drosophila remodelling ATPase ISWI at a single, conserved lysine, K753, in vivo and in vitro. Eugenol 119-123 Gcn5 acetyltransferase Drosophila melanogaster 30-34 17760996-6 2007 The histone acetyltransferase GCN5 can acetylate the Drosophila remodelling ATPase ISWI at a single, conserved lysine, K753, in vivo and in vitro. Eugenol 119-123 Imitation SWI Drosophila melanogaster 83-87 17509409-4 2007 Eugenol was shown to block the release of the bone resorbing mediators, including interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), and prostaglandin E2 from LPS-stimulated macrophages. Eugenol 0-7 interleukin 1 beta Homo sapiens 82-99 17509409-4 2007 Eugenol was shown to block the release of the bone resorbing mediators, including interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), and prostaglandin E2 from LPS-stimulated macrophages. Eugenol 0-7 interleukin 1 beta Homo sapiens 101-109 17509409-4 2007 Eugenol was shown to block the release of the bone resorbing mediators, including interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), and prostaglandin E2 from LPS-stimulated macrophages. Eugenol 0-7 tumor necrosis factor Homo sapiens 112-139 17509409-4 2007 Eugenol was shown to block the release of the bone resorbing mediators, including interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), and prostaglandin E2 from LPS-stimulated macrophages. Eugenol 0-7 tumor necrosis factor Homo sapiens 141-150 17509409-6 2007 Consistent with downregulation of bone-resorbing mediators, eugenol suppressed the messenger RNA expression of LPS-induced IL-1beta, TNF-alpha, and cyclooxygenase-2 in macrophages. Eugenol 60-67 interleukin 1 beta Homo sapiens 123-131 17509409-6 2007 Consistent with downregulation of bone-resorbing mediators, eugenol suppressed the messenger RNA expression of LPS-induced IL-1beta, TNF-alpha, and cyclooxygenase-2 in macrophages. Eugenol 60-67 tumor necrosis factor Homo sapiens 133-142 17509409-6 2007 Consistent with downregulation of bone-resorbing mediators, eugenol suppressed the messenger RNA expression of LPS-induced IL-1beta, TNF-alpha, and cyclooxygenase-2 in macrophages. Eugenol 60-67 prostaglandin-endoperoxide synthase 2 Homo sapiens 148-164 17419730-11 2007 The bacterial oxidase efficiently oxidizes eugenol into coniferyl alcohol (KM=1.0 microM, kcat=3.1 s-1). Eugenol 43-50 multicopper oxidase family protein Rhodococcus jostii RHA1 14-21 17275817-4 2007 CYP1A1 and CYP1B1 activity, which catalyze the biotransformation of DMBA, were strongly inhibited by eugenol. Eugenol 101-108 cytochrome P450 family 1 subfamily B member 1 Homo sapiens 11-17 16563641-3 2006 Eugenol (10-100 micromol/l) dose-dependently and reversibly suppressed both epileptiform field potentials and spreading depression Eugenol also reversibly decreased the amplitude of the field postsynaptic potentials evoked in CA1 area of hippocampus and the third layer of neocortex. Eugenol 0-7 carbonic anhydrase 1 Rattus norvegicus 226-229 16838348-4 2007 The aim of this study was to investigate the effects of zinc oxide-eugenol-based root canal sealer N2 and epoxy resin-based root canal sealer Topseal on the expression of HO-1 protein in cultured human gingival fibroblasts (HGFs). Eugenol 67-74 heme oxygenase 1 Homo sapiens 171-175 16998128-7 2006 Our results demonstrated that eugenol inhibits I(Na) in a TRPV1-independent manner. Eugenol 30-37 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 58-63 16972787-0 2006 Impact of the arylhydrocarbon receptor on eugenol- and isoeugenol-induced cell cycle arrest in human immortalized keratinocytes (HaCaT). Eugenol 42-49 aryl hydrocarbon receptor Homo sapiens 14-38 16972787-3 2006 In the present study we investigated whether the cell cycle arrest of eugenol and isoeugenol is mediated by the AhR in HaCaT cells. Eugenol 70-77 aryl hydrocarbon receptor Homo sapiens 112-115 16972787-7 2006 In summary, these results, together with our previous findings that both compounds induce translocation of the AhR into the nucleus, provide good evidence that the effects of eugenol and isoeugenol in skin and keratinocytes are mediated by the AhR. Eugenol 175-182 aryl hydrocarbon receptor Homo sapiens 111-114 16972787-7 2006 In summary, these results, together with our previous findings that both compounds induce translocation of the AhR into the nucleus, provide good evidence that the effects of eugenol and isoeugenol in skin and keratinocytes are mediated by the AhR. Eugenol 175-182 aryl hydrocarbon receptor Homo sapiens 244-247 23105625-2 2006 In continuation of initialin vitro studies revealing eugenol to be a potent calcineurin inhibitor, we investigated its ability to reverse isoproterenol-induced cardiac hypertrophy in rats. Eugenol 53-60 calcineurin binding protein 1 Rattus norvegicus 76-97 16341694-8 2006 Although eugenol decreased MRP2 level more effectively than PBL extract, it exhibited less sensitizing effect. Eugenol 9-16 ATP binding cassette subfamily C member 2 Homo sapiens 27-31 16640638-8 2006 Addition of NAC extracellularly protected the cells from eugenol-induced cytotoxicity (P < 0.05). Eugenol 57-64 X-linked Kx blood group Homo sapiens 12-15 16109996-4 2005 The HVACC inhibition by eugenol was not blocked by capsazepine, a competitive transient receptor potential vanilloid 1 (TRPV1) antagonist. Eugenol 24-31 transient receptor potential cation channel subfamily V member 1 Homo sapiens 78-118 16101137-0 2005 Induction of cytotoxicity and apoptosis and inhibition of cyclooxygenase-2 gene expression by eugenol-related compounds. Eugenol 94-101 prostaglandin-endoperoxide synthase 2 Homo sapiens 58-74 16101137-8 2005 The regulatory effects of eugenol-related compounds on lipopolysaccharide (LPS)-induced cyclooxygenase-2 (COX-2) gene expression in RAW 264.7 cells were investigated by Northern blot analysis. Eugenol 26-33 prostaglandin-endoperoxide synthase 2 Mus musculus 88-104 16101137-8 2005 The regulatory effects of eugenol-related compounds on lipopolysaccharide (LPS)-induced cyclooxygenase-2 (COX-2) gene expression in RAW 264.7 cells were investigated by Northern blot analysis. Eugenol 26-33 prostaglandin-endoperoxide synthase 2 Mus musculus 106-111 16417936-14 2006 The release of ATP from eugenol and carvacrol-treated cells and absence of release from cinnamaldehyde-treated cells could indicate that eugenol and carvacrol possess ATPase inhibiting activity. Eugenol 137-144 ATPase Escherichia coli 167-173 16707845-2 2006 Eugenol and isoeugenol inhibited lipopolysaccharide (LPS)-dependent production of NO, which was due to the inhibition of protein synthesis of inducible nitric oxide synthase (iNOS). Eugenol 0-7 nitric oxide synthase 2 Homo sapiens 142-173 16707845-2 2006 Eugenol and isoeugenol inhibited lipopolysaccharide (LPS)-dependent production of NO, which was due to the inhibition of protein synthesis of inducible nitric oxide synthase (iNOS). Eugenol 0-7 nitric oxide synthase 2 Homo sapiens 175-179 16707845-4 2006 LPS-dependent expression of cyclooxygenase-2 (COX-2) protein was also inhibited markedly by isoeugenol, and less effectively by eugenol. Eugenol 95-102 prostaglandin-endoperoxide synthase 2 Homo sapiens 28-44 16707845-4 2006 LPS-dependent expression of cyclooxygenase-2 (COX-2) protein was also inhibited markedly by isoeugenol, and less effectively by eugenol. Eugenol 95-102 prostaglandin-endoperoxide synthase 2 Homo sapiens 46-51 16707845-5 2006 Anti-inflammatory action of eugenol compounds may be explained by the inhibition of NO production and COX-2 expression, the pro-inflammatory mediators. Eugenol 28-35 prostaglandin-endoperoxide synthase 2 Homo sapiens 102-107 16216483-0 2006 Eugenol--the active principle from cloves inhibits 5-lipoxygenase activity and leukotriene-C4 in human PMNL cells. Eugenol 0-7 arachidonate 5-lipoxygenase Homo sapiens 51-65 16123706-9 2005 Taken together, the activation of IL-6 and IL-8 mRNA gene expression may be one of the pathogenesis of zinc oxide-eugenol based and epoxy resin based root canal sealers-induced periapical inflammation. Eugenol 114-121 interleukin 6 Homo sapiens 34-38 16123706-9 2005 Taken together, the activation of IL-6 and IL-8 mRNA gene expression may be one of the pathogenesis of zinc oxide-eugenol based and epoxy resin based root canal sealers-induced periapical inflammation. Eugenol 114-121 C-X-C motif chemokine ligand 8 Homo sapiens 43-47 16109996-4 2005 The HVACC inhibition by eugenol was not blocked by capsazepine, a competitive transient receptor potential vanilloid 1 (TRPV1) antagonist. Eugenol 24-31 transient receptor potential cation channel subfamily V member 1 Homo sapiens 120-125 16109996-5 2005 Eugenol inhibited N-type calcium currents in the cell line C2D7, stably expressing the human N-type calcium channels, where TRPV1 was not endogenously expressed. Eugenol 0-7 transient receptor potential cation channel subfamily V member 1 Homo sapiens 124-129 15936201-0 2005 Eugenol and its structural analogs inhibit monoamine oxidase A and exhibit antidepressant-like activity. Eugenol 0-7 monoamine oxidase A Mus musculus 43-62 15936201-3 2005 Results from this study show that eugenol inhibits monoamine oxidase A (MAOA) preferentially with a K(i)=26 microM. Eugenol 34-41 monoamine oxidase A Mus musculus 51-70 15936201-3 2005 Results from this study show that eugenol inhibits monoamine oxidase A (MAOA) preferentially with a K(i)=26 microM. Eugenol 34-41 monoamine oxidase A Mus musculus 72-76 15936201-10 2005 Results suggest a potential link between the antidepressant activity of eugenol and its MAOA inhibitory activity. Eugenol 72-79 monoamine oxidase A Mus musculus 88-92 15922856-4 2005 We observed that eugenol transduced the apoptotic signal via ROS generation, thereby inducing mitochondrial permeability transition (MPT), reducing anti-apoptotic protein bcl-2 level, inducing cytochrome c release to the cytosol, and subsequent apoptotic cell death. Eugenol 17-24 BCL2 apoptosis regulator Homo sapiens 171-176 15922856-4 2005 We observed that eugenol transduced the apoptotic signal via ROS generation, thereby inducing mitochondrial permeability transition (MPT), reducing anti-apoptotic protein bcl-2 level, inducing cytochrome c release to the cytosol, and subsequent apoptotic cell death. Eugenol 17-24 cytochrome c, somatic Homo sapiens 193-205 15711935-0 2005 Phospho-ser 15-p53 translocates into mitochondria and interacts with Bcl-2 and Bcl-xL in eugenol-induced apoptosis. Eugenol 89-96 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 15-18 15986384-6 2005 Competitive binding data using cell membranes expressing either OAMB or Pa oa1 demonstrated significantly decreased binding activity in binding assays performed in the presence of plant essential oils, eugenol, cinnamic alcohol, and trans-anethole. Eugenol 202-209 Octopamine receptor in mushroom bodies Drosophila melanogaster 64-68 15986384-10 2005 The toxicity of tested chemicals against wild type and octopamine mutant (iav) fly strains suggested that an octopamine receptor mediates the toxicity of cinnamic alcohol, eugenol, trans-antehole, and 2-phenethyl propionate against fruit flies. Eugenol 172-179 Octopamine receptor in mushroom bodies Drosophila melanogaster 109-128 16041649-6 2005 EC50 values for the induction of Ca2+ mobilization and MAPK activation were around 10 - 30 microM for both carvacrol and eugenol. Eugenol 121-128 mitogen-activated protein kinase 1 Homo sapiens 55-59 15574415-0 2005 Eugenol causes melanoma growth suppression through inhibition of E2F1 transcriptional activity. Eugenol 0-7 E2F transcription factor 1 Homo sapiens 65-69 15574415-10 2005 Transient transfection assays and electrophoretic mobility shift assays showed that eugenol inhibits the transcriptional activity of E2F1. Eugenol 84-91 E2F transcription factor 1 Homo sapiens 133-137 15574415-12 2005 These results indicate that deregulation of E2F1 may be a key factor in eugenol-mediated melanoma growth inhibition both in vitro and in vivo. Eugenol 72-79 E2F transcription factor 1 Homo sapiens 44-48 15711935-0 2005 Phospho-ser 15-p53 translocates into mitochondria and interacts with Bcl-2 and Bcl-xL in eugenol-induced apoptosis. Eugenol 89-96 BCL2, apoptosis regulator Rattus norvegicus 69-74 15711935-0 2005 Phospho-ser 15-p53 translocates into mitochondria and interacts with Bcl-2 and Bcl-xL in eugenol-induced apoptosis. Eugenol 89-96 Bcl2-like 1 Rattus norvegicus 79-85 15711935-5 2005 RBL-2H3 cells treated with eugenol showed typical apoptotic manifestations and translocation of p53 into mitochondria. Eugenol 27-34 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 96-99 15711935-10 2005 In conclusion, eugenol induces apoptosis in mast cells via translocation of phospho-ser 15-p53 into mitochondria. Eugenol 15-22 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 91-94 15467253-3 2004 Here we show that mOR-EG, a mouse olfactory receptor that was isolated from a eugenol-responsive cell, recognizes 22 different odorants with EC50 values ranging from a few microM to several hundred microM. Eugenol 78-85 olfactory receptor family 5 subfamily D member 18 Mus musculus 18-24 15576237-4 2004 Eugenol induced Cu(II)-mediated DNA damage in the presence of cytochrome P450 (CYP)1A1, 1A2, 2C9, 2D6, or 2E1. Eugenol 0-7 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 62-86 15576237-4 2004 Eugenol induced Cu(II)-mediated DNA damage in the presence of cytochrome P450 (CYP)1A1, 1A2, 2C9, 2D6, or 2E1. Eugenol 0-7 olfactory receptor family 2 subfamily E member 1 pseudogene Homo sapiens 103-109 15576237-5 2004 CYP2D6 mediated eugenol-dependent DNA damage most efficiently. Eugenol 16-23 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-6 15576237-7 2004 Interestingly, CYP2D6-treated eugenol strongly damaged C and G of the 5"-ACG-3" sequence complementary to codon 273 of the p53 gene. Eugenol 30-37 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 15-21 15576237-7 2004 Interestingly, CYP2D6-treated eugenol strongly damaged C and G of the 5"-ACG-3" sequence complementary to codon 273 of the p53 gene. Eugenol 30-37 tumor protein p53 Homo sapiens 123-126 15576237-8 2004 These results suggest that CYP2D6-treated eugenol can cause double base lesions. Eugenol 42-49 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 27-33 15576237-11 2004 Formation of 8-oxo-7,8-dihydro-2"-deoxyguanosine was significantly increased by CYP2D6-treated eugenol in the presence of Cu(II). Eugenol 95-102 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 80-86 15576237-12 2004 Time-of-flight-mass spectrometry demonstrated that CYP2D6 catalyzed O-demethylation of eugenol to produce hydroxychavicol, capable of causing DNA damage. Eugenol 87-94 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 51-57 15467253-6 2004 Mutations of some amino acid residues in TM3, TM5, and TM6 dramatically affected the EC50 value of eugenol in Ca2+ imaging. Eugenol 99-106 tropomyosin 3 Homo sapiens 41-44 15467253-6 2004 Mutations of some amino acid residues in TM3, TM5, and TM6 dramatically affected the EC50 value of eugenol in Ca2+ imaging. Eugenol 99-106 tropomyosin 3 Homo sapiens 46-49 15210026-3 2004 The aim of this work was to test the effect of zinc released from zinc oxide-eugenol (ZOE) cements, on the activity of the major pulpal gelatinolytic MMPs. Eugenol 77-84 matrix metallopeptidase 2 Homo sapiens 150-154 15517910-1 2004 The dimers bis-EUG, bis-MMP, bis-BHA, bis-BMP and bis-DBP were synthesized from the monomers 4-allyl-2-methoxyphenol (EUG), 2-methoxy-4-methylphenol (MMP), 2-t-butyl-4-methoxyphenol (BHA), 2-t-butyl-4-methylphenol (BMP) and 2,4-di-t-butylphenol (DBP), respectively. Eugenol 93-116 bone morphogenetic protein 1 Homo sapiens 42-45 15341529-2 2004 Each OR appears to recognize odorants based on similarities in molecular structures such that mOR-EG, a mouse OR, binds eugenol, vanillin, and some other structurally related odorants. Eugenol 120-127 olfactory receptor family 5 subfamily D member 18 Mus musculus 94-100 15157811-0 2004 Eugenol exhibits antidepressant-like activity in mice and induces expression of metallothionein-III in the hippocampus. Eugenol 0-7 metallothionein 3 Mus musculus 80-99 15157811-2 2004 Furthermore, we show that both eugenol and imipramine induce brain-derived neurotrophic factor (BDNF) in the hippocampus with and without induction of metallothionein-III (MT-III), respectively. Eugenol 31-38 brain derived neurotrophic factor Mus musculus 61-94 15157811-2 2004 Furthermore, we show that both eugenol and imipramine induce brain-derived neurotrophic factor (BDNF) in the hippocampus with and without induction of metallothionein-III (MT-III), respectively. Eugenol 31-38 brain derived neurotrophic factor Mus musculus 96-100 15157811-3 2004 It may be possible that MT-III expression is involved in the exhibition of antidepressant-like activity of eugenol, not of imipramine. Eugenol 107-114 metallothionein 3 Mus musculus 24-30 12695357-5 2003 The higher glucuronidation activity was measured with alizarin (125 pmol x min(-1) x mg protein(-1)), whereas UGT2B17 conjugated eugenol, scopoletin, and galangin with glucuronidation rates of 102.5, 102, and 58 pmol x min(-1) x mg protein(-1), respectively. Eugenol 129-136 UDP glucuronosyltransferase family 2 member B17 Homo sapiens 110-117 14514756-0 2003 Activation of vanilloid receptor 1 (VR1) by eugenol. Eugenol 44-51 transient receptor potential cation channel subfamily V member 1 Homo sapiens 14-34 14514756-0 2003 Activation of vanilloid receptor 1 (VR1) by eugenol. Eugenol 44-51 transient receptor potential cation channel subfamily V member 1 Homo sapiens 36-39 14514756-3 2003 In vanilloid receptor 1 (VR1)-expressing human embryonic kidney (HEK) 293 cells and trigeminal ganglion (TG) neurons, eugenol activated inward currents, whereas capsazepine, a competitive VR antagonist, and ruthenium red (RR), a functional VR antagonist, completely blocked eugenol-induced inward currents. Eugenol 118-125 transient receptor potential cation channel subfamily V member 1 Homo sapiens 3-23 14514756-3 2003 In vanilloid receptor 1 (VR1)-expressing human embryonic kidney (HEK) 293 cells and trigeminal ganglion (TG) neurons, eugenol activated inward currents, whereas capsazepine, a competitive VR antagonist, and ruthenium red (RR), a functional VR antagonist, completely blocked eugenol-induced inward currents. Eugenol 118-125 transient receptor potential cation channel subfamily V member 1 Homo sapiens 25-28 14514756-4 2003 Moreover, eugenol caused elevation of [Ca(2+)](i), and this was completely abolished by both capsazepine and ruthenium red in VR1-expressing HEK 293 cells and TG neurons. Eugenol 10-17 transient receptor potential cation channel subfamily V member 1 Homo sapiens 126-129 14514756-5 2003 Our results provide strong evidence that eugenol produces its effects, at least in part, via VR1 expressed by the sensory nerve endings in the teeth. Eugenol 41-48 transient receptor potential cation channel subfamily V member 1 Homo sapiens 93-96 12963494-5 2003 We observed that bis-eugenol, but not eugenol, clearly inhibited the degradation of inhibitory kappa B-alpha in RAW264.7 murine macrophages stimulated with lipopolysaccharide and, consequently, the transcriptional activity of the stimulated NF-kappa B in the cells. Eugenol 21-28 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 241-251 12757841-0 2003 Eugenol suppresses cyclooxygenase-2 expression in lipopolysaccharide-stimulated mouse macrophage RAW264.7 cells. Eugenol 0-7 prostaglandin-endoperoxide synthase 2 Mus musculus 19-35 12757841-6 2003 In addition, eugenol suppressed the cyclooxygenase-2 (COX-2) gene expression in LPS-stimulated mouse macrophage cells. Eugenol 13-20 prostaglandin-endoperoxide synthase 2 Mus musculus 36-52 12757841-6 2003 In addition, eugenol suppressed the cyclooxygenase-2 (COX-2) gene expression in LPS-stimulated mouse macrophage cells. Eugenol 13-20 prostaglandin-endoperoxide synthase 2 Mus musculus 54-59 12757841-7 2003 On the line of COX-2 playing an important role in colon carcinogenesis further study was designed to investigate the effect of eugenol on the growth and COX-2 expression in HT-29 human colon cancer cells. Eugenol 127-134 prostaglandin-endoperoxide synthase 2 Mus musculus 153-158 12757841-8 2003 Eugenol inhibited the proliferation of HT-29 cells and the mRNA expression of COX-2, but not COX-1. Eugenol 0-7 prostaglandin-endoperoxide synthase 2 Mus musculus 78-83 12757841-9 2003 This result suggests that eugenol might be a plausible lead candidate for further developing the COX-2 inhibitor as an anti-inflammatory or cancer chemopreventive agent. Eugenol 26-33 prostaglandin-endoperoxide synthase 2 Mus musculus 97-102 12615477-0 2003 Induction of cyclooxygenase-2 mRNA and protein expression by epoxy resin and zinc oxide-eugenol based root canal sealers in human osteoblastic cells. Eugenol 88-95 prostaglandin-endoperoxide synthase 2 Homo sapiens 13-29 12615477-5 2003 The aim of the present study was to investigate the effects of epoxy resin (AH26) and zinc oxide-eugenol based (Endomethansone and N2) root canal sealers on the expression of COX-2 mRNA gene and protein in cultured human osteoblastic cells. Eugenol 97-104 prostaglandin-endoperoxide synthase 2 Homo sapiens 175-180 12830493-7 2003 Super EBA is less cytotoxic than IRM, suggesting that the decreased eugenol in Super EBA allows it to be less irritating. Eugenol 68-75 maternally expressed 8, small nucleolar RNA host gene Homo sapiens 33-36 12444669-5 2002 Of these 49 plant metabolites, eugenol, pyrogallol, and cinnamaldehyde (with IC(50) values of 129, 144, and 245 microM, respectively) were found to inhibit COX-2. Eugenol 31-38 prostaglandin-endoperoxide synthase 2 Homo sapiens 156-161 12200281-1 2002 The gene loci ehyAB, calA, and calB, encoding eugenol hydroxylase, coniferyl alcohol dehydrogenase, and coniferyl aldehyde dehydrogenase, respectively, which are involved in the first steps of eugenol catabolism in Pseudomonas sp. Eugenol 46-53 H16_RS03055 Ralstonia eutropha H16 77-98 12200281-1 2002 The gene loci ehyAB, calA, and calB, encoding eugenol hydroxylase, coniferyl alcohol dehydrogenase, and coniferyl aldehyde dehydrogenase, respectively, which are involved in the first steps of eugenol catabolism in Pseudomonas sp. Eugenol 46-53 H16_RS01130 Ralstonia eutropha H16 104-136 11312644-7 2001 Interestingly, stimulation of eugenol and isoeugenol was increased in the presence of antigen-modified human liver microsomes (CYP450) or recombinant CYP1A1 in five of seven cases. Eugenol 30-37 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 150-156 12553890-11 2002 However, cinnamyl alcohol, trans -cinnamic acid and eugenol exhibited only weak inhibition against aldose reductase. Eugenol 52-59 aldo-keto reductase family 1 member B1 Rattus norvegicus 99-115 11374444-3 2001 The survival of both HSG and HGF cells treated with eugenol was significantly decreased as the VL irradiation time and/or the pH of the medium was increased. Eugenol 52-59 hepatocyte growth factor Homo sapiens 29-32 9525278-2 1998 Treatment of myeloperoxidase containing HL-60 cells with eugenol, produced a dose-dependent formation of three DNA adducts as detected with P1-enhanced 32P-post-labeling. Eugenol 57-64 myeloperoxidase Homo sapiens 13-28 9779930-3 1998 There was significant preservation of neuronal cells in the CA1 region in the eugenol-treated groups 7 days after the ischemic insult in the TF condition, with respective survival values of 26, 43, and 68%. Eugenol 78-85 carbonic anhydrase 1 Homo sapiens 60-63 9560327-5 1998 The expressed enzyme in Escherichia coli displayed high P-ST activity towards phenolic odorants such as eugenol and guaiacol, and it showed a high N-hydroxy-2-acetylaminofluorene sulphation activity in comparison with the rat ST1C1 enzyme. Eugenol 104-111 sulfotransferase family 1A, phenol-preferring, member 1 Mus musculus 56-60 9560327-5 1998 The expressed enzyme in Escherichia coli displayed high P-ST activity towards phenolic odorants such as eugenol and guaiacol, and it showed a high N-hydroxy-2-acetylaminofluorene sulphation activity in comparison with the rat ST1C1 enzyme. Eugenol 104-111 sulfotransferase family 1C member 3 Rattus norvegicus 226-231 10930724-0 2000 Preventive effect of eugenol on PAF and ethanol-induced gastric mucosal damage. Eugenol 21-28 PCNA clamp associated factor Homo sapiens 32-35 10930724-2 2000 Gastric ulcers, induced by administration of two ulcerogenic agents, i.e. platelet activating factor (PAF) and ethanol, were dose-dependently and significantly reduced by eugenol (10-100 mg/kg, p.o.) Eugenol 171-178 PCNA clamp associated factor Homo sapiens 74-100 10930724-2 2000 Gastric ulcers, induced by administration of two ulcerogenic agents, i.e. platelet activating factor (PAF) and ethanol, were dose-dependently and significantly reduced by eugenol (10-100 mg/kg, p.o.) Eugenol 171-178 PCNA clamp associated factor Homo sapiens 102-105 9525278-4 1998 In vitro activation of eugenol with either horseradish peroxidase or myeloperoxidase and H2O2 produced three DNA adducts that were inhibited by the addition of either ascorbic acid or glutathione, by 66 and 90%, respectively. Eugenol 23-30 myeloperoxidase Homo sapiens 69-84 9372790-12 1997 Our results suggest that eugenol activates a Ca(2+)-permeable ion channel in rat DRG neurons through two different mechanisms: a capsaicin receptor-mediated pathway and a pathway independent of the capsaicin-receptor. Eugenol 25-32 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 198-216 8645503-17 1996 A significant reduction in alpha-class GSTs in plasma (P < 0.05), but not in the other measured biotransformation parameters, was found in volunteers during the eugenol-periods as compared to the placebo-period. Eugenol 164-171 glutathione S-transferase kappa 1 Homo sapiens 39-43 9364930-9 1997 The activity of UGT2B9 was tested with over 60 compounds and was demonstrated to be active on C18, C19, and C21 steroids, bile acids, and several xenobiotics including eugenol, 1-naphthol, and p-nitrophenol. Eugenol 168-175 UDP-glucuronosyltransferase 2B9 Macaca fascicularis 16-22 8887459-2 1996 Pretreatment with isosafrole, safrole, dihydrosafrole, and benzodioxole at dosages as low as 10 mg/kg significantly prevented the increase in plasma transaminase levels and histochemical changes associated with CCl4-induced liver necrosis, whereas piperonyl butoxide (PBO), eugenol, isoeugenol, sesamol, and curcumin did not prevent CCl4 hepatotoxicity even at 200 mg/kg. Eugenol 274-281 chemokine (C-C motif) ligand 4 Mus musculus 211-215 9147382-1 1997 We examined the neuroprotective efficacy of eugenol against N-methyl-D-aspartate (NMDA)-, oxygen-glucose deprivation-, and xanthine/xanthine oxidase-induced neurotoxicity in primary murine cortical cultures. Eugenol 44-51 xanthine dehydrogenase Mus musculus 132-148 9147382-5 1997 Oxidative neuronal injury induced by xanthine/xanthine oxidase was also significantly reduced (75-90%) by eugenol (100- 300 microM) addition. Eugenol 106-113 xanthine dehydrogenase Mus musculus 46-62 8645503-18 1996 This may either reflect GST-inhibition by eugenol or protection against background damage of liver cells by eugenol. Eugenol 42-49 glutathione S-transferase kappa 1 Homo sapiens 24-27 8620581-0 1996 Inhibition of rat, mouse, and human glutathione S-transferase by eugenol and its oxidation products. Eugenol 65-72 glutathione S-transferase kappa 1 Homo sapiens 36-61 8597030-3 1996 Oral administration of spice principles, curcumin from turmeric (30 mg/kg body weight) or eugenol from cloves (100 mg/kg body weight), for 10 days lowered the liver and serum lipid peroxide levels, serum ALAT, ASAT and LDH, enhanced by i.p. Eugenol 90-97 glutamic--pyruvic transaminase Rattus norvegicus 204-208 8597030-3 1996 Oral administration of spice principles, curcumin from turmeric (30 mg/kg body weight) or eugenol from cloves (100 mg/kg body weight), for 10 days lowered the liver and serum lipid peroxide levels, serum ALAT, ASAT and LDH, enhanced by i.p. Eugenol 90-97 glutamic-oxaloacetic transaminase 2 Rattus norvegicus 210-214 8620581-1 1996 The irreversible and reversible inhibition of glutathione S-transferases (GSTs) by eugenol was studied in rat, mouse and man. Eugenol 83-90 glutathione S-transferase kappa 1 Homo sapiens 74-78 8620581-2 1996 Using liver cytosol of human, rat and mouse, species differences were found in the rate of irreversible inhibition of GSTs by eugenol in the presence of the enzyme tyrosinase. Eugenol 126-133 glutathione S-transferase cluster Mus musculus 118-122 8620581-2 1996 Using liver cytosol of human, rat and mouse, species differences were found in the rate of irreversible inhibition of GSTs by eugenol in the presence of the enzyme tyrosinase. Eugenol 126-133 tyrosinase Mus musculus 164-174 8620581-3 1996 Tyrosinase was used to oxidize eugenol. Eugenol 31-38 tyrosinase Homo sapiens 0-10 8620581-6 1996 In addition, the irreversible inhibition of human and rat GSTs by eugenol was studied using purified isoenzymes of man and rat. Eugenol 66-73 glutathione S-transferase kappa 1 Homo sapiens 58-62 8620581-7 1996 The human GST isoenzymes A1-1, M1a-1a and P1-1 and the rat GST isoenzymes 1-1, 2-2, 3-3, 4-4 and 7-7 were irreversibly inhibited by eugenol in the presence of tyrosinase. Eugenol 132-139 S100 calcium binding protein A10 Homo sapiens 42-46 8620581-7 1996 The human GST isoenzymes A1-1, M1a-1a and P1-1 and the rat GST isoenzymes 1-1, 2-2, 3-3, 4-4 and 7-7 were irreversibly inhibited by eugenol in the presence of tyrosinase. Eugenol 132-139 tyrosinase Rattus norvegicus 159-169 23196096-3 1995 Eugenol strongly inhibited PAF-induced platelet aggregation with lesser effect against AA and collegen. Eugenol 0-7 PCNA clamp associated factor Homo sapiens 27-30 8574354-1 1995 Our earlier studies in vitro have shown that eugenol inhibits liver microsomal monooxygenase activities and carbon tetrachloride (CCl4)-induced lipid peroxidation (Free Rad. Eugenol 45-52 C-C motif chemokine ligand 4 Rattus norvegicus 130-134 8574354-4 1995 The objective of the present investigation was to study the in vivo protective effect of eugenol against CCl4 toxicity. Eugenol 89-96 C-C motif chemokine ligand 4 Rattus norvegicus 105-109 8574354-13 1995 The protective effect of eugenol against CCl4 induced hepatotoxicity is more evident when it is given concurrently or soon after rather than much before CCl4 treatment. Eugenol 25-32 C-C motif chemokine ligand 4 Rattus norvegicus 41-45 8574354-13 1995 The protective effect of eugenol against CCl4 induced hepatotoxicity is more evident when it is given concurrently or soon after rather than much before CCl4 treatment. Eugenol 25-32 C-C motif chemokine ligand 4 Rattus norvegicus 153-157 23196096-0 1995 Eugenol: a dual inhibitor of platelet-activating factor and arachidonic acid metabolism. Eugenol 0-7 PCNA clamp associated factor Homo sapiens 29-55 23196096-5 1995 In addition, eugenol stimulated PAF-acetylhydrolase activity suggesting that inhibition of PAF could be due to its inactivation to lyso-PAF. Eugenol 13-20 PCNA clamp associated factor Homo sapiens 32-35 23196096-5 1995 In addition, eugenol stimulated PAF-acetylhydrolase activity suggesting that inhibition of PAF could be due to its inactivation to lyso-PAF. Eugenol 13-20 PCNA clamp associated factor Homo sapiens 91-94 23196096-5 1995 In addition, eugenol stimulated PAF-acetylhydrolase activity suggesting that inhibition of PAF could be due to its inactivation to lyso-PAF. Eugenol 13-20 PCNA clamp associated factor Homo sapiens 91-94 23196096-6 1995 Pretreatment of rabbits with eugenol (50-100 mg/kg) prevented the lethal effects of intravenous PAF (11 mugg/kg) or AA (2 mg/kg) in a dose-dependent fashion. Eugenol 29-36 PCNA clamp associated factor Homo sapiens 96-99 23196096-7 1995 The protective effects of eugenol in the rabbits, however, were more pronounced against PAF-induced mortality (100% protection). Eugenol 26-33 PCNA clamp associated factor Homo sapiens 88-91 23196096-13 1995 These results provide evidence that eugenol acts as a dual antagonist of AA and PAF. Eugenol 36-43 PCNA clamp associated factor Homo sapiens 80-83 7786311-1 1995 The chemoprotection extended by eugenol against carbon tetrachloride (CCl4) intoxication was established by studies on drug-metabolizing phase I and phase II enzymes. Eugenol 32-39 C-C motif chemokine ligand 4 Rattus norvegicus 70-74 7786311-5 1995 Further, the chemical onslaught imposed by CCl4 on the drug-metabolizing system was removed successfully by eugenol. Eugenol 108-115 C-C motif chemokine ligand 4 Rattus norvegicus 43-47 7844474-5 1995 Pretreatment with intravenous superoxide dismutase (SOD) or catalase but not dimethylthiourea (DMTU) decreased BALF protein content after infusion of 4 microliters and 8 microliters of eugenol. Eugenol 185-192 catalase Rattus norvegicus 60-68 7542715-2 1995 Intravenous injections of water extracts of P. betle inflorescence (PBE), eugenol, and safrole in rats induced hypotensive and bradycardiac effects, whereas both intraarterial and intrathecal injections of PBE, eugenol and safrole resulted in hypotensive and tachycardiac effects. Eugenol 211-218 enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase Rattus norvegicus 68-71 7844474-6 1995 SOD and catalase but not DMTU decreased lung wet-to-dry weight ratios in animals infused with 8 microliters of eugenol. Eugenol 111-118 catalase Rattus norvegicus 8-16 2047567-6 1991 These results suggest that eugenol is activated by a cytochrome-P-450-dependent metabolic reaction and that the liver injury is caused by inadequate rates of detoxification of the resulting metabolite in mice depleted of hepatic GSH by BSO treatment. Eugenol 27-34 cytochrome P450, family 21, subfamily a, polypeptide 1 Mus musculus 53-69 8205227-11 1994 Eugenol elicited type 1 changes in the spectrum of microsomal cytochrome P-450. Eugenol 0-7 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 62-78 8205227-13 1994 Eugenol significantly protected against the degradation of cytochrome P-450 during lipid peroxidation with all the systems tested. Eugenol 0-7 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 59-75 8406240-4 1993 Administration of 1000 mg eugenol/kg body weight, but not the lower doses, significantly increased cytochrome P-450-dependent 7-ethoxy-resorufin O-deethylation (EROD) and 7-pentoxyresorufin O-depentylation (PROD); administration of trans-anethole (125 or 250 mg/kg body weight) did not alter EROD and PROD activities. Eugenol 26-33 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 99-115 8406240-7 1993 Enhancement of cytosolic glutathione S-transferase (GST) activity towards 1-chloro-2,4-dinitrobenzene was found for all eugenol- and trans-anethole-treated rats. Eugenol 120-127 hematopoietic prostaglandin D synthase Rattus norvegicus 25-50 8406240-7 1993 Enhancement of cytosolic glutathione S-transferase (GST) activity towards 1-chloro-2,4-dinitrobenzene was found for all eugenol- and trans-anethole-treated rats. Eugenol 120-127 hematopoietic prostaglandin D synthase Rattus norvegicus 52-55 8406240-8 1993 In addition, significantly increased levels of GST subunit 2 were measured by HPLC in the liver cytosol of rats treated with eugenol (500 or 1000 mg/kg body eight) or trans-anethole (250 mg/kg body weight). Eugenol 125-132 hematopoietic prostaglandin D synthase Rattus norvegicus 47-50 1432793-4 1992 The Temp Bond zinc oxide-eugenol luting agent exhibited a lower mean retentive strength than the IRM reinforced zinc oxide-eugenol and Life calcium hydroxide luting agents. Eugenol 25-32 chromosome 1 open reading frame 210 Homo sapiens 4-8 33822104-0 2021 Eugenol modulates insulin sensitivity by upregulating insulin receptor substrate-2 in non-alcoholic fatty liver disease in rats. Eugenol 0-7 insulin receptor substrate 2 Rattus norvegicus 54-82 34676584-5 2021 Cinnamaldehyde and eugenol pre-treatments decreased TNF-alpha, IL-1beta, and IL-6 levels as compared to LPS group at all concentrations. Eugenol 19-26 tumor necrosis factor Mus musculus 52-61 33765098-6 2021 Moreover, using electroolfactogram, we showed that a treatment of the OE with beta-glucuronidase, an enzyme which counterbalance the UGTs activity, increased the response to eugenol which is a strong odorant UGT substrate. Eugenol 174-181 glucuronidase beta Homo sapiens 78-96 33765098-6 2021 Moreover, using electroolfactogram, we showed that a treatment of the OE with beta-glucuronidase, an enzyme which counterbalance the UGTs activity, increased the response to eugenol which is a strong odorant UGT substrate. Eugenol 174-181 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 133-136 7835232-8 1994 Apparent KM and enzyme efficiency values for certain food-derived substrates (e.g., naringenin and eugenol) for expressed UGT2B15 were similar to those determined for endobiotic substrates, suggesting that some naturally occurring substances are good substrates for this enzyme and that glucuronidation of endogenous compounds could be affected by xenobiotics derived from dietary sources. Eugenol 99-106 UDP glucuronosyltransferase family 2 member B15 Homo sapiens 122-129 34962586-4 2021 The aim of the study has been on the eugenol compounds, which has potent actions on Eralpha, PR, EGFR, CDK2, mTOR, ERBB2, c-Src, HSP90, and chemokines receptors inhibition. Eugenol 37-44 estrogen receptor 1 Homo sapiens 84-91 34962586-4 2021 The aim of the study has been on the eugenol compounds, which has potent actions on Eralpha, PR, EGFR, CDK2, mTOR, ERBB2, c-Src, HSP90, and chemokines receptors inhibition. Eugenol 37-44 transmembrane protein 37 Homo sapiens 93-95 34962586-4 2021 The aim of the study has been on the eugenol compounds, which has potent actions on Eralpha, PR, EGFR, CDK2, mTOR, ERBB2, c-Src, HSP90, and chemokines receptors inhibition. Eugenol 37-44 epidermal growth factor receptor Homo sapiens 97-101 34962586-4 2021 The aim of the study has been on the eugenol compounds, which has potent actions on Eralpha, PR, EGFR, CDK2, mTOR, ERBB2, c-Src, HSP90, and chemokines receptors inhibition. Eugenol 37-44 cyclin dependent kinase 2 Homo sapiens 103-107 34962586-4 2021 The aim of the study has been on the eugenol compounds, which has potent actions on Eralpha, PR, EGFR, CDK2, mTOR, ERBB2, c-Src, HSP90, and chemokines receptors inhibition. Eugenol 37-44 mechanistic target of rapamycin kinase Homo sapiens 109-113 34962586-4 2021 The aim of the study has been on the eugenol compounds, which has potent actions on Eralpha, PR, EGFR, CDK2, mTOR, ERBB2, c-Src, HSP90, and chemokines receptors inhibition. Eugenol 37-44 erb-b2 receptor tyrosine kinase 2 Homo sapiens 115-120 34962586-4 2021 The aim of the study has been on the eugenol compounds, which has potent actions on Eralpha, PR, EGFR, CDK2, mTOR, ERBB2, c-Src, HSP90, and chemokines receptors inhibition. Eugenol 37-44 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 122-127 34962586-4 2021 The aim of the study has been on the eugenol compounds, which has potent actions on Eralpha, PR, EGFR, CDK2, mTOR, ERBB2, c-Src, HSP90, and chemokines receptors inhibition. Eugenol 37-44 heat shock protein 90 alpha family class A member 1 Homo sapiens 129-134 34676584-5 2021 Cinnamaldehyde and eugenol pre-treatments decreased TNF-alpha, IL-1beta, and IL-6 levels as compared to LPS group at all concentrations. Eugenol 19-26 interleukin 1 alpha Mus musculus 63-71 34677731-0 2021 Eugenol, a Component of Holy Basil (Tulsi) and Common Spice Clove, Inhibits the Interaction Between SARS-CoV-2 Spike S1 and ACE2 to Induce Therapeutic Responses. Eugenol 0-7 angiotensin converting enzyme 2 Homo sapiens 124-128 34676584-5 2021 Cinnamaldehyde and eugenol pre-treatments decreased TNF-alpha, IL-1beta, and IL-6 levels as compared to LPS group at all concentrations. Eugenol 19-26 interleukin 6 Mus musculus 77-81 34677731-4 2021 Therefore, we screened different components of Tulsi leaf and found that eugenol, but not other major components (e.g. ursolic acid, oleanolic acid and beta-caryophylline), inhibited the interaction between spike S1 and ACE2 in an AlphaScreen-based assay. Eugenol 73-80 angiotensin converting enzyme 2 Homo sapiens 220-224 34677731-6 2021 Accordingly, eugenol strongly suppressed the entry of pseudotyped SARS-CoV-2, but not vesicular stomatitis virus (VSV), into human ACE2-expressing HEK293 cells. Eugenol 13-20 angiotensin converting enzyme 2 Homo sapiens 131-135 34840582-0 2021 A Metabolomic Investigation of Eugenol on Colorectal Cancer Cell Line HT-29 by Modifying the Expression of APC, p53, and KRAS Genes. Eugenol 31-38 tumor protein p53 Homo sapiens 112-115 34677731-7 2021 Eugenol also reduced SARS-CoV-2 spike S1-induced activation of NF-kappaB and the expression of IL-6, IL-1beta and TNFalpha in human A549 lung cells. Eugenol 0-7 nuclear factor kappa B subunit 1 Homo sapiens 63-72 34677731-7 2021 Eugenol also reduced SARS-CoV-2 spike S1-induced activation of NF-kappaB and the expression of IL-6, IL-1beta and TNFalpha in human A549 lung cells. Eugenol 0-7 interleukin 6 Homo sapiens 95-99 34677731-7 2021 Eugenol also reduced SARS-CoV-2 spike S1-induced activation of NF-kappaB and the expression of IL-6, IL-1beta and TNFalpha in human A549 lung cells. Eugenol 0-7 interleukin 1 alpha Homo sapiens 101-109 34677731-7 2021 Eugenol also reduced SARS-CoV-2 spike S1-induced activation of NF-kappaB and the expression of IL-6, IL-1beta and TNFalpha in human A549 lung cells. Eugenol 0-7 tumor necrosis factor Homo sapiens 114-122 34840582-0 2021 A Metabolomic Investigation of Eugenol on Colorectal Cancer Cell Line HT-29 by Modifying the Expression of APC, p53, and KRAS Genes. Eugenol 31-38 KRAS proto-oncogene, GTPase Homo sapiens 121-125 34840582-5 2021 The purpose of this research was to investigate the anticancer effects of eugenol and variations in p53, KRAS, and APC gene expression and metabolic changes associated with the abovementioned gene expressions using 1HNMR spectroscopy. Eugenol 74-81 tumor protein p53 Homo sapiens 100-103 34840582-5 2021 The purpose of this research was to investigate the anticancer effects of eugenol and variations in p53, KRAS, and APC gene expression and metabolic changes associated with the abovementioned gene expressions using 1HNMR spectroscopy. Eugenol 74-81 KRAS proto-oncogene, GTPase Homo sapiens 105-109 34840582-7 2021 After treating HT-29 cells with IC50 concentration of eugenol, RNA was extracted and cDNA was obtained from them and the expression of p53, KRAS, and APC genes was measured using the qRT-PCR technique. Eugenol 54-61 tumor protein p53 Homo sapiens 135-138 34840582-7 2021 After treating HT-29 cells with IC50 concentration of eugenol, RNA was extracted and cDNA was obtained from them and the expression of p53, KRAS, and APC genes was measured using the qRT-PCR technique. Eugenol 54-61 KRAS proto-oncogene, GTPase Homo sapiens 140-144 34840582-11 2021 The observed IC50 for eugenol was 500 muM, and the relative expression of APC and p53 genes in the treated cells increased compared to the control group, and the expression of KRAS oncogene gene decreased significantly. Eugenol 22-29 tumor protein p53 Homo sapiens 82-85 34840582-11 2021 The observed IC50 for eugenol was 500 muM, and the relative expression of APC and p53 genes in the treated cells increased compared to the control group, and the expression of KRAS oncogene gene decreased significantly. Eugenol 22-29 KRAS proto-oncogene, GTPase Homo sapiens 176-180 34217764-5 2021 The interaction of eugenol with Nav1.5 could also contribute to its antiarrhythmic properties in vitro and ex vivo. Eugenol 19-26 sodium voltage-gated channel alpha subunit 5 Homo sapiens 32-38 34829680-8 2021 Activity test and molecular docking results show that eugenol could inhibit tyrosinase. Eugenol 54-61 tyrosinase Homo sapiens 76-86 34802518-6 2021 The mortality of late larvae treated with eugenol was higher than that of the control group after RNA interference (RNAi) against TcOBPC12, which indicates that the OBP gene is involved in the eugenol defense mechanism and leads to a decrease in sensitivity to eugenol. Eugenol 42-49 B1 protein Tribolium castaneum 130-138 34802518-6 2021 The mortality of late larvae treated with eugenol was higher than that of the control group after RNA interference (RNAi) against TcOBPC12, which indicates that the OBP gene is involved in the eugenol defense mechanism and leads to a decrease in sensitivity to eugenol. Eugenol 193-200 B1 protein Tribolium castaneum 130-138 34802518-6 2021 The mortality of late larvae treated with eugenol was higher than that of the control group after RNA interference (RNAi) against TcOBPC12, which indicates that the OBP gene is involved in the eugenol defense mechanism and leads to a decrease in sensitivity to eugenol. Eugenol 261-268 B1 protein Tribolium castaneum 130-138 34669914-15 2021 It is concluded that the eugenol and its liposome-based nanocarriers exert anxiolytic activity by down-regulating GLO-1 protein expression in mice. Eugenol 25-32 glyoxalase 1 Mus musculus 114-119 34473867-0 2021 Eugenol modulates genomic methylation and inactivates breast cancer-associated fibroblasts through E2F1-dependent downregulation of DNMT1/DNMT3A. Eugenol 0-7 E2F transcription factor 1 Homo sapiens 99-103 34473867-0 2021 Eugenol modulates genomic methylation and inactivates breast cancer-associated fibroblasts through E2F1-dependent downregulation of DNMT1/DNMT3A. Eugenol 0-7 DNA methyltransferase 1 Homo sapiens 132-137 34473867-0 2021 Eugenol modulates genomic methylation and inactivates breast cancer-associated fibroblasts through E2F1-dependent downregulation of DNMT1/DNMT3A. Eugenol 0-7 DNA methyltransferase 3 alpha Homo sapiens 138-144 34473867-4 2021 We have shown that decitabine (5-Aza-2"-deoxycytidine, DAC) and eugenol inhibit the expression of the DNA methyltransferase genes DNMT1 and DNMT3A at both the protein and mRNA levels in breast CAF cells. Eugenol 64-71 DNA methyltransferase 1 Homo sapiens 130-135 34473867-4 2021 We have shown that decitabine (5-Aza-2"-deoxycytidine, DAC) and eugenol inhibit the expression of the DNA methyltransferase genes DNMT1 and DNMT3A at both the protein and mRNA levels in breast CAF cells. Eugenol 64-71 DNA methyltransferase 3 alpha Homo sapiens 140-146 34473867-7 2021 Interestingly, these inhibitory effects of decitabine and eugenol were mediated through E2F1 downregulation. Eugenol 58-65 E2F transcription factor 1 Homo sapiens 88-92 34473867-8 2021 Indeed, ectopic expression of E2F1 upregulated both genes and attenuated the effects of eugenol. Eugenol 88-95 E2F transcription factor 1 Homo sapiens 30-34 34473867-10 2021 Importantly, the E2F1 promoter was also hypermethylated and the gene downregulated in response to eugenol. Eugenol 98-105 E2F transcription factor 1 Homo sapiens 17-21 34473867-11 2021 Together, these findings show that the active features of breast CAF cells can be normalized through eugenol-dependent targeting of DNMT1/DNMT3A and the consequent modulation in gene methylation. Eugenol 101-108 DNA methyltransferase 1 Homo sapiens 132-137 34473867-11 2021 Together, these findings show that the active features of breast CAF cells can be normalized through eugenol-dependent targeting of DNMT1/DNMT3A and the consequent modulation in gene methylation. Eugenol 101-108 DNA methyltransferase 3 alpha Homo sapiens 138-144 34629046-12 2021 CONCLUSION: The present work demonstrated eugenol as a potential anti-ageing compound which may curtail ageing, improve heath span by enhancing resistance to oxidative stress and exerts its effect independent of DAF-16 pathway. Eugenol 42-49 Fork-head domain-containing protein;Forkhead box protein O Caenorhabditis elegans 212-218 34411848-0 2021 Corrigendum to "Combination of 2-methoxyestradiol (2-ME2) and eugenol for apoptosis induction synergistically in androgen independent prostate cancer cells" (J. Eugenol 62-69 malic enzyme 2 Homo sapiens 53-56 34217764-15 2021 SIGNIFICANCE: Overall, our findings demonstrate that eugenol has antiarrhythmic activity due, at least in part, to its interaction with Nav1.5. Eugenol 53-60 sodium voltage-gated channel alpha subunit 5 Homo sapiens 136-142 34502165-9 2021 The protein levels of AKT serine/threonine kinase 1 (AKT), forkhead box O3 (FOXO3a), cyclin dependent kinase inhibitor 1A (p21), cyclin-dependent kinase inhibitor (p27), and Caspase-3 and -9 increased significantly in Eugenol-treated cells. Eugenol 218-225 cyclin dependent kinase inhibitor 3 Homo sapiens 129-162 34502165-0 2021 Eugenol-Induced Autophagy and Apoptosis in Breast Cancer Cells via PI3K/AKT/FOXO3a Pathway Inhibition. Eugenol 0-7 AKT serine/threonine kinase 1 Homo sapiens 72-75 34486841-3 2021 The prepared F-COP was applied as a coating adsorbent for solid phase microextraction (SPME) to enrich three kinds of eugenol anesthetics in aquatic products. Eugenol 118-125 caspase recruitment domain family member 16 Homo sapiens 15-18 34486841-16 2021 By combining F-COP-based SPME with HPLC-UV analysis, an effective method was developed for the extraction and determination of eugenol, eugenyl acetate, and methyl eugenol residues in aquatic products. Eugenol 127-134 caspase recruitment domain family member 16 Homo sapiens 15-18 34486841-20 2021 These results demonstrated that the F-COP is promising for use as an adsorbent in SPME for the determination of eugenol anesthetics in aquatic products. Eugenol 112-119 caspase recruitment domain family member 16 Homo sapiens 38-41 34502165-0 2021 Eugenol-Induced Autophagy and Apoptosis in Breast Cancer Cells via PI3K/AKT/FOXO3a Pathway Inhibition. Eugenol 0-7 forkhead box O3 Homo sapiens 76-82 34502165-9 2021 The protein levels of AKT serine/threonine kinase 1 (AKT), forkhead box O3 (FOXO3a), cyclin dependent kinase inhibitor 1A (p21), cyclin-dependent kinase inhibitor (p27), and Caspase-3 and -9 increased significantly in Eugenol-treated cells. Eugenol 218-225 dynactin subunit 6 Homo sapiens 164-167 34502165-9 2021 The protein levels of AKT serine/threonine kinase 1 (AKT), forkhead box O3 (FOXO3a), cyclin dependent kinase inhibitor 1A (p21), cyclin-dependent kinase inhibitor (p27), and Caspase-3 and -9 increased significantly in Eugenol-treated cells. Eugenol 218-225 AKT serine/threonine kinase 1 Homo sapiens 22-51 34502165-9 2021 The protein levels of AKT serine/threonine kinase 1 (AKT), forkhead box O3 (FOXO3a), cyclin dependent kinase inhibitor 1A (p21), cyclin-dependent kinase inhibitor (p27), and Caspase-3 and -9 increased significantly in Eugenol-treated cells. Eugenol 218-225 AKT serine/threonine kinase 1 Homo sapiens 53-56 34502165-9 2021 The protein levels of AKT serine/threonine kinase 1 (AKT), forkhead box O3 (FOXO3a), cyclin dependent kinase inhibitor 1A (p21), cyclin-dependent kinase inhibitor (p27), and Caspase-3 and -9 increased significantly in Eugenol-treated cells. Eugenol 218-225 caspase 3 Homo sapiens 174-190 34502165-9 2021 The protein levels of AKT serine/threonine kinase 1 (AKT), forkhead box O3 (FOXO3a), cyclin dependent kinase inhibitor 1A (p21), cyclin-dependent kinase inhibitor (p27), and Caspase-3 and -9 increased significantly in Eugenol-treated cells. Eugenol 218-225 forkhead box O3 Homo sapiens 59-74 34502165-9 2021 The protein levels of AKT serine/threonine kinase 1 (AKT), forkhead box O3 (FOXO3a), cyclin dependent kinase inhibitor 1A (p21), cyclin-dependent kinase inhibitor (p27), and Caspase-3 and -9 increased significantly in Eugenol-treated cells. Eugenol 218-225 forkhead box O3 Homo sapiens 76-82 34502165-10 2021 Eugenol also induced autophagy by upregulating the expression levels of microtubule-associated protein 1 light chain 3 (LC3) and downregulating the expression of nucleoporin 62 (NU p62). Eugenol 0-7 microtubule associated protein 1 light chain 3 alpha Homo sapiens 120-123 34502165-10 2021 Eugenol also induced autophagy by upregulating the expression levels of microtubule-associated protein 1 light chain 3 (LC3) and downregulating the expression of nucleoporin 62 (NU p62). Eugenol 0-7 nucleoporin 62 Homo sapiens 162-176 34502165-9 2021 The protein levels of AKT serine/threonine kinase 1 (AKT), forkhead box O3 (FOXO3a), cyclin dependent kinase inhibitor 1A (p21), cyclin-dependent kinase inhibitor (p27), and Caspase-3 and -9 increased significantly in Eugenol-treated cells. Eugenol 218-225 cyclin dependent kinase inhibitor 1A Homo sapiens 85-121 34502165-9 2021 The protein levels of AKT serine/threonine kinase 1 (AKT), forkhead box O3 (FOXO3a), cyclin dependent kinase inhibitor 1A (p21), cyclin-dependent kinase inhibitor (p27), and Caspase-3 and -9 increased significantly in Eugenol-treated cells. Eugenol 218-225 cyclin dependent kinase inhibitor 1A Homo sapiens 123-126 34502165-10 2021 Eugenol also induced autophagy by upregulating the expression levels of microtubule-associated protein 1 light chain 3 (LC3) and downregulating the expression of nucleoporin 62 (NU p62). Eugenol 0-7 nucleoporin 62 Homo sapiens 181-184 34502165-11 2021 Eugenol is a promising natural anti-cancer agent against triple-negative and HER2-positive breast cancer. Eugenol 0-7 erb-b2 receptor tyrosine kinase 2 Homo sapiens 77-81 35419714-2 2022 Here, a nerve conduction carboxylesterase and a detoxifying glutathione S-transferase were significantly inhibited after eugenol exposure, resulting in the paralysis or death of beetles. Eugenol 121-128 glutathione S-transferase Tribolium castaneum 60-85 35508252-0 2022 Eugenol alleviated nonalcoholic fatty liver disease in rat via a gut-brain-liver axis involving glucagon-like Peptide-1. Eugenol 0-7 glucagon Rattus norvegicus 96-119 35508252-2 2022 This study aimed to investigate whether eugenol regulates liver lipid accumulation in high-fat diet (HFD) induced nonalcoholic fatty liver disease (NAFLD) rats via the gut-brain-liver axis involving glucagon-like peptide-1 (GLP-1). Eugenol 40-47 glucagon Rattus norvegicus 199-222 35504091-0 2022 Eugenol suppresses the proliferation and invasion of TNF-alpha-induced fibroblast-like synoviocytes via regulating NF-kappaB and COX-2. Eugenol 0-7 tumor necrosis factor Homo sapiens 53-62 35504091-0 2022 Eugenol suppresses the proliferation and invasion of TNF-alpha-induced fibroblast-like synoviocytes via regulating NF-kappaB and COX-2. Eugenol 0-7 nuclear factor kappa B subunit 1 Homo sapiens 115-124 35504091-0 2022 Eugenol suppresses the proliferation and invasion of TNF-alpha-induced fibroblast-like synoviocytes via regulating NF-kappaB and COX-2. Eugenol 0-7 mitochondrially encoded cytochrome c oxidase II Homo sapiens 129-134 35504091-4 2022 In this study, we found eugenol could inhibit TNF-alpha-induced proliferation, migration, invasion, angiogenesis and inflammatory response of fibroblast-like synovial cells, and promote apoptosis. Eugenol 24-31 tumor necrosis factor Homo sapiens 46-55 35504091-5 2022 Eugenol"s target genes were significantly associated with vascular endothelial growth factor (VEGF) and NF-kappaB (NF-kappaB) signaling pathway. Eugenol 0-7 vascular endothelial growth factor A Homo sapiens 58-92 35504091-5 2022 Eugenol"s target genes were significantly associated with vascular endothelial growth factor (VEGF) and NF-kappaB (NF-kappaB) signaling pathway. Eugenol 0-7 vascular endothelial growth factor A Homo sapiens 94-98 35504091-5 2022 Eugenol"s target genes were significantly associated with vascular endothelial growth factor (VEGF) and NF-kappaB (NF-kappaB) signaling pathway. Eugenol 0-7 nuclear factor kappa B subunit 1 Homo sapiens 104-113 35504091-5 2022 Eugenol"s target genes were significantly associated with vascular endothelial growth factor (VEGF) and NF-kappaB (NF-kappaB) signaling pathway. Eugenol 0-7 nuclear factor kappa B subunit 1 Homo sapiens 115-124 35504091-6 2022 Eugenol reversed the promoting effect of TNF-alpha on the expression of NF-kappaB signaling pathway-related proteins as well as prostaglandin-endoperoxide synthase 2 (PTGS2, also known as COX-2) protein. Eugenol 0-7 tumor necrosis factor Homo sapiens 41-50 35504091-6 2022 Eugenol reversed the promoting effect of TNF-alpha on the expression of NF-kappaB signaling pathway-related proteins as well as prostaglandin-endoperoxide synthase 2 (PTGS2, also known as COX-2) protein. Eugenol 0-7 nuclear factor kappa B subunit 1 Homo sapiens 72-81 35504091-6 2022 Eugenol reversed the promoting effect of TNF-alpha on the expression of NF-kappaB signaling pathway-related proteins as well as prostaglandin-endoperoxide synthase 2 (PTGS2, also known as COX-2) protein. Eugenol 0-7 prostaglandin-endoperoxide synthase 2 Homo sapiens 128-165 35504091-6 2022 Eugenol reversed the promoting effect of TNF-alpha on the expression of NF-kappaB signaling pathway-related proteins as well as prostaglandin-endoperoxide synthase 2 (PTGS2, also known as COX-2) protein. Eugenol 0-7 prostaglandin-endoperoxide synthase 2 Homo sapiens 167-172 35504091-6 2022 Eugenol reversed the promoting effect of TNF-alpha on the expression of NF-kappaB signaling pathway-related proteins as well as prostaglandin-endoperoxide synthase 2 (PTGS2, also known as COX-2) protein. Eugenol 0-7 mitochondrially encoded cytochrome c oxidase II Homo sapiens 188-193 35504091-8 2022 In conclusion, eugenol may represent a novel drug to suppress the progression of RA by inhibiting NF-kappaB signaling pathway and COX-2 expression in fibroblast-like synovial cells. Eugenol 15-22 nuclear factor kappa B subunit 1 Homo sapiens 98-107 35504091-8 2022 In conclusion, eugenol may represent a novel drug to suppress the progression of RA by inhibiting NF-kappaB signaling pathway and COX-2 expression in fibroblast-like synovial cells. Eugenol 15-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 130-135 35101571-12 2022 Pre-treatment with eugenol on the ethanol-induced ulcer reduced the plasma NO levels and increased PGE2 along with a decreased TNF-alpha and IL-6 concentration. Eugenol 19-26 tumor necrosis factor Rattus norvegicus 127-136 35101571-12 2022 Pre-treatment with eugenol on the ethanol-induced ulcer reduced the plasma NO levels and increased PGE2 along with a decreased TNF-alpha and IL-6 concentration. Eugenol 19-26 interleukin 6 Rattus norvegicus 141-145 35101571-13 2022 Additionally, significant transcriptional and translational upregulation of HSP70 and downregulation of iNOS were detected in the eugenol-treated rat stomach tissue. Eugenol 130-137 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 76-81 35101571-13 2022 Additionally, significant transcriptional and translational upregulation of HSP70 and downregulation of iNOS were detected in the eugenol-treated rat stomach tissue. Eugenol 130-137 nitric oxide synthase 2 Rattus norvegicus 104-108 35586688-6 2022 Minocycline plus zinc oxide eugenol cement was associated with significantly lower positive rates of HIF-1alpha and Bcl-2 and lower levels of TNF-alpha versus minocycline alone (p < 0.05). Eugenol 28-35 hypoxia inducible factor 1 subunit alpha Homo sapiens 101-111 35586688-6 2022 Minocycline plus zinc oxide eugenol cement was associated with significantly lower positive rates of HIF-1alpha and Bcl-2 and lower levels of TNF-alpha versus minocycline alone (p < 0.05). Eugenol 28-35 BCL2 apoptosis regulator Homo sapiens 116-121 35586688-6 2022 Minocycline plus zinc oxide eugenol cement was associated with significantly lower positive rates of HIF-1alpha and Bcl-2 and lower levels of TNF-alpha versus minocycline alone (p < 0.05). Eugenol 28-35 tumor necrosis factor Homo sapiens 142-151 35586688-8 2022 Conclusion: Minocycline plus zinc oxide eugenol cement offers a viable alternative for acute pulpitis as it mitigates the pain of patients, alleviates inflammatory responses, and lowers the positive rate of HIF-1alpha and Bcl-2, so it is worthy of clinical promotion. Eugenol 40-47 hypoxia inducible factor 1 subunit alpha Homo sapiens 207-217 35586688-8 2022 Conclusion: Minocycline plus zinc oxide eugenol cement offers a viable alternative for acute pulpitis as it mitigates the pain of patients, alleviates inflammatory responses, and lowers the positive rate of HIF-1alpha and Bcl-2, so it is worthy of clinical promotion. Eugenol 40-47 BCL2 apoptosis regulator Homo sapiens 222-227 34381064-7 2021 RT-qPCR for apoptotic genes (BCL2, CASP3 and CASP8) and necrosis genes (MLKL, RIPK1 and RIPK3) did not show significant differences between control and treated cells of both types, with the exception of eugenol-treated HeLa cells in which expression of BCL2, MLKL and RIPK1 was significantly higher than controls. Eugenol 203-210 caspase 3 Homo sapiens 35-40 34381064-7 2021 RT-qPCR for apoptotic genes (BCL2, CASP3 and CASP8) and necrosis genes (MLKL, RIPK1 and RIPK3) did not show significant differences between control and treated cells of both types, with the exception of eugenol-treated HeLa cells in which expression of BCL2, MLKL and RIPK1 was significantly higher than controls. Eugenol 203-210 caspase 8 Homo sapiens 45-50 34381064-7 2021 RT-qPCR for apoptotic genes (BCL2, CASP3 and CASP8) and necrosis genes (MLKL, RIPK1 and RIPK3) did not show significant differences between control and treated cells of both types, with the exception of eugenol-treated HeLa cells in which expression of BCL2, MLKL and RIPK1 was significantly higher than controls. Eugenol 203-210 mixed lineage kinase domain like pseudokinase Homo sapiens 72-76 34381064-7 2021 RT-qPCR for apoptotic genes (BCL2, CASP3 and CASP8) and necrosis genes (MLKL, RIPK1 and RIPK3) did not show significant differences between control and treated cells of both types, with the exception of eugenol-treated HeLa cells in which expression of BCL2, MLKL and RIPK1 was significantly higher than controls. Eugenol 203-210 receptor interacting serine/threonine kinase 1 Homo sapiens 78-83 34381064-7 2021 RT-qPCR for apoptotic genes (BCL2, CASP3 and CASP8) and necrosis genes (MLKL, RIPK1 and RIPK3) did not show significant differences between control and treated cells of both types, with the exception of eugenol-treated HeLa cells in which expression of BCL2, MLKL and RIPK1 was significantly higher than controls. Eugenol 203-210 receptor interacting serine/threonine kinase 3 Homo sapiens 88-93 34381064-7 2021 RT-qPCR for apoptotic genes (BCL2, CASP3 and CASP8) and necrosis genes (MLKL, RIPK1 and RIPK3) did not show significant differences between control and treated cells of both types, with the exception of eugenol-treated HeLa cells in which expression of BCL2, MLKL and RIPK1 was significantly higher than controls. Eugenol 203-210 BCL2 apoptosis regulator Homo sapiens 253-257 34381064-7 2021 RT-qPCR for apoptotic genes (BCL2, CASP3 and CASP8) and necrosis genes (MLKL, RIPK1 and RIPK3) did not show significant differences between control and treated cells of both types, with the exception of eugenol-treated HeLa cells in which expression of BCL2, MLKL and RIPK1 was significantly higher than controls. Eugenol 203-210 mixed lineage kinase domain like pseudokinase Homo sapiens 259-263 34381064-7 2021 RT-qPCR for apoptotic genes (BCL2, CASP3 and CASP8) and necrosis genes (MLKL, RIPK1 and RIPK3) did not show significant differences between control and treated cells of both types, with the exception of eugenol-treated HeLa cells in which expression of BCL2, MLKL and RIPK1 was significantly higher than controls. Eugenol 203-210 receptor interacting serine/threonine kinase 1 Homo sapiens 268-273 35508252-6 2022 Eugenol promoted the secretion of GLP-1 into the blood, increased GLP-1 receptor (GLP-1R) expression in the duodenum, liver, arcuate nucleus (ARC) and paraventricular nucleus (PVN), increased c-fos expression in the nucleus tractus solitarii (NTS), and promoted ZO-1 and occludin expression in duodenum. Eugenol 0-7 glucagon Rattus norvegicus 34-39 35508252-6 2022 Eugenol promoted the secretion of GLP-1 into the blood, increased GLP-1 receptor (GLP-1R) expression in the duodenum, liver, arcuate nucleus (ARC) and paraventricular nucleus (PVN), increased c-fos expression in the nucleus tractus solitarii (NTS), and promoted ZO-1 and occludin expression in duodenum. Eugenol 0-7 glucagon-like peptide 1 receptor Rattus norvegicus 66-80 35508252-6 2022 Eugenol promoted the secretion of GLP-1 into the blood, increased GLP-1 receptor (GLP-1R) expression in the duodenum, liver, arcuate nucleus (ARC) and paraventricular nucleus (PVN), increased c-fos expression in the nucleus tractus solitarii (NTS), and promoted ZO-1 and occludin expression in duodenum. Eugenol 0-7 glucagon-like peptide 1 receptor Rattus norvegicus 82-88 35508252-6 2022 Eugenol promoted the secretion of GLP-1 into the blood, increased GLP-1 receptor (GLP-1R) expression in the duodenum, liver, arcuate nucleus (ARC) and paraventricular nucleus (PVN), increased c-fos expression in the nucleus tractus solitarii (NTS), and promoted ZO-1 and occludin expression in duodenum. Eugenol 0-7 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 192-197 35508252-6 2022 Eugenol promoted the secretion of GLP-1 into the blood, increased GLP-1 receptor (GLP-1R) expression in the duodenum, liver, arcuate nucleus (ARC) and paraventricular nucleus (PVN), increased c-fos expression in the nucleus tractus solitarii (NTS), and promoted ZO-1 and occludin expression in duodenum. Eugenol 0-7 tight junction protein 1 Rattus norvegicus 262-266 35508252-6 2022 Eugenol promoted the secretion of GLP-1 into the blood, increased GLP-1 receptor (GLP-1R) expression in the duodenum, liver, arcuate nucleus (ARC) and paraventricular nucleus (PVN), increased c-fos expression in the nucleus tractus solitarii (NTS), and promoted ZO-1 and occludin expression in duodenum. Eugenol 0-7 occludin Rattus norvegicus 271-279 35508252-9 2022 In conclusion, eugenol regulates hepatic lipid metabolism via a gut-brain-liver axis involving in GLP-1, providing a new strategy for the treatment of NAFLD. Eugenol 15-22 glucagon Rattus norvegicus 98-103 35576327-2 2022 Three P450 genes (TcCYP4Q3, TcCYP4Q5, TcCYP4Q7) are associated with the response of eugenol in Tribolium castaneum. Eugenol 84-91 cytochrome P450 monooxigenase CYP4Q3 Tribolium castaneum 18-26 35576327-2 2022 Three P450 genes (TcCYP4Q3, TcCYP4Q5, TcCYP4Q7) are associated with the response of eugenol in Tribolium castaneum. Eugenol 84-91 cytochrome P450, family 4, subfamily Q, polypeptide 7 Tribolium castaneum 38-46 35419714-6 2022 Moreover, several DEGs including Hexokinase type 2, Isocitrate dehydrogenase, and Cytochrome b-related protein, might participate in the respiratory metabolism of eugenol-exposed beetles. Eugenol 163-170 hexokinase type 2 Tribolium castaneum 33-50 35419714-6 2022 Moreover, several DEGs including Hexokinase type 2, Isocitrate dehydrogenase, and Cytochrome b-related protein, might participate in the respiratory metabolism of eugenol-exposed beetles. Eugenol 163-170 cytochrome b Tribolium castaneum 82-94 35419714-8 2022 Additionally, TcOBPC11/ TcGSTs7, detected by qRT-PCR and RNA-interference against these genes, significantly increased the mortality of eugenol-treated T. castaneum, providing further evidence for the involvement of OBP/GST in eugenol metabolic detoxification in T. castaneum. Eugenol 136-143 B1 protein Tribolium castaneum 14-22 35419714-8 2022 Additionally, TcOBPC11/ TcGSTs7, detected by qRT-PCR and RNA-interference against these genes, significantly increased the mortality of eugenol-treated T. castaneum, providing further evidence for the involvement of OBP/GST in eugenol metabolic detoxification in T. castaneum. Eugenol 227-234 B1 protein Tribolium castaneum 14-22 35132703-0 2022 Eugenol restrains abdominal aortic aneurysm progression with down-regulations on NF-kappaB and COX-2. Eugenol 0-7 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 81-90 35405892-10 2022 Additionally, eugenol and the trans-cinnamaldehyde mixture had protective activities via the down-regulation of XDR C. jejuni (flaA, virB11 and wlaN) virulence genes and proinflammatory cytokines (TNF-alpha, IL-2, IL-6, and IL-8), and the up-regulation of anti-inflammatory cytokine IL-10. Eugenol 14-21 lipopolysaccharide induced TNF factor Gallus gallus 197-206 35405892-10 2022 Additionally, eugenol and the trans-cinnamaldehyde mixture had protective activities via the down-regulation of XDR C. jejuni (flaA, virB11 and wlaN) virulence genes and proinflammatory cytokines (TNF-alpha, IL-2, IL-6, and IL-8), and the up-regulation of anti-inflammatory cytokine IL-10. Eugenol 14-21 interleukin 15 Gallus gallus 208-212 35405892-10 2022 Additionally, eugenol and the trans-cinnamaldehyde mixture had protective activities via the down-regulation of XDR C. jejuni (flaA, virB11 and wlaN) virulence genes and proinflammatory cytokines (TNF-alpha, IL-2, IL-6, and IL-8), and the up-regulation of anti-inflammatory cytokine IL-10. Eugenol 14-21 interleukin 6 Gallus gallus 214-218 35405892-10 2022 Additionally, eugenol and the trans-cinnamaldehyde mixture had protective activities via the down-regulation of XDR C. jejuni (flaA, virB11 and wlaN) virulence genes and proinflammatory cytokines (TNF-alpha, IL-2, IL-6, and IL-8), and the up-regulation of anti-inflammatory cytokine IL-10. Eugenol 14-21 interleukin 8-like 2 Gallus gallus 224-228 35405892-10 2022 Additionally, eugenol and the trans-cinnamaldehyde mixture had protective activities via the down-regulation of XDR C. jejuni (flaA, virB11 and wlaN) virulence genes and proinflammatory cytokines (TNF-alpha, IL-2, IL-6, and IL-8), and the up-regulation of anti-inflammatory cytokine IL-10. Eugenol 14-21 interleukin 10 Gallus gallus 283-288 35132703-0 2022 Eugenol restrains abdominal aortic aneurysm progression with down-regulations on NF-kappaB and COX-2. Eugenol 0-7 cytochrome c oxidase II, mitochondrial Mus musculus 95-100 35132703-7 2022 After elucidation the efficiency of eugenol against AAA progression by AAA diameter, hematoxylin-eosin staining and orcein staining, the down-regulations of eugenol on COX-2 and NF-kappaB were further detected by immunohistochemistry and western blot. Eugenol 157-164 cytochrome c oxidase II, mitochondrial Mus musculus 168-173 35132703-7 2022 After elucidation the efficiency of eugenol against AAA progression by AAA diameter, hematoxylin-eosin staining and orcein staining, the down-regulations of eugenol on COX-2 and NF-kappaB were further detected by immunohistochemistry and western blot. Eugenol 157-164 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 178-187 35132703-9 2022 Excellent efficiency, high oral bioavailability and down-regulation on COX-2/NF-kappaB endowed eugenol great potential for future AAA therapy. Eugenol 95-102 cytochrome c oxidase II, mitochondrial Mus musculus 71-76 35132703-9 2022 Excellent efficiency, high oral bioavailability and down-regulation on COX-2/NF-kappaB endowed eugenol great potential for future AAA therapy. Eugenol 95-102 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 77-86 35088963-9 2022 In alphaPN, CAR, TY and EG with GEN and TET, synergistic/partial synergistic interaction was observed against S.aureus strains, while indifferent interaction was detected in E.coli and P.aeruginosa strains. Eugenol 24-26 tetracycline-resistance protein Staphylococcus aureus 40-43